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CHAPTER 1 
General Introduction 
G e n e r a l I n t r o d u c t i o n 
F A T T Y A C I D S T R U C T U R E A N D N O M E N C L A T U R E 
Fatty acids are hydrocarbon chains with at a methyl group (-CH3) at one end and a 
carboxyl group (-COOIi) at the other end. Based on the number of double bonds, they 
can be categorized as saturated or unsaturated fatty acids. A fatty acid is saturated if it 
does not contain any double bonds, so that all the carbon atoms are saturated with the 
maximum number of hydrogen atoms possible. In contrast, fatty acids that do contain 
double bonds are called unsaturated because there are two hydrogen atoms missing for 
each double bond that is present in the fatty acid chain. More specifically, if fatty acids 
contain only one double bond they are called monounsaturated, whereas fatty acids that 
contain two or more double bonds are referred to as polyunsaturated. 
There are two fatty acid nomenclature systems that are both based on the number 
of carbon atoms and the number of double bonds in a fatty acid chain, but differ with 
respect to how the locations of the double bonds are denoted. In the delta notation (A), 
the double bonds are counted from the carboxyl end. In the omega («) or "n minus" 
notation, the double bonds are counted from the methyl end. Based on the latter 
nomenclature, the unsaturated fatty acids can be subdivided into 4 distinct fatty acid 
families: the n-9, n-7, n-6 and n-3 fatty acids. Most polyunsaturated fatty acids are 
members of the n-6 or n-3 family, which have linoleic and a-linolenic acid as the 
respective parent compounds. Typically, n-6 fatty acids contain their first double bond 
between the 6th and the 7th carbon atom counting from the carbon atom of the methyl 
terminus, whereas in n-3 fatty acids the double bond is located between 3rd and the 
4lh carbon atom. In humans, there is no interconversion between the different fatty acids 
families. A fatty acid will always remain within its family since the introduction of new 
double bonds and carbon atoms will take place between the last double bond and the 
carboxyl end. 
E S S E N T I A L F A T T Y A C I D S 
Our diet does not need to provide all fatty acids for optimal functioning because the 
human body can synthesize saturated and polyunsaturated fatty acids de novo. 
However, there are two polyunsaturated fatty acids, linoleic acid (LA; CI8:2n-6) and 
a-linolenic acid (ALA; C18:3n-3) that humans - unlike plants - cannot form themselves 
because they lack the necessary delta-12 and delta-15 desaturase enzymes. 
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Figure 1 
Schematic presentation of the conversion pathways of linoleic acid and a-Hnolenic acid in humans 
Despite the human body's inability to make these two fatty acids de novo, their 
structural and physiological roles make them indispensable for human health []]. That is 
why LA and ALA are called essential fatty acids (EFAs). The only way for humans to 
acquire them is through dietary sources. Therefore, LA and ALA have to be supplied in 
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adequate amounts through the diet. ALA is predominantly found in nuts and nut oils, in 
vegetable oils such as rapeseed, soybean and lineseed oil, and also to a lesser extent in 
the chloroplasts of green leafy vegetables. Dietary sources rich in LA are sunflower, 
soybean, nut and corn oils. 
Once ALA and LA are ingested, humans can convert them into longer and more 
unsaturated fatty acids through alternating enzymatic desaturation and elongation 
reactions. An elongase enzyme extends the fatty acid chain by 2 carbon atoms, while a 
desaturase introduces a new double bound between the last double bond and the -COOH 
terminus of the fatty acid chain. Figure 1 depicts the pathway through which the 
precursor compounds LA and ALA are converted into the long-chain polyunsaturated 
fatty acids (LCPUFAs). The complete conversion cascade involves 3 desaturation and 
3 elongation steps which take place in the endoplasmatic reticulum, while the final 
chain shortening p-oxidation step in the synthesis of DHA occurs in the peroxisomes 
[2,3]. Dihomo-y-linolenic acid (DHGL; C20:3n-6) and arachidonic acid (AA; 
C20:4n-6), which can serve as precursors for eicosanoid synthesis, are the most 
important LCPUFAs derived from LA. The principle long-chain derivates of ALA are 
eicosapentaenoic acid (EPA; C20:5n-3), docosapentaenoic acid (DPA; C22:5n-3) and 
docosahexaenoic acid (DHA; C22:6n-3). The structures of LA, ALA, EPA and DHA 
are presented in Figure 2, 
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Figure 2 
Structure of iinoleic acid, a-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid 
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M E T A B O L I S M OF A L A AND ITS Q U A N T I F I C A T I O N 
EPA and DHA are known as marine or fish fatty acids since they are primarily present 
in fish oil. EPA and DHA have become subject of interest due to their postulated 
favorable health effects, particularly with regard to the risk reduction for cardiovascular 
disease (CVD) [4]. Their precise mechanisms of action at the cardio-vascular level are 
largely unknown, but positive effects on endothelial function, blood pressure, 
triacylglycerol concentrations, hemostatic function, inflammation, and arrhythmias have 
been mentioned [5-13]. 
Considering their beneficial and protective health effects, international 
nutritional guidelines have incorporated recommendations for the marine derived fatty 
acids and advocate a regular intake of fatty fish. Most diets, however, still supply 
amounts of EPA and DHA below those recommended. An increase in ALA 
consumption might be an alternative to compensate for a low EPA and DHA intake, as 
it is a precursor for EPA and DHA synthesis, while it is widespread and readily 
available from vegetable sources. However, dietary ALA has three metabolic fates: 
storage, conversion into LCPUFAs and p-oxidation [14-17]. So far the extent of ALA 
conversion and its determinants are poorly understood. Hence, it is relevant to obtain 
quantitative insight into the pathways of ALA metabolism to establish whether this 
plant derived fatty acid is indeed a suitable substitute for the marine fatty acids. 
A straightforward method to estimate ALA conversion in humans does not exist 
at the present. It is studied using two main approaches: through dietary ALA 
intervention studies and through stable isotope studies [16, 18]. Dietary intervention 
studies address the influence of a changed ALA intake on the accumulation of ALA and 
its derivates in tissues, membranes and plasma lipid fractions. The few human 
intervention studies with an increased ALA intake demonstrated increased proportions 
of ALA and EPA in lipid fractions, but detected either no or only minor changes in 
DHA proportions [19-23]. The downside of feeding studies, however, is that the dietary 
induced shifts in the distinct n-3 fatty acid levels provide merely a qualitative or 
semi-quantitative reflection of the underlying conversion pathways. In contrast, stable 
isotope studies with deuterated or l3C-labeled ALA isotopes do enable quantification of 
the n-3 fatty acid conversion cascade in vivo. So far, the number of ALA tracer 
conversion studies in humans is sparse [19,24-31], and the majority of these studies have 
used the area under the curve (AUC) technique to estimate ALA conversion [19, 24, 25, 
30, 31]. Results from stable isotope studies using the AUC approach indicate that the 
extent to which ALA is converted into EPA is less than 10 % [24, 25, 30, 31], whereas 
conversion into DHA is extremely marginal [24,25]. However, AUC values are summary 
measures, which are useful to assess overall biosyntheses of n-3 fatty acids but, unlike 
compartmental modeling, can not accurately discriminate between the metabolic 
parameters that determine ALA conversion. The first study to apply compartmental 
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modeling as a means to estimate conversion of ALA in adults, estimated that solely 
0.2% of ALA was converted into EPA [281. Of this small traction, 6 3 % was 
subsequently converted into DPA and 37 % into DHA. In this study, however, a single 
large tracer dose of 1 gram deuterated alpha-linolenate ethyl ester (d5-C18:3n-3) was 
given, which exceeded by far the habitual daily ALA intake. Except for the fact that 
such high amounts of tracer may disrupt the system that is studied, synthesis of DPA 
and DHA proceeds slowly, as was previously shown in the study by Vermunt et al. [27]. 
Hence, compartmental modeling following a longer-term oral tracer dosing is a more 
convenient approach to quantify dietary ALA conversion. 
The interplay between ALA and LA further complicates the estimation of 
n-3 conversion. Competitive inhibition exists between ALA and LA because they share 
the same enzymatic conversion system [32]. For example, the delta-6 desaturation step, 
which is the initial reaction for the synthesis of EPA from ALA and AA from LA, is 
assumed to be the rate-limiting step in the conversion pathway [18], Despite that this 
enzyme favors ALA as substrate over LA, LA has a competitive advantage, as it is far 
more abundant in most diets than ALA [32]. A high LA intake may therefore limit 
conversion of ALA considerably. In a stable isotope study, Emken et al. [31] estimated 
using AUC of total plasma lipid enrichments, that conversion in young men was 18.5 % 
after a saturated fatty acid rich diet (4.7 energy percent (En%) LA, 0.6 En% ALA, ALA 
to LA ratio of 1:8), whereas it was 11 % on a polyunsaturated fatty acid enriched diet 
(9.3 En% LA, 0.3 En% ALA, ALA to LA ratio of 1:30). Despite that the authors 
attributed this 40 % decrease in ALA conversion solely to the influence of an increased 
amount of LA in the diet, these results might also be due to the decreased intake of ALA 
or the decreased ALA to LA ratio. Nevertheless, conversion of ALA into the n-3 
LCPUFAs can be enhanced by increasing its availability for the converting enzymes. 
Theoretically, this can be achieved in three distinct ways: through an increase of ALA 
intake, via a decrease in the consumption of LA or rather by increasing the ALA to LA 
ratio in the diet. The outcome of each approach separately has not been quantitatively 
assessed in humans before. 
Aside from the already poor understanding of the effect of the dietary ALA and 
LA content on ALA metabolism, even less is known about the extent to which specific 
subject characteristics act as determinants. Findings from a few recent studies point 
towards a higher conversion capacity of n-3 fatty acids in women of reproductive age 
than in men [24, 25,33-35]. In a study with 103 women and 72 men who consumed diets 
with well controlled and comparable n-3 levels, Giltay et al. showed that the proportion 
of DHA in plasma cholesterylesters was 15 % higher in women than in men [33]. 
Moreover, a 10% higher DHA concentration was observed in women taking oral 
contraceptives than in women not taking them [33]. To date, only three stable isotope 
studies have quantitatively explored whether diet-induced changes in ALA conversion 
are gender-dependent [24, 25, 35]. Burdge et al. performed one study in young women 
13 
C h a p t e r 3 
and one in men o f the same age group, using comparable experimental c o n d i t i o n s 
[24,25]. Although no formal statistical analyses were reported, results from both s t u d i e s 
were suggestive. In women, conversion of ALA into EPA and DHA, a s q u a n t i f i e d f r o m 
total plasma lipids using the area under the l3C-labeled n-3 fatty acid c o n c e n t r a t i o n t i m e 
curves, was 21 % and 9 % respectively [25]. In contrast, men only synthesized 9 aA* 
EPA and 0 % of DHA de novo [24]. In response to Burdge et al's findings, P a w l o s k i y et 
al. published a select number of kinetic parameters that were derived from p o s t - h o c 
analyses of data from a study that was not primarily designed to investigate g e n d e r 
effects [35]. Results suggested that, depending on the composition of the b a c k g r o u n d 
diet, gender indeed affected synthesis of DHA. In women, significantly h igher r a t e 
coefficients for the conversion of DPA to DHA were observed when a beef-based d i e t 
was consumed, whereas they only tended to increase following an ad libitum d i e t a n d 
were not changed after a fish-based diet. However, it should be noted that the l a c l c o f 
complete and detailed modeling information hampers a clear interpretation of r e s u l t s 
and does not provide significant insight into gender effects. In addition to g e n d e r a n d 
reproductive status, other subject characteristics might affect conversion. I n a 
multivariate analysis concerning the impact of several biomarkers on the p r o p o r t i o n o f 
EPA and DHA of human erythrocytes, it was recently shown that age and BMI w e r e 
positively related to the proportion of EPA + DHA in RBC [36]. However, a q u a n t i t a t i v e 
exploration of these latter two factors within the setting of a tracer conversion s t u d y l i a s 
never been performed. 
Other than being a precursor for LCPUFAs synthesis, ALA serves as an e n e r g y 
source and is also incorporated into membranes and fat tissue. In fact, a m o n g t h e 
possible metabolic fates for ALA, (^-oxidation is quantitatively considered as the m o s t 
important [I7j. ALA oxidation studies in humans estimate that, within a time p e r i o d o f 
9 - 4 8 hours, about 1 6 - 3 3 % of ALA is recovered as C02 in breath [24-27, 37, 3 8 ] , 
Furthermore, it is postulated that the extent of ALA oxidation determines its a v a i l a b i l i t y 
for conversion [14]. Whether the ALA and LA content of the background diet, o r t h e i r 
ratio, modulates the extent of partitioning towards ALA oxidation is not k n o w n . 
Also, little is known about potential determinants of ALA oxidation. It is presumed t h a t 
men oxidize more ALA than women, so that less ALA is available and shunted t o w a r d s 
the pathway of conversion [14]. However, most of the ALA oxidation studies e i t h e r 
focused on ALA oxidation in men [24, 26, 37, 38] or did not present separate r e su l t s f o r 
men and women [27]. Burdge et al. found that men oxidize about 33 % of ingested A L A 
tracer, whereas in a different, but comparable study with female subjects, t r a c e r 
recovery was approximately 22 % [24, 25]. Whether ALA oxidation is truly g e n d e r 
dependent, has not yet been appropriately addressed. 
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E F F E C T S OF A L A VERSUS THOSE OF L A AND E P A / D H A ON 
C A R D I O V A S C U L A R D I S F A S F RISK FACTORS 
For the last decades, many studies have focused on the effects of EPA and DMA on 
CVD risk factors. Their effects on lipoprotein levels have received a lot of attention. 
Although findings are not equivocal, results do indicate that fish fatty acids 
characteristically decrease serum triacylglycerol concentrations (TG) \lK 11,12, 3()]. HDL 
concentrations, however, are generally unaffected whereas LDL cholesterol 
concentrations seem to increase slightly, particularly in hypertriacylglycerolemic 
subjects [12]. These specific properties of fish fatty acids are probably not typical for 
ALA, their plant derived parent fatty acid [iij. Findings from a sparse number of dietary 
intervention studies suggest that ALA has similar effects on serum lipid levels as its n-6 
fatty acid analog LA [21, 40-42], Effects of the ALA and LA ratio can however not be 
excluded. A controlled human intervention study, to distinguish directly the effects of 
the ALA to LA ratio from those of dietary ALA and LA on lipoprotein levels, 
lipoprotein subclass distributions and particle sizes, does not exist. Furthermore, the 
number of studies that have compared the effects of EPA and DHA with those of ALA 
on CVD risk markers other than serum lipid concentrations is extremely scarce. The few 
recent study findings that do exist, suggest that plant and marine n-3 fatty acids have a 
similar influence on blood coagulation and fibrinolytic factors [23. 43. 44]. Furthermore, 
recent findings suggest that n-3 fatty acids have favorable effects on endothelial markers 
[45-50]. Since most of the studies have been performed in young or middle-aged subjects, 
it is not known whether effects of n-3 fatty acids on CVD risk markers can be extended 
to an elderly population over the age of 60 years. As the subgroup of aged people is 
steadily growing and the CVD risk increases with age, they might benefit from a dietary 
modulation with n-3 fatty acids [51, 52]. 
OUTLINE OF THE THESIS 
This thesis focuses on the effects of dietary ALA, LA and their ratio on conversion of 
n-3 fatty acids in humans and on cardiovascular risk markers. Chapter 2 describes the 
development of the compartmental model for quantification of n-3 fatty acid conversion 
11 
following a longer-term intake of multiple uniformly labeled [ C]ALA boluses. 
The modeling assumptions, model predictions, kinetic calculations, and the advantages 
and restrictions of the modeling approach are discussed in detail. Chapter 3 focuses on 
the implementation of this kinetic model to disentangle the effects of an increase in 
dietary ALA, a decrease in dietary LA and an increase in the ALA to LA ratio on the 
conversion of dietary ALA. The influence of gender, reproductive status, age and fat 
15 
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mass as potential determinants of ALA metabolism were explored in Chapter 4. 
Chapter 5 unravels the effects of ALA, LA and their ratio on serum lipid profile and 
lipoprotein subclass distributions. Chapter 6 compares the effect of ALA with those of 
EPA/DHA on cardiovascular risk markers in elderly subjects between 60 - 78 y. 
The General Discussion, Chapter 7, addresses the main outcomes and implications of 
these studies. In addition, suggestions for future studies are provided. 
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CHAPTER 2 
Compartmeiital modeling to quantify a-linolenic acid 
conversion after longer term intake of multiple tracer 
boluses 
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A B S T R A C T 
To estimate in vivo a-Iinolenic acid (ALA; C18:3n-3) conversion, 29 healthy subjects 
consumed for 28 days a diet providing 7 % of energy from linoleic acid (LA; C18:2n~6) 
and 0.4% from ALA. On day 19, subjects received a single bolus of 30 mg of 
11 
uniformly labeled [ C]ALA and for the next 8 days 10 mg twice daily. Fasting plasma 
* 1 1 
phospholipid concentrations of UC- and MC-labeled ALA, eicosapentaenoic acid 
(EPA; C20:5n-3), docosapentaenoic acid (DPA; C22:5n-3), and docosahexaenoic acid 
(DHA; C22:6n-3) were determined on days 19, 21, 23, 26, 27, and 28. To estimate 
hepatic conversion of n-3 fatty acids, a tracer model was developed based on the 
averaged 13C data of the participants. A similar tracee model was solved using the 
averaged ,2C values, the kinetic parameters derived from the tracer model, and mean 
ALA consumption. ALA incorporation into plasma phospholipids was estimated by 
solving both models simultaneously. It was found that nearly 7 % of dietary ALA was 
incorporated into plasma phospholipids. From this pool, 99,8 % was converted into 
EPA, and 1 % was converted into DPA and subsequently into DHA. 
Conclusion 
The limited incorporation of dietary ALA into the hepatic phospholipid pool contributes 
to the low hepatic conversion of ALA into EPA. A low conversion of ALA-derived 
EPA into DPA might be an additional obstacle for DHA synthesis. 
I N T R O D U C T I O N 
a-Linolenic acid (ALA; C18:3n-3) is an essential fatty acid of the n-3 family, that is 
present in unhydrogenated canola and soybean oils and in foods prepared with these 
oils 11-3]. Humans are unable to synthesize ALA because they lack the necessary 
A-15 desaturase enzymes [4-6]. Therefore, ALA must be provided in adequate amounts 
through the diet. After consumption, ALA can be converted in the liver into longer and 
more unsaturated fatty acids such as eicosapentaenoic acid (EPA; C20:5n-3) and 
docosahexaenoic acid (DHA; C22:6n-3). These latter two fatty acids, which are also 
present in fatty fish, play an essential role in many physiological processes [7]. Whether 
ALA is a useful source for EPA and DHA synthesis depends on the efficacy of ALA 
conversion. 
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Several animal and human intervention studies have examined the effects of 
diets rich in ALA on n-3 fatty acid metabolism and accretion in tissues [8-10]. Although 
the results indicate that ALA is converted, these studies only allow a qualitative or semi 
quantitative description of n-3 metabolism. In contrast, the use of stable isotopes offers 
a means to assess quantitatively the in vivo conversion of ALA [ll]. Nevertheless, 
quantification of the separate conversion reactions remains complex. The few studies 
that were performed with deuterated or l3C-labeled ALA tracers mostly used area under 
the curve (AUC) values, which give a global impression of n-3 fatty acid 
conversion [1215], Compartmental modeling, however, provides more accurate 
estimates of the various metabolic parameters underlying the n-3 fatty acid cascade. 
The first study to apply compartmental modeling to quantify the conversion of ALA in 
adults was published by Pawlosky et al. [16]. In that study, the conversion of ALA was 
examined after oral administration of a single I g dose of deuterated ALA, which was 
quite high compared with daily ALA intake. In addition, enrichments of n-3 fatty acids 
were measured in total plasma lipids, although the fatty acid composition of plasma 
phospholipids may more closely resemble hepatic n-3 fatty acid metabolism. Therefore, 
we decided to use compartmental modeling to quantify ALA conversion after ingestion 
of multiple trace amounts of uniformly labeled [l3C]ALA ([U-13C]ALA) for 9 days, and 
enrichments of ALA and its long-chain polyunsaturated fatty acids (LCPUFAs) were 
measured in plasma phospholipids. 
M A T E R I A L S AND METHODS 
S u b j e c t s 
Thirty healthy volunteers (15 men and 15 women) participated in the study. One male 
subject was excluded before analysis of the results because of gastrointestinal 
complaints and related weight loss during the study. The mean ± SD age of the 
remaining 29 subjects was 49.9 ± 13.4 years (range, 21 - 63 years). Volunteers did not 
use medication, had a stable body weight for at least 3 months preceding the study 
(<3 kg loss or gain of weight), and had a body mass index of 24.3 ± 3 . 1 kg/m2. 
The study protocol was approved by the Medical Ethics Committee of Maastricht 
University, and written informed consent was obtained from each participant. 
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Diet 
This tracer study was part of a dietary intervention trial that studied the effects of 
polyunsaturated fatty acids on cardiovascular risk markers. For this part of the project, 
only data from the 4 week run-in period were used, during which all subjects received 
the same control diet. At the start of the study, each subject weighed and recorded his or 
her food intake for 3 consecutive days: 2 working days and 1 weekend day. Energy 
intake was calculated using the Dutch food composition table, and each subject was 
assigned a diet that met his or her energy requirement [17]. To this end, nine different 
diets were formulated with varying amounts of energy (7.5- 13.4 MJ). The target 
composition of the diet consumed during the first four weeks consisted of 15 percent of 
energy (En%) protein, 50 En% carbohydrates, and 35 En% fat (13 En% saturated fatty 
acids, 13 En% monounsaturated fatty acids, 7 En% linoieic acid (LA), and 0.4 En% 
ALA). Thus, the ALA:LA ratio of the control diet was 1:19. EPA and DHA intakes 
were less than 0.1 En%. To achieve these intakes, subjects received each week products 
such as pies, pastry, and margarine that were made from an experimental fat (Table 1). 
The margarine as well as the experimental fat, which was composed of a mixture of 
30.4 % sunflower oil, 33.1 % olive oil, 11.5% rapeseed oil, and 25 % hardstock made 
from fully hydrogenated palm kernel and palm oils, were made by NIZO Food Research 
(Ede, The Netherlands). Depending on energy intake, the products supplied provided 
62-71 % of total fat intake or 22 - 25 En% of total energy. In addition, subjects were 
given strict written dietary guidelines concerning the preparation and consumption of 
other food items. The use of fish or seafood was prohibited during the entire study 
period. Body weight was monitored weekly. Subjects were assigned to another energy 
intake level whenever weight changed by > 2 kg compared with the body weight at trial 
entry. 
Table 1 
Fatty acid composition of the experimental fat 
g/100 g Fatty acids 
Saturated fatty acids 
Monounsaturated fatty acids 
Polyunsaturated fatly acids 
29.3 
41.0 
29.4 
27.9 LA 
ALA 1.3 
LA, linoieic acid; ALA, a-linolenic acid. 
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Tracer protocol and blood sampl ing 
[U-13C]ALA was purchased from Isotec, Inc. (Miamisburg, OH), as free fatty acid 
tracer with an isotopic purity of 99 %. The total amount of [U-t3C]ALA was dissolved 
in olive oil and then pipetted into capsules with a volume of 0.3 mL, such that each 
capsule contained 10 mg of tracer. 
At day 19, 10 days before the end of the run-in period, a first blood sample was 
drawn (t = 0 h), after subjects had fasted for at least 12 h and abstained from alcohol for 
24 h. Subjects then received an oral bolus of 30 mg of [U-13C]ALA. For the next 8 days 
(days 20-27), subjects consumed one capsule at 8 AM. and one capsule at 8 PM. 
On these days, total daily [U-i3C]ALA intake was 20 mg. Fasting blood samples were 
drawn at days 21 (t = 48 h after the first tracer administration), 23 (t == 96 h), 
26 (t - 168 h), 27 (t = 192 h) and 28 (t - 216 h). 
Sample analysis 
Blood was collected into precooled EDTA tubes and centrifuged at 2000 g (3500 rpm) 
for 30 min at 4 °C within 1 h after sampling. Aliquots from the midportion of the plasma 
were taken, snap-frozen in liquid nitrogen, and stored at -80 °C until analysis. After the 
trial, all samples from one subject were analyzed in the same run. 
Total lipids from plasma were extracted according to a modified procedure of the 
Folch method with 1,2-dinonadecanoyl phosphatidylcholine as an internal standard [18]. 
Phospholipids were then isolated using an Extract-Clean NH2-aminopropylsilyl column 
(500 mg, 4.0 mL; Alltech Associates, Inc., Deerfield, IL) and hydrolyzed and 
methylated into their corresponding fatty acid methyl esters (FAMEs) [19,20]. 
The FAMEs were separated and quantified by means of a gas chromatographyflame 
ionization detector (Perkin-Elmer Autosystem, Norwalk, CT). For separation, a CP-Sil 
88 capillary column (50 m x 0.25 mm, 0.20 jim film thickness; Chrompack, 
Middelburg, The Netherlands) was used with helium as the carrier gas (injector inlet 
pressure of 130 kPa) as described previously [21]. Both the injection and the detector 
temperature were set at 300 °C. The temperature of the oven started at 160 °C and 
increased for 10 to 190 °C in steps of 3.2 °C/min. It remained at 190 °C for 15 min and 
then increased at 5 °C/min to 230 °C and was kept constant for 7 min. 
Isotopic 13C enrichments of the FAMEs of ALA, EPA, docosapentaenoic acid 
(DPA), and DHA were determined on a gas chromatograph-combustion-isotope ratio 
mass spectrometer (MAT 252; Finnigan, Bremen, Germany) with a BPX-70 column 
(50 m x 0.33 mm, 0.25 \im film thickness; SGE, Austin, TX) and helium as the carrier 
gas (injector inlet pressure of 124 kPa). The sample injection temperature was 250 °C. 
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Two different temperature programs were used to obtain a complete separation of the 
peaks of interest. For ALA, EPA, and DHA, the oven was programmed at 185 °C for 
35 min and increased at 30 °C/min up to 260 °C for 33 min. For DPA, the oven was 
programmed at 205 °C for 20 min and increased at 30 °C/min up to 260 °C for 25 min. 
13C enrichments of the FAMEs were expressed as tracer-to-tracee ratios as follows [221. 
r , 3 c i r 13 \ c 
TTR = sample - 12 
V 1Z p V J c j 
background (Eq. 1) 
The tracer-to-tracee ratios were adjusted for the extra carbon atoms added to the 
13C-labeled fatty acids through elongation and methylation. It was assumed that these 
additional carbon fragments were not enriched above background. At each time 
point (t), the above background concentrations of the labeled (CTRACER) and 
unlabeled (CTRACEE) fatty acids were derived according to the following formulas [23]: 
cTRACER ( 0 = CTOTAL ( t ) x 
/ 
\ 
TTR(t)  
1 + TTR(t) 
\ 
(Eq. 2) 
/ 
and 
/ 
C TRACEE (T) = ^TOTAL ( 0 X 
1 
1 + TTR(t) 
\ 
(Eq. 3) 
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where CTOTALW is the total concentration (12C + 13C) in mmol/L of a given fatty acid as 
determined by gas chromatography-flame ionization detection at time point (t). 
Model input parameters such as the daily ALA consumption and the l2C and 
C n-3 fatty acid concentrations in the plasma phospholipid pool followed a normal 
distribution. Quantification of n-3 fatty acid conversion was carried out using 
compartmental modeling by means of the SAAM II version 1.2 software package 
(SAAM Institute, Inc., Seattle, WA). A constant standard deviation error model 
(SD = 0.001) was specified for each fatty acid and implemented as "data-relative" 
within the SAAM II modeling framework [24]. The structural model developed from the 
mean data was applied to each subject's data individually using PopKinetics software 
(SAAM Institute) and Bayesian parameter priors. The analysis resulted in maximum a 
posteriori Bayesian estimates of the parameters. 
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M O D E L D E V E L O P M E N T AND RESULTS 
Genera l model ing s t ra tegy 
The main objective of a tracer study is to obtain information on tracer kinetics, which 
can be used to describe the kinetic behavior of the unlabeled or tracee substances [25]. 
Information on the kinetics of the tracer is obtained by structuring the system into a 
mathematical model from which the exchange, input, and output of tracer material can 
be resolved [26]. For our study, a structural model (Figure 1) was developed based on 
the mean tracer data of the 29 participants. Mean values were used to reduce the 
influence of random noise during model development. Thereafter, a structurally 
comparable tracee model (Figure 2) was set up that incorporated the kinetic parameters 
derived from the tracer system, the averaged values of the tracee measurements of the 
29 subjects, and their mean daily dietary ALA intake. The tracer and tracee models were 
13 * 
then solved simultaneously in order to estimate incorporation of [U- C]ALA into 
plasma phospholipids. 
Tracer model 
The final tracer model is shown in Figure 1. The experimental period was defined from 
0 to 216 h. In agreement with the known conversions of ALA into its LCPUFAs, the 
main structure of the model consists of a string of 4 compartments (ql, q2, q3 , and q4), 
that represent the total amounts (ixmol) of 13C-labeled ALA, EPA, DP A, and DMA, 
1 7 
respectively, in plasma phospholipids. Because the exogenous [U- C]ALA tracer was 
administered orally, it enters the system via the gastro-intestinal tract, which causes a 
delay (d6) before its appearance into plasma phospholipids as ALA. The ALA tracer is 
then either irreversibly lost [k(0,j)J from the delay compartment or proceeds through the 
conversion cascade (k(ij)), as represented by the arrows and their corresponding 
transfer rate constants. The rate constants, k(i,j), denote the fraction of tracer from the 
plasma phospholipid pool that is transferred per unit of time from compartment j to i. 
The fraction of tracer, that is irreversibly lost from each compartment j , is denoted 
k(0j). Tracer n-3 fatty acid concentrations (pmol/L) were measured in plasma 
phospholipids as designated by the closed circles (si). Because our results were 
expressed in units of concentration (fimol/L) and compartmental modeling is based on 
the principle of mass balance, the volume of distribution, which was assumed to be the 
plasma volume, was incorporated. As plasma volume was not measured, it was assumed 
to be 4.5 % of body weight [27]. 
The details of the various model structures and assumptions that were tested 
before arriving at the final model are described below. 
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Figure 1 
Tracer model for n-3 conversion 
Circles denoted q l , q2, q3, and q4 represent the plasma a-linolenic acid (ALA), eicosapentaenoic acid (1£PA), 
docosapentaenoic acid (DPA), and docosahexacnoic acid (DHA) tracer phospholipid compartments, 
respectively. Delay compartments, which were introduced to account for the delayed appearance of the tracer, 
are depicted by the rectangular boxes d6 and d7. The exogenous oral tracer input exl into compartment q5 is 
symbolized by a syringe. The small closed circles s i , s2, s3, s4 attached to each compartment represent the 
blood samples that were taken to measure the concentration of 13C-labeled n-3 fatty acids in plasma 
phospholipids. 
Tracer uptake 
The oral boluses of the tracer (exl) first enter the stomach, compartment q5. 
The assumption was made that there was no irreversible loss of tracer from the stomach. 
A gastric residence time of 30 min was assumed by setting the rate of gastric emptying, 
k(6,5), at 2 h"1. The tracer then enters a delay compartment (d6), which depicts all 
metabolic processes between arrival of [U-13C]ALA in the small intestine and the 
appearance of the tracer in the ALA plasma phospholipid compartment (ql). In our 
model, the delay consisted of a series of 5 compartments. Several models were analyzed 
with a physiologically relevant delay time between 3 and 5 h. Because the model was 
insensitive to the length of the delay time, the delay was set at 5 h. After the delay 
13 
compartment, [U- C ] A L A can follow two different routes: it is either irreversibly lost 
or it arrives in the plasma phospholipid pool. The irreversible loss, which is denoted 
d(0,6) = 1-incorp, includes the fraction of ALA tracer that is not absorbed, as well as the 
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fraction of ALA tracer that is not incorporated into ALA plasma phospholipids after 
intestinal uptake. The tracer, for example, can be oxidized or incorporated into 
nonplasma phospholipids, membranes, and tissues. The fraction of ingested 
[U-nC]ALA that, per unit of time, appears in the plasma phospholipid compartment is 
defined as d{ 1,6) = incorp. Because this appearance could not be determined as an 
adjustable parameter, different values for it were tested. When appearance values were 
close to 5 %, model convergence was obtained. In contrast, values much greater than 
5 % resulted either in nonconvergence of the model or in too high estimates of the 
tracee masses. Therefore, it was decided to fix the appearance parameter temporarily at 
5 % to solve the tracer model. This constraint of 5 % was later replaced by a constraint 
equation, as detailed under the description of the tracee model. 
Figure 2 
Tracee model for n-3 conversion 
Circles denoted Ql , Q2, Q3, and Q4 represent the plasma ALA, EPA, DPA, and DBA tracee phospholipids 
compartments, respechvely. U(5) represents the daily dietary intake of tracee ALA. The direct endogenous 
Z t t l v d v ° H A ^ ^ p h o s p h o l i p i d s compartments are given by U(2), U(3), and U(4), 
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ALA to EPA 
The [U-13C]ALA tracer present in the plasma phospholipid pool was described by a 
single compartment ql . The fraction of the ALA tracer irreversibly lost from ql is 
depicted by k(0,I), and the fraction that was further elongated and desaturated into EPA 
is represented by k(2,l). The rate constant, k(0,l), was fixed at zero, as its value was 
close to zero, when solving the model. The plot of the predicted values and the averaged 
ALA tracer data is shown in Figure 3. The cyclical nature of the dosing protocol is 
clearly visible in the predicted curve. Analyzed values were on or near the nadirs of the 
fitted curve. This was as expected, because blood was sampled in the morning after an 
overnight fast and before the intake of the next capsule. 
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Figure 3 
Model predicted fit through the observed ALA tracer data obtained with the final tracer model 
EPA to DPA 
The structure of the model implied that all newly formed [ nC]EPA originated from the 
plasma ALA phospholipid compartment. As observed for ALA, the predicted values 
also exhibited a cyclic pattern (Figure 4). However, the amplitudes were smaller and, 
because of the time needed to synthesize EPA from ALA, shifted to the right on the 
x axis. Unlike for ALA, the observed EPA values increased along the curve until at the 
end of the study an apparent plateau was reached, which was between the maximum and 
minimum of the predicted values. 
29 
C h a p t e r 3 
This finding can be explained by a slow conversion of EPA into DPA or by an influx of 
labeled EPA from the nonphospholipid [U-13C]ALA pool. The latter possibility was 
explored by introducing an additional input, d(2,6), into the EPA compartment from the 
delay compartment. This input d(2,6) was estimated by testing several models in which 
d( 1,6) was set as a fixed or adjustable parameter, and k(2,l) was set as adjustable or 
equal to zero. Model convergence was obtained only when d(l,6) was fixed at 5 %, 
k(2,l) was fixed at zero, and k(0,l) was set as adjustable. This model was not 
considered further, as it was not physiologically meaningful and did not describe the 
EPA data significantly better than the initial model, Although not evident from our data, 
it cannot be ruled out that some influx of labeled EPA from the nonphospholipid 
[U-,3C]ALA pool did take place. However, combined with the information from the 
DPA data, as described below, the most likely explanation for the increase in observed 
[,3C]EPA over time is that the turnover of EPA to DPA is slower than that of ALA to 
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Mode! predicted fit through the observed EPA tracer data obtained with the final tracer mode! 
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DP A to DHA 
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Compartment q3 represents the C-labeled DPA in plasma phospholipids, derived from 
[l3C]EPA through elongation. The irreversible loss from DPA was indistinguishable 
from zero, and k(0,3) therefore was fixed at zero. The plot of the predicted values 
(Figure 5a) shows that DPA was still increasing steeply by the end of the experiment, 
which may be one explanation for why k(0,3) was close to zero. The curve of the 
predicted DPA values was also very different from those of ALA and EPA. Not only 
was the curve still increasing, the cyclical shape resulting from the multiple input dosing 
protocol was reduced to minute oscillations. This indicates that conversion of EPA into 
DPA is much slower than conversion of ALA into EPA. Furthermore, the curve of the 
predicted values overestimated the first two data points, whereas it slightly 
underestimated the final points. As this indicated, that too much material was introduced 
too fast into the DPA compartment, a delay (d7) was inserted between the EPA and 
DPA compartments. The time of the delay was fixed at 30 h, because this resulted in the 
best possible description of the data (Figure 5b). 
DHA compartment 
The amount of DHA in the plasma phospholipids compartment q4 was first described 
by a single inflow and a single outflow of tracer. The irreversible loss, k(0,4), was small 
but could be estimated. The plot of the predicted DHA curve, however, showed that this 
model underestimated the amount of DHA during the initial phase of the study 
(Figure 6a). This implied that additional input into the DHA compartment was required 
to better describe the data. Therefore, two other models were examined. One model 
included a pathway, k(4,l), from ALA to DHA, and the other model included a 
pathway, k(4,2), from EPA to DHA. As k(4,l) and k(4,2) were very small, other 
transfer rates were not changed or were changed only slightly. As the direct conversion 
in the liver from ALA to DHA seemed more physiological than the conversion of 
plasma EPA to DHA, we formulated the final model with k(4,l). This resulted in 
excellent agreement between the predicted and observed values for the [ l3C]DHA tracer 
(Figure 6b). 
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Model predicted fit through the observed DPA data obtained with the final tracer model 
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Tracer Results 
The rate constants describing the final model are presented in Table 2. The small 
coefficients of variation show that estimations were quite precise. 
Table 2 
Results of the tracer model parameters and derived variables 
Transfer rates (if1) Value Coefficient of variation 
k(6,5) 2 
0.4 d(0,6) 0.93041 
0.06959 5.7 
k(2.I) 0.44981 5.7 
k(4 J ) 0.00081 16.4 
k(0.2) 0.48015 9.0 
M7,2> 0.00496 8.9 
d(3,7) 1 
k(4,3) 0.00613 3.4 
k(0,4) 0.00916 11.3 
Tracee model 
The rate constants obtained from the tracer model were used to calculate conversions 
and fluxes of the tracee data. If the tracee system is in a steady state, and the transfer 
rates are known from the tracer model, the differential equations that describe the tracee 
n-3 fatty acids system become algebraic equations that can be solved. In the present 
study, concentrations of the tracee n-3 fatty acids did not change systematically during 
the tracer experiment, as evident from the results of the GC analyses (data not shown). 
As can be seen from Figure 2, the tracee model is structurally identical to the 
tracer model (Figure 1) and has the same k(i,j) values. The various compartments 
associated with tracee fatty acids are comparable to those of the 13C-labeled tracer fatty 
acids (Figure 1), except that now uppercase letters (e.g. Qi, Di) are used. A main 
difference between the tracee and tracer model is that the tracee model contains 
additional input arrows denoted U(i). The arrow U(5) into compartment Q5 (stomach) 
of the tracee model represents the daily consumption of tracee ALA and is expressed as 
a continuous input (pmol/h). Also, three other direct endogenous inputs, U(2), U(3), and 
U(4), were created into the EPA, DP A, and DHA compartments, respectively. 
Furthermore, to estimate the incorporation of dietary ALA into the ALA plasma 
phospholipid compartment, a constraint equation was incorporated, which could be 
solved by resolving the tracer and tracee model simultaneously. 
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The derivation of the constraint equation and the rationale for introducing the 
endogenous inputs U(i) are described below. 
Appearance constraint 
Recall that for the development of the tracer model, the appearance of the tracer in the 
ALA compartment d(l,6) was temporarily fixed at 5 %. To obtain a more accurate 
estimate for incorporation into the ALA plasma phospholipid compartment, additional 
information was provided by the known daily intake of dietary ALA and the 
concentration of tracee n-3 fatty acids into plasma phospholipids. The constraint 
equation was based on the concept that, to keep the tracee system in a steady-state 
situation, the maximal input of tracee ALA into the ALA compartment is equal to the 
sum of tracee ALA that is lost from this compartment. 
Tracee ALA in the plasma phospholipid pool can originate from dietary ALA as 
well as from ALA stored in endogenous depots. It was not possible to estimate both 
inputs at the same time, and there was no quantitative information on the fraction of 
endogenous input or the proportion of the endogenous input and the dietary absorption. 
Therefore, we assumed that all of the tracee ALA came from the diet. The adopted 
constraint equation was derived as described below. 
First, the total ALA output from compartment Q1 was calculated as 
A L A o u w r = Q 1 x [ k ( 2 , l ) + k ( 0 J ) + k(4,l) l (EqA) 
or equivalently 
A L AOUTPUT = C A L A X V ALA X[K(2 ,l) + k(Q,l) + k(4,L)J (Eq.5) 
where Qi = the mass of the ALA tracee compartment, C L^A — concentration 
()imol/L) of tracee ALA in plasma phospholipids, VALA ~ plasma volume (liters), 
estimated as 4.5 % of body weight 
The total dietary ALA input into the plasma ALA phospholipid compartment (Ql) was 
given by 
ALA u p t a k e = d( 1,6) X U(5) {Eq. 6) 
As the fractional output d( 1,6) from the delay compartment into compartment Ql was 
defined as 
d(l,6) = incorp (Eq. 7) 
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the ALA uptake could be rewritten as 
A L A UPTAKE = incorp x U(5) (E i l - 8> 
Furthermore, because at steady state the input into Q1 equaled the output from Ql , 
ALAUPTAKF could be presented as 
A L A UPTAKE = A L A OUTPUT ^ 9 ) 
or alternatively 
incorp xU(5) = C A L A x V A L A x [k (2 , l ) + k(0, l) + k ( 4 , l ) ] (Eq.10) 
The tracer and tracee models were then linked by the following constraint equation 
incorp 
A L A Q U T P U T C A L A x V A L A x [ k ( 2 t l ) + k(0J) + k(4,l)] ( E q U ) 
U(5) U(5) 
and both models were then solved simultaneously. 
Endogenous inputs 
Initially, when the tracee model was solved, it was assumed that the tracee fatty acids 
EPA, DP A, and DHA in plasma phospholipids originated directly from Ql . However, 
the compartmental masses of these LCPUFAs were then underestimated, which 
indicated that the EPA, DPA, and DHA compartments were also fed via other routes. 
Therefore, endogenous input routes U(2), U(3), and U(4) were introduced into the 
model. 
C a l c u l a t i o n s 
The steady state masses in Qi were obtained by multiplying the l2C-labeled fatty acid 
concentrations with 4.5 % of the average body weight of the 29 participants, which was 
73.3 kg. The tracee flux (|Limol/h) from compartment j to i was calculated by 
multiplying the compartmental tracee mass Qj with the rate constant k(ij). Similarly, 
the irreversible flux out of compartment j was calculated by multiplying compartmental 
tracee mass Qj with the rate constant k(0,j). 
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The proportion of fatty acid transferred from compartment j to i was defined as follows: 
frac%_ i, j = x 100% (Eq. 12) 
HI j) 
where k(j,j) represented the sum of all losses from compartment j. 
The relative contribution of the endogenous flux U(i) (mass/h) could be determined for 
EPA, DPA, and DHA. Because the total tracee influx into compartment Q(i) was equal 
to the sum of the separate influxes, the fractional contribution of U(i) was calculated as 
frac%_U(i) = — x 100% (Eq. 13) 
U(i) + I Q j x k( i , j ) 
H 
4 I 
R E S U L T S 
The steady-state compartmental masses of the tracee n-3 fatty acids, the tracee fluxes, as 
well as the endogenous inputs are shown in Table 3. The incorporation of dietary ALA 
into plasma phospholipids and the subsequent conversion to its n-3 fatty acid 
derivatives, expressed in percentages and absolute amounts of dietary ALA, are given in 
Table 4. 
Values were first calculated using averaged data from the 29 subjects. 
The average daily ALA intake equaled 1129 mg or 4056 fimol. Approximately 78.5 mg 
or 6.96 % of dietary ALA was incorporated as ALA into plasma phospholipids. Of this 
ALA pool, 99.98 % was converted to EPA, which corresponded to 6.95 % (78.4 mg) of 
ALA intake. The remaining 0.18 % of the ALA plasma phospholipid pool, which was 
equivalent to 0.013 % (0.14 mg) of ALA in the diet, was converted directly to DHA in 
the liver, before it appeared in the plasma phospholipids as DHA. Only 1 % of the EPA 
in plasma phospholipids, which was equivalent to 0.07 % (0.80 mg) of ALA 
consumption, was converted to DPA. All DPA from the plasma phospholipid pool was 
converted into DHA. Thus, the total amount of ALA from the diet that was ultimately 
converted to DHA was 0.08 % (0.94 mg). As can be seen from Table 4, the estimates 
based on the individual values were essentially similar. 
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Table 3 
Results of the traeee model parameters and derived variables 
Parameter Value 
ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapcntacnoic acid; 
DHA, docosahexaenoic acid. 
Coefficient 
of variation 
Compartmental iracee mass (jamol) 
Q5 Stomach 84.51 
Q1 ALA 26.10 
Q2 EPA 92.41 
Q3 DPA 113.55 
Q4 DHA 397.41 
Tracee fluxes (^mol/h) 
F!u\(6,5) Stomach delay d6 169.010 
riux( 1.6} Delay ALA compartment 11.761 5.72 
Flu\(0,6) Loss from delay 157.249 0.43 
FIu\{2,I) ALA EPA 11.740 5.73 
Flu\ (4J) ALA DHA 0.021 16.36 
I;l»\{7,2) - Flux(3,7) EPA delay DPA 0.459 8.89 
Flu.\(0,2) Loss from EPA compartment 0.021 9.03 
Flux(4,3) DPA DMA 0.696 3.39 
Flux(0,4) Loss from DHA compartment 3.642 11.34 
Endogenous input (jamol/h) 
U(5) Into stomach 169.01 
Into EPA 33.09 11.7 
U(3) Into DPA 0.24 19.6 
U(4) Into DHA 2.92 13.7 
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Table 4 
Incorporation of dietary ALA into plasma phospholipids and subsequent conversion to its n-3 fatty acid derivatives expressed in percentage and absolute 
amounts of dietaiy ALA 
Based on averaged data 
of 29 subjects Based on individual data of 29 subjects 
Incorporation and conversion Value Mean SD Minimum Maximum 
Dietaiy ALA intake or U(5) (mg/d) 1129 1129 124 907 1369 
Incorporation of dietaiy ALA into ALA compartment (%) 6.96 7.72 3.25 1.88 15.69 
Percentage of dietary ALA converted from 
ALA EPA 6.946 7.705 3.24 1.88 15.68 
ALA DHA 0.013 0.016 0.03 0.00 0.16 
ALA EPA DPA DHA 0.071 0.073 0.04 0.02 0.20 
Incorporation of dietary ALA into ALA compartment (mg) 78.54 6.28 35.31 20.81 173.27 
Absolute amount (mg) of dietary ALA converted from 
ALA EPA 78.39 86.11 35.25 20.73 173.23 
ALA DHA 0.14 0.17 0.31 0.00 1.54 
ALA EPA DPA DHA 0.80 0.82 0.43 0.22 2.05 
ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 
Table 5 
Percentage fractional contribution of endogenous inputs and percentage fractional transfers 
Based on averaged data 
of 29 subjects Based on individual data of 29 subjects 
Contribution and transfer Value Mean SD Minimum Maximum 
Percentage fractional transfer 
Incorp% Into ALA compartment 6.96 7.72 3.25 1.88 15.69 
Frac% 02 Loss from EPA compartment 98.98 98.95 0.52 97.90 99.69 
Frac% 21 ALA EPA 99.82 99.81 0.29 98.85 100.00 
Frac% 41 ALA DHA 0.18 0.19 0.29 0.00 1.15 
Frac% 72 EPA DPA 1.02 1.05 0.52 0.33 2.10 
Frac% 43 DPA DHA 100.00 100.00 0.00 100.00 100.00 
Percentage fractional contribution of U(i) 
Frac% U2 Endogenous input into EPA compartment 73.81 73.78 4.70 65.21 82.43 
Frac% U3 Endogenous input into DPA compartment 34.11 34.10 25.30 0.00 80.06 
Frac%_U4 Endogenous input into DHA compartment 80.31 64.29 38.30 0.00 97.10 
ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 
a - L i n o l e n i c a c i d c o n v e r s i o n in a d u l t s 
Table 5 shows that there was considerable endogenous input of each of the 
12C-labeled tracee fatty acids into the EPA, DP A, and DHA plasma phospholipid pools. 
For example, U(2) corresponded to 33.09 \xmo\/h l2C-labeled EPA, or 73.8% of the 
total flux into the EPA plasma phospholipids pool that was not derived from the ALA 
plasma phospholipid pool. This EPA could have originated from sea food, which had to 
be consumed before the start of the study, as intake of these products was prohibited 
during the study. It is also possible that this EPA was partly derived from ALA, which 
was consumed before or during the tracer study and stored in tissues other than plasma 
phospholipids. Similarly, the endogenous input [U(3)] explained 34.1 % of the total 
inflow into the DP A plasma phospholipid pool, whereas 80.3 % of total inflow into the 
DHA compartment was DHA obtained from non-phospholipids sources [U(4)]. Except 
for the mean endogenous inflow into the DHA compartment, the estimates based on 
individual values were very comparable to the estimates based on the averaged data. 
This discrepancy (64.3 % vs. 80.3 %) may be attributable to the individually estimated 
values for k(0,4) derived from the tracer data. In some individuals, this parameter was 
close to zero. When this happened, U(4) [and in some cases U(3)] resulted in a small 
negative number to satisfy the mass balance requirement. For these subjects, U(4) was 
set to zero. Furthermore, k(0,4) values close to zero could result from measurement 
variability or from individuals exhibiting slow clearance of tracer DHA, so that a loss 
from the DHA compartment [k(0,4)] is difficult to estimate. 
D I S C U S S I O N 
Using compartmental modeling, we found that nearly 7 % of daily ALA consumption 
was incorporated into plasma phospholipids, Approximately 99.8 % of ALA from this 
pool was subsequently converted to EPA, whereas only 1 % of the EPA plasma 
phospholipid pool was converted to DPA. Essentially all DPA was used for synthesis of 
DHA. Usually, the limiting step within the n-3 cascade is considered to be the A-6 
desaturation that is necessary for the conversion of ALA to C18:4n-3 [28-31]. However, 
our study suggests that this is not the limiting step, as nearly all EPA in the plasma 
phospholipid pool was derived from the ALA plasma phospholipid pool. Thus, entry 
into the hepatic phospholipid pool is a limiting factor for ALA conversion to DHA. 
Only a few studies have used stable isotopes to quantitatively study ALA 
metabolism in adults [12-16, 32, 33]. From there pioneering studies, Emken, Adlof, and 
Gulley [15] estimated that conversion of ALA to its LCPUFAs was 18.5 % on a diet rich 
in saturated fatty acids and 11 % on a polyunsaturated-rich diet. We estimated that 
only ~ 7 % of dietary ALA was converted to its LCPUFAs. 
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The higher n-3 conversion values observed by Emken, Adlof, and Gulley may have 
been attributable to the use of AUCs [15]. Indeed, Demmelmair et al. have shown that 
AUC-derived calculations, compared with compartmental modeling, resulted in two 
times and four to five times higher estimates for the conversion of LA into 
dihomo-y-linolenic acid and arachidonic acid, respectively [34], Compared with AUC 
values, compartmental modeling is considered to be more accurate, as it accounts for 
appearance and disappearance rates of ALA and its various metabolites. 
For our modeling framework, we chose plasma phospholipid fatty acid 
compositions to reflect hepatic conversions. Plasma triacylglycerol (TG), which 
contains even more ALA than phospholipids, could also have been an option. Data from 
the stable isotope studies of Burdge and colleagues, however, showed that only trace 
amounts of the labeled elongation products of ALA are incorporated into plasma 
t j 
TG [12,13], In the present study, we also analyzed in 78 samples the C-labeled n-3 
fatty acid enrichments of plasma TG, which were isolated by thin-layer 
chromatography. Enrichments in the long chain n-3-fatty acids, were too low to be 
measured reliably. 
Except for phospholipids and TG, plasma total lipids also consist of free fatty 
acids, chylomicrons, and cholesteryl esters (CEs). We believe that neither of these lipid 
fractions reflect hepatic n-3 conversion reliably. From the studies of Burdge and 
colleagues [12, 13], it can be estimated that in women only 2. 1 % of the total [13C]ALA 
plasma pool was found in plasma free fatty acids over a period of 21 days. For EPA, 
DPA, and DHA, these values were 0.3, 0.0, and 1.5 %, respectively [13]. For men, 4.8 % 
of total plasma [13C]ALA was found in the plasma free fatty acid fraction, whereas 
other 13C-labeled n-3 fatty acids were not traced at all [12J. Chylomicrons are also not 
representative for hepatic n-3 fatty acid conversion, as they contain a fraction of i 7 
[ C]ALA that has not yet been taken up and metabolized by the liver. Thus, if 
l3C-labeled n-3 LCPUFAs are present in chylomicrons, these fatty acids may be derived 
from conversion within the enterocyte and not from conversion within the liver. Plasma 
CEs are formed from cholesterol released from peripheral tissues through the action of 
LCAT, which transfers a fatty acid from a phospholipid to free cholesterol. CEs are also 
synthesized in the intestine and liver. If the CE-derived n-3 LCPUFAs originate from 
plasma phospholipids, the CE pool will not provide new information on hepatic ALA 
conversion, because these fatty acids are part of the loss parameters, leaving from the 
various plasma phospholipid compartments. If the CEs are of intestinal origin, the 
CE-derived l3C-labeled n-3 LCPUFAs, if any, are produced by the enterocyte and 
therefore do not represent n-3 conversion in liver. Only CEs produced by the liver itself 
might reflect hepatic ALA conversion, but, as for TG, plasma CEs are rather poor in 
n-3 LCPUFAs [35]. Therefore, including masses of any other n-3 fatty acid lipid pool in 
the model would mainly increase the mass of the ALA compartment. Masses of the 
other compartments would be minimally affected. As a result, the increased mass of the 
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ALA compartment would be reflected by an increased loss from the ALA compartment 
rather than by changed fluxes into the other compartments. 
Pawlosky et al. were the first to use compartmental modeling to quantify 
iv3 conversion in adults [16]. In contrast to our results, their findings suggested that only 
0.2 % of ALA from plasma total lipids was used for EPA synthesis. Approximately 
63 % from the plasma total lipid EPA pool was converted to DPA, and 37 % of DPA 
was converted to DHA. As already discussed, plasma total lipids may not be the most 
appropriate lipid fraction for the quantification of hepatic n-3 fatty acid conversion. 
The discrepancies between our results and those of Pawlosky et al. may further be 
attributable to other differences in experimental protocols. In our study, tracer intake on 
the first day (30 mg/d) was ~ 2.7 % of dietary ALA intake, and on the other eight days 
(20 mg/d) it was 1.8 %. In contrast, Pawlosky et al. gave a single bolus of 1000 mg of 
deuterated a-linolenate ethyl ester (d5-C18:3n-3), dissolved in a low-fat yogurt, 
followed by a morning meal and a lunch four hours later. This tracer bolus constituted 
as much as - 89 % of the dietary ALA consumption during the study period. Because 
isotope intake clearly exceeded trace amounts, perturbation of the kinetic behavior of 
1 *) 
the "C-labeled n-3 fatty acids cannot be ruled out [251, Another difference between our 
study and that of Pawlosky et al. is the mode of administration of the stable isotopes. As 
in most other studies, Pawlosky et al. administered the ALA tracer as a single bolus, 
whereas we provided the tracer in fractionated portions over time. 
We chose this approach to mimic the longer term supply and metabolism of ALA and to 
ensure measurable values for DHA. It has already been demonstrated by Vermunt et al. i ^ 
that after administration of a single bolus of [ C]ALA, enrichment of DHA increased 
only marginally and slowly [33J, Burdge, Jones, and Wootton, also could not detect any 
significant DHA enrichment over a period of 21 days in plasma phosphatidylcholine, 
chylomicron TG or nonesterified fatty acids after administration of a single bolus of 
[ l 3C]ALA [12]. It is further known that, at least for LA, the mode of tracer 
administration influenced the modeling outcomes [34]. The estimated conversions of LA 
into dihomo-Y-linolenic acid and of LA to arachidonic acid after a fractionated intake of 
LA tracer were higher compared with the estimated conversions after a single bolus of 
the same tracer amount. 
One possible limitation of our model is that it mirrored hepatic conversion of 
dietary ALA. Although it is generally accepted that in humans the liver is the most 
significant site for n-3 fatty acid conversion, studies with primates suggest that other 
tissues, such as nervous tissue, are also able to convert ALA [36]. Hence, the total 
n-3 fatty acid conversion might have been underestimated. However, from the present 
findings, we can conclude that the limited incorporation of dietary ALA into the 
phospholipid pool contributes to the low hepatic conversion of dietary ALA into EPA. 
We further found that the conversion of EPA to DPA, which involves an elongation 
reaction, might be an additional bottleneck within the hepatic n-3 cascade. 
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A B S T R A C T 
Background 
Human in vivo data on dietary determinants of a-linolenic acid (ALA; C18:3n 3) 
metabolism are scarce. 
Objective 
To examine whether intakes of ALA, linoleic acid (LA; C18:2n-6), or their ratio 
influence ALA metabolism. 
Design 
During 4 wk, 29 subjects received a control diet (7 % of energy from LA, 0.4 % of 
energy from ALA, ALA-to-LA ratio = 1:19). For the next 6 wk, a control diet, a low LA 
diet (3 % of energy from LA, 0.4 % of energy from ALA, ratio = 1:7) or a high ALA 
diet (7 % of energy from LA, 1.1 % of energy from ALA, ratio = 1:7) was consumed. 
1 7 
Ten days before the end of each dietary period, [U- C] ALA was administered orally for 
9 d. ALA oxidation was determined from breath. Conversion was estimated by using I l ^ 
compartmental modeling of C- and ~C- n-3 fatty acids concentrations in fasting 
plasma phospholipids. 
Results 
Compared with the control group, ALA incorporation into phospholipids increased by 
3.6 % in the low LA group (P = 0.012) and decreased by 8.0 % in the high ALA group 
(P < 0.001). In absolute amounts, it increased by 34.3 mg (P = 0.020) in the low LA 
group but hardly changed in the high ALA group. Nearly all ALA from the plasma 
phospholipid pool was converted into eicosapentaenoic acid. Conversion of 
eicosapentaenoic acid into docosapentaenoic acid and docosahexaenoic acid hardly 
changed in the 3 groups and was < 0.1 % of dietary ALA. In absolute amounts, it was 
unchanged in the low LA group, but increased from 0.7 to 1.9 mg (P = 0.001) in the 
high ALA group. ALA oxidation was unchanged by the dietary interventions. 
Conclusion 
The amounts of ALA and LA in the diet, but not their ratio, determine ALA conversion. 
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INTRODUCTION 
Eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3) 
play a vital role in many metabolic processes. Although these two fatty acids are readily 
available from fish, these marine-derived fatty acids can also be synthesized by humans 
from a-Iinolenic acid (ALA; C18:3n-3). Humans, however, can obtain ALA only 
through their diets, because the absence of the required A-12 and, A-15 desaturase 
enzymes makes de novo synthesis from stearic acid impossible. Furthermore, 
conversion of dietary ALA into EPA is limited. Because the efficacy of n-3 long-chain 
polyunsaturated fatty acids (LCPUFAs) synthesis decreases down the cascade of ALA 
conversion, DHA synthesis from ALA is even more restricted than that of EPA [I, 2]. 
It is generally assumed that linoleic acid (LA; Cl8:2n 6) reduces EPA synthesis because 
of the competition between ALA and LA for common desaturation and elongation 
enzymes [1-4]. Hence, conversion of a-linolenic acid into the n-3 LCPUFAs might be 
changed by increasing ALA intake or by decreasing LA intake [5-9]. In many of these 
studies, however, the intakes of both ALA and LA changed, and as a result, so did their 
ratio. In addition, it has been suggested that the ALA to LA ratio in the diet determines 
ALA conversion independent of the absolute intakes of both fatty acids [8]. 
This suggestion does not agree with a recent study in rats [10]. Human studies, however, 
were not able to disentangle the effect of the ALA to LA ratio on ALA metabolism from 
the effects of the absolute intake of these 2 fatty acids. The present nutritional 
intervention trial was designed to determine whether in vivo conversion of dietary ALA 
is influenced by the absolute amounts of LA or ALA in the diet or by the ALA to LA 
ratio, To that end, we used compartmental modeling to study ALA conversion at 
various absolute intakes and ratios of LA and ALA in the diet. In addition, effects of the 
diets on oxidation of uniformly labeled I3C-ALA ([U-13C]ALA) were examined. 
S U B J E C T S AND METHODS 
Subjects 
The present study was part of a trial that was designed to examine the effects of PUFAs 
on cardiovascular disease risk markers. The characteristics of the study population have 
been previously described in detail [11]. Thirty healthy subjects, fifteen men and fifteen 
women, completed the study. During study weeks 3 and 4, one male subject had flu 
with associated gastro-intestinal complaints and weight loss. Therefore, it was decided 
not to use his data in the analysis of the results. Of the remaining twenty-nine subjects, 
2 men and 3 women smoked, 7 women were postmenopausal, and 5 of the 
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8 premenopausal women used oral contraceptives. The men were on average 
53.8 ± 11.6 y old (mean ± SD), weighed 79.6 ±9.7 kg and had a body mass index 
(in kg/m2) of 25.2 ± 3.4. The women were 46.2 ± 14.4 y old, weighed 67.6 ± 8.2 kg, and 
had a body mass index of 23.5 =fc 2.8, The study was approved by the Medical Ethics 
Committee of Maastricht, and all participants were informed in detail about the purpose 
and nature of the study before they gave their written informed consent. 
Diet and s tudy des ign 
The study consisted of a run-in period of 4 wk that was immediately followed by an 
experimental period of 6 wk. The study was designed as a double-blind, nutritional 
intervention trial with 3 parallel arms: a low ratio control group, a high ratio low LA 
group, and a high ratio high ALA group. For each of these 3 intervention groups, diets 
were formulated at 9 different energy levels. These energy levels varied from 7.5 MJ to 
13.4 MJ, whereas the difference between 2 successive energy levels equaled 0.84 MJ. 
Before the start of the study, subjects weighed and reported in a 3-d food record all 
foods and drinks consumed during 1 weekend day and 2 working days. Using the Dutch 
food composition table [12], we estimated the energy intakes of the subjects' habitual 
diets. At trial entry, the subjects were allocated to the energy level that matched their 
estimated energy requirements. Body weights were measured once weekly. The subjects 
remained on the assigned energy level as long as their body weight did not change 
by > 2 kg compared with their weight at the start of the study. Otherwise, they were 
placed into a more appropriate energy level. During the run-in period, all participants 
consumed a control diet with a nutrient composition that approximated the dietary 
intake of the Dutch population. This control diet had an ALA to LA ratio of 1:19 by 
supplying 7 % of energy of LA and 0.4 % of energy of ALA. At the end of the run-in 
period, the subjects were randomly divided over the 3 experimental groups stratified for 
gender, age, and total cholesterol concentrations as determined at the screening visit. 
During the experimental period, one group continued to consume the control diet, 
whereas the other 2 groups consumed either a low LA or a high ALA diet. As reported 
previously [11], the diets of the 3 groups were comparable with respect to protein (15 % 
of energy), carbohydrate (50 % of energy), cholesterol (11.5-13.5 mg/MJ) and fiber 
(30 - 35 g) intakes. The diets differed, however, with respect to fatty acid composition. 
The ALA to LA ratio of both the low LA and high ALA diets was about 1:7, which was 
higher than the ratio of 1:19 of the control diet. On the low LA diet, the ALA to LA 
ratio was increased by decreasing the proportion of LA from 7 % of energy to 3 % of 
energy, whereas ALA intake did not change. In contrast, the ALA to LA ratio of the 
high ALA diet was increased by increasing the intake of ALA from 0.4 % of energy to 
1.1 % of energy, whereas LA intake did not change. The modification of the proportions 
of dietary LA or ALA in the experimental groups was done in exchange for mainly 
oleic acid and to a small extent saturated fatty acids. 
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The targeted compositions of the 3 diets were achieved through consumption of 
nonexperimental and experimental food items which accounted for 10 - 13 % of energy 
and 22 - 25 % of energy from fat intake respectively. For each of the 9 energy levels, 
dietary guidelines were provided, describing the type, daily amounts, and preparation of 
the nonexperimental food items. These guidelines were identical for the 3 intervention 
groups and had to be followed precisely. In contrast, each intervention group received 
experimental products that were made from different experimental fats (NIZO food 
research, Ede, The Netherlands), such as a margarine (NIZO food research) and 
pastries. The fatty acid composition of the experimental fats has been presented 
before [11]. 
Once weekly, the subjects had to visit the department to receive a specific 
amount of experimental products, such as margarines and pastries (cookies, pies, and 
cake) in which these margarines were incorporated. The margarines, which contained 
84 % absorbable fats and 16 % water, had to be used daily for cooking, baking, or as 
spread on bread. The pastries were prepared by a local bakery and were consumed daily 
(cookies) or weekly (pies, cake). The amount of experimental products that the 
participants received was determined by their assigned energy level. To estimate their 
energy and nutrient intakes during the study, subjects had to weigh and record their food 
intake for 2 working days and 1 weekend day in the last week of both the run-in and the 
intervention periods. The subjects were asked not to change their level of physical 
exercise, smoking habits, use of alcohol, or use of oral contraceptives during their 
participation in the study. Consumption of fish or marine foods was prohibited. 
Each day, the subjects had to record in diaries any signs of illness, including the 
date and time of occurrence, duration, date of resolution, and medication used. 
The subjects were also asked to note their menstrual phase and record in detail any 
deviations from both the protocol and the amounts of products that had to be consumed. 
Each week, the diaries were checked in the presence of the subjects by a registered 
dietician. 
Tracer protocol and sampling of blood and breath 
An amount of 11.4 g of [U-nC]ALA (isotopic purity of 99 %) was bought from Isotec 
(Isotec Inc., Miamisburg, Ohio, USA), in 2 batches of 5.7 g each. Each batch was 
diluted by 27.28 times in olive oil, after which capsules of 0.3 mL were completely 
filled to obtain 10 mg [U-13C]ALA per capsule. 
Ten days before the end of the run-in period and 10 d before the end of the 
experimental period, on days 19 and 61 respectively, the subjects reported to the 
department after fasting overnight and abstaining from alcohol for 24 h. The volume of 
CO, expiration (VC02) was measured by using a ventilated-hood system (Omnical, 
Maastricht University, the Netherlands) [13], and breath was sampled to detennine the 
baseline nC/ I2C ratio of expired C02. For the latter measurement, the subjects had to 
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breath for 3 min through a mouthpiece with 2-way nonrebreathing valves (2700 series; 
Hans Rudolph Inc., Kansas City, USA), that were connected to a mixing chamber of 
6.75 L. From this mixing chamber breath was sampled directly into a 10 mL vacutainer 
(Becton Dickinson, Meyland, France). Thereafter, a fasting blood sample (t = 0 h) was 
drawn to measure the background enrichment of 13C-labeled ALA, EPA, 
docosapentaenoic acid (DPA), and DHA in plasma phospholipids. Subjects then 
i ^ 
received a single oral bolus of 30 mg [U- C]ALA that was provided in 3 capsules. 
Immediately after tracer intake, the subjects had to consume a standardized meal 
consisting of 200 mL orange juice and 3 slices of bread, each spread with 5 g of the 
assigned experimental margarine and with 15 g jam. The subjects were allowed to 
choose between tea and decaffeinated coffee and were free to add milk or sugar. Breath 
samples were collected at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, and 9 hours after tracer 
intake and stored at room temperature for later analysis. VC0 2 production was 
measured before a breath sample was taken. About 5 after tracer intake, the subjects 
received a lunch. At day 19 of the run-in period, their meal consisted of bread spread 
with experimental control margarine as well as experimental and nonexperimental food 
items according to their choice. The amount and type of the food items had to meet their 
individual dietary guidelines. All food items and beverages that were consumed on 
day 19 were weighed and recorded. At day 61 of the experimental period, the subjects 
were provided with an identical lunch that included the assigned spread and 
experimental products. 
For the 8 d after the tracer oxidation test, the subjects took 20 mg [U-13C]ALA 
per day: one capsule at 8 a.m. and one at 8 p.m. Tracer capsules for the next days were 
provided after blood sampling. Fasting blood samples were further collected at 48, 96, 
168, 192, and 216 h, which corresponded with days 21, 23, 26, 27 and 28 of the run-in 
period and days 63, 65, 68, 69 and 70 of the experimental period. 
Blood was sampled by venipuncture with a 0.9 x 38 mm needle (PrecisionGlide; 
Becton Dickinson Vacutainer System, Plymouth, UK) under minimal stasis with the 
subject in recumbent position. Blood was collected in EDTA-containing tubes, which 
were kept on ice before and after blood sampling. Plasma was obtained within 1 h after 
blood sampling by centrifugation of the EDTA-coated tubes for 30 min at 4 ° C and 
2000 x g, Aliquots from the midportion of plasma were taken and snap frozen in liquid 
nitrogen. Plasma was stored at -80 °C until analyzed for fatty acid composition and the 
n-3 fatty acid enrichment of the plasma phospholipids. 
Sample ana lys i s 
Total lipids were first extracted from plasma by means of a modified procedure of the 
Folch method with 2-dinonadecanoyl phosphatidylcholine (PC[C19:0]2) as an internal 
standard [14]. Subsequently, phospholipids were isolated from the total lipid extract on 
an Extract-Clean NH2-aminopropylsilyl column (500 mg, 4.0 mL; Alltech Associates 
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Inc, Deerfield, IL) and where then hydrolyzed and methylated into their corresponding 
fatty acid methyl esters [15, 16], The obtained fatty acid methyl esters were then 
separated and quantified on a gas chromatograph-flame ionization detector (GC/FID, 
Perkin Elmer Autosystem, Norwalk, Connecticut, USA). 
As described earlier in detail [7, 17], the l3C enrichments of the n-3 fatty acid 
methylesters from plasma phospholipids were analyzed on a gas 
chromatograph-combustion-isotope ratio mass spectrometer (GC combustion-IRMS, 
Finnigan MAT 252, Bremen, Germany). The ,3C/12C ratio of expired C02 was 
determined on a chromatograph-isotope ratio mass spectrometer fGC-IRMS, Finnigan 
MAT 252) using a coating PoraPLOT Q column (25 m x 0.32 mm, Chrompack 
International, Varian, California, USA). Helium was used as earner gas, C02 was used 
as the reference gas, and the injector and column temperature were both 40 °C. 
All plasma and breath samples from one subject were analyzed in a single run, at the 
e n d o f t h e t r i a l . 
Quant i f i ca t ion of n-3 fatty acid metabo l i sm 
The 13C enrichments of the breath samples as well as the plasma phospholipid-derived 
fatty acid methyl esters were expressed as tracer-to-tracee ratio's (TTRs). 
The percentage of [U-13C] ALA tracer that was recovered as l3C in expired breath during 
the first 9 h after tracer intake, was calculated from the TTR in breath and VC02 
production [7, 18]. The above background concentrations of the tracer and tracee n-3 
fatty acids in plasma phospholipids were calculated as described elsewhere [17]. 
As recently described in detail [17], a compartmental model (Figure 1) was 
derived by using the SAAM II version 1.2 software package (SAAM Institute Inc., 
Seattle, WA, USA) to quantify the hepatic conversion of n-3 fatty acids. For each 
individual, this model was applied to the tracer and tracee data from both the run-in and 
the experimental periods, by using PopKinetics software (SAAM Institute Inc, Seattle, 
WA, USA) [17]. Briefly, the 13C-labeled n-3 fatty acid data were first incorporated into a 
compartmental tracer model to estimate transfer rate coefficients [k(ij) and k(0,j)]. 
These kinetic parameters were then implemented into a compartmental tracee model 
(Figure 1) to estimate simultaneously with dietary intakes of ALA and unlabeled (or 
1 ^  
"C-labeled) n-3 fatty acids, the fractions of dietary ALA incorporated into plasma 
phospholipids and subsequently converted into EPA, DPA, and DHA, 
The compartmental models considered the liver as the principal site for n-3 conversion. 
Furthermore, it was assumed that de novo generated n-3 long-chain fatty acids, as well 
as their dietary precursor ALA, were assembled in plasma phospholipids. Phospholipids 
were chosen as the modeling framework instead of plasma total lipids, because the latter 
also consists of lipid fractions that contain only negligible amounts of n-3 LCPUFAS or 
do not represent hepatic conversion. The tracee n-3 fatty acid concentrations in plasma 
phospholipids were stable over time at the end of the run-in period and at the end of the 
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experimental period, as determined by repeated-measures analysis of variance (data not 
shown). The modeling assumptions, the limitations, and the advantages of the model 
that was used to estimate the kinetic parameters have already been described and 
discussed in detail [17]. 
i i 
Figure 1 
Compartments I tracee model for the conversion of n-3 fatty acids 
The circles symbolize the compartments, whereas the rectangular delay boxes represent the delayed passage 
of n-3 fatty acids between compartments. The first compartment (Q5) represents the stomach, whereas dietary 
ALA intake is given as U(5). The compartments Q l , Q2, Q3, and Q4 correspond to, respectively, the masses 
(pmol) of unlabeled a-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and 
docosahexaenoic acid (DMA) in plasma phospholipids. The arrows reflect the flow of fatty acids. The k ( i j ) 
parameters are the transfer rate coefficients, which represents the fraction of fatty acids that is transferred per 
unit of time (h-1) from compartment j to i. Similarly, k(0 j ) equals the fraction of fatty acids that is irreversibly 
lost per unit of time (h"1) from compartment j. The flux(ij) denotes the flow of mass per unit of time (|imol/h) 
from compartment j to i. The flux(i j ) is derived by multiplying the mass of compartment j by the transfer rate 
coefficient k(i j) . Comparably, the flux(Oj) represents the outflow of mass from compartment j. The 
parameters U(2), U(3), and U(4) represent the endogenous inflow (|imol/h) of EPA, DPA, and DHA, 
respectively, from endogenous sources other than plasma phospholipids. Reprinted with permission from 
reference (17). 
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Linoleic acid (% of energy) 
a-Unolenic acid (% of energy) 
ALA: LA 
Effect of increased ALA:LA 
achieved by decreasing LA 
Effect of increased ALA:LA 
achieved by increasing ALA 
Effect of A L A U 
Figure 2 
Interpretation of the effects of the absolute amounts of dietary a-linolenic acid (ALA), linoleic acid (LA), and 
their ratio in the control group, the low LA group, and the high ALA group 
The present study was specifically designed to disentangle the effects of the ALA to LA ratio from those of 
the absolute amounts of ALA and LA in the diet on the metabolism of ALA. The following comparisons can 
be made: I) Differences between the low LA group and the control group are due to the decreased intake of 
LA or the increase in the ALA to LA ratio, 2) Differences between the high ALA group and the control group 
are due to the increased intake of ALA or the increase in the ALA to LA ratio. 3) If the effects of the low LA 
group and the high ALA group are the same, and at the same time differ from those in the control group, these 
effects are due to the increase in the ALA to LA ratio. 
Sta t i s t ica l analys is 
Results are expressed as mean ± SD. The possible comparisons that can be made 
between the 3 study groups to disentangle the effects of the absolute amounts of dietary 
ALA, LA and their ratio on metabolism of ALA are depicted in Figure 2. Responses to 
the experimental diets were calculated for each subject by subtracting the value of a 
parameter obtained at the end of the run-in period from the value obtained at the end of 
the experimental period. The effects of the diets were examined with analysis of 
variance by using the General Linear Models (GLM) procedure in SAS (SAS System 
release 8.2; SAS Institute Inc., Cary, NC, USA). The response to the experimental diet 
was defined as the dependent variable and dietary group was a fixed factor. When 
significant differences were found (P value < 0.05), a Tukey post hoc test was used to 
make pairwise comparisons of the diets. Although the statistical power may have been 
too low, additional analyses were performed to see whether dietary effects were 
modified by gender, use of oral contraceptives, or smoking. For this, analyses were 
repeated by including the interaction term between diet and these factors into the model. 
Control Low-LA High-ALA 
group group group 
7 3 7 
0.4 0.4 1.1 
1:19 1:7 1:7 
t i 
t 
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These interactions terms, however, never reached statistical significance (results not 
shown). 
R E S U L T S 
Body we igh t and f a t t y acid c o m p o s i t i o n of p l a s m a p h o s p h o l i p i d s 
Changes in body weight during the experimental period were minor: 0.0 ± 0.6 kg for the 
control group, -0.4 ± 1.1 kg for the Low LA group, and -0.1 ± 1.0 kg for the high ALA 
group (P = 0.612 for difference in changes between the groups). Compliance with the 
diets was confirmed by the changes in the fatty acid compositions of plasma 
phospholipids (Table 1). As opposed to the control and the high ALA diets, the 
proportion of monounsaturated fatty acids (MUFAs) in the low LA diet was increased at 
the expense of the proportion of LA (P < 0.001 vs. control group, P < 0.001 vs. high 
ALA group). Consumption of the low LA and the high ALA diets both raised the 
proportions of ALA (LA group: P = 0.001, ALA group: P < 0.001) and EPA (LA group: 
P < 0,001, ALA group: P < 0.001) compared with the control diet. DPA was 
significantly higher after consumption of the high ALA diet than after consumption of 
the low LA diet (P = 0.016). Changes in DBA were not significantly different between 
the 3 study groups. 
O x i d a t i o n 
During the run-in period, the proportion of tracer that was recovered in breath, 9 h after 
tracer ingestion, was 19 % for the control group, 18 % for the low LA group and 21 % 
for the high ALA group (Table 2), After the experimental period, changes in tracer 
recovery were not significantly different between the 3 groups. 
Steady s t a t e c o m p a r t m e n t a l masses 
The steady state compartmental masses (Qi) presented in Table 3 were obtained by 
multiplying the tracee n-3 fatty acid concentrations (jamol/L), which were measured in 
plasma phospholipids, by plasma volume. The latter was assumed to be 4.5 % of body 
weight [19]. Compared with the control diet, the low LA diet and the high ALA diet both 
raised the amount of unlabeled ALA and EPA in plasma phospholipids (all P < 0.01). 
The increases in ALA and EPA, however, were not significantly different between these 
2 experimental diets. The changes in the masses of unlabeled DPA and DHA did not 
differ significantly between the 3 study diets 
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Table 1 
Effect of the control diet, the low linoleic acid (LA) diet and the high a-iinolenic acid (ALA) diet on the fatty acid composition of plasma phospholipids 
in healthy humans 1 
Control group Low LA group High ALA group 
n = 9 n = 10 n = 10 
Run-in period Change2 Run-in period Change2 Run-in period Change2 
% of total fatty acids 
Saturated fatty acids 44.7 ± 1.1 0.5 ± 0.4 45.1 ± 1.3 -0.4 ± 1.1 45.1 ± 0.8 -0.4 ± 0.8 
Monounsaturated fatty acids 12.7 ± 0.5 0.1 ± 0.6 a 13.1 ± 0.8 3.5 ± 0.7 b 12.9 « 0.9 0.1 ± 0.5 a 
OA: C18:ln-9 8.1 ± 0.6 0.2 ± 0.6 a 8.4 ± 0.8 3.1 ± 0.6 b 8.1 0.4 -0.2 ± 0.5 a 
Polyunsaturated fatty acids 4L7 ± 1.1 -0.5 ± 0.7 a 41.1 f L2 -3.0 ± 0.9 b 41.2 ± 0.6 0.3 » It 0.9 J 
n-6 Fattv acids + 37.1 ± 1.2 -0.3 ± 0.9a 36.6 ± 1.4 -3.4 ± 1.1 b 36.2 ± L0 0.1 ± 0.9 a 
LA: C18:2n-6 22.7 ± 1.8 -0.6 ± 1.2 a 21.6 r 2.5 -2.2 ± 1.3 b 22.1 ± 2.8 0.3 » 0.6a 
AA: C20:4n-6 9.5 ± L4 0.03 ± 0.6 10.0 ± 0.8 -0.96 ± 1.58 9.0 ± 1.96 -0.00 - i . 1.08 
n-3 Fattv acids 4.5 ± 0.5 -0.19 ± 0.35 a 4.3 ± 0.3 0.28 ± 0.21 b 4.9 ± 0.9 0.27 ± 0.34 
ALA: C18:3n-3 0.15 ± 0.04 0.01 — 0.04a 0.15 - < - 0.05 0.10 _U 0.04 b 0.18 ± 0.05 0.11 ± 0.06 
EPA: C20:5n-3 0.58 ± 0-15 0.02 ± 0.04a 0.55 ± 0.21 0.29 0.12 b 0.66 ± 0.21 0.20 ± 0.07 
DPA: C22:5n-3 0.80 ± 0.22 0.03 t 0.07 a"b 0.86 ± 0.23 0.02 ± 0.07 3 0.84 ± 0.17 0.12 ± 0.09 
DHA: C22:6n-3 2.9 ± 0.4 -0.25 ± 0.33 2.6 ± 0.3 -0.13 ± 0.13 3.1 ± 0.73 -0.15 ± 0.26 
Trans fatty acids 0.84 ± 0.10 -0.11 ± 0.10 0.76 ± 0.20 -0.07 > 0.13 0.74 ± 0.19 -0.03 ± 0.12 
OA, oleic acid; AA, arachidonic acid; EPA eicosapentaenoic acid; DP A, docosapentaenoic acid; DHA, docosahexaenoic acid. 
1 All values are means ± SD. Values at the end of the run-in period did not differ significantly between the 3 diet groups (ANOVA with the run-in values as the 
dependent variables and dietary group as a fixed factor). Adapted with permission from Journal of Nutrition (11). 
" Diet effects were analyzed by ANOVA with the change to the diet as the dependent variable and the dietary group as a fixed factor. Values in a row with different 
superscript letters are significantly different, P < 0.05 (Tukey post-hoc tests for pairwise comparisons). 
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ive l3C recovery in breath carbon dioxide as a percentage of [U- ,3C] a-linolenic acid (ALA) 
Dllected over a period of 9 h after tracer intake, for the control group, the low linoleic acid (LA) 
id the high ALA group 1 
Control group Low LA group High ALA group 
n = 9 n = 10 n = 10 
% 
eriod 19.2 ± 2.4 17.8 ± 5.4 20.7 ± 2.1 
ental period 15.7 ± 3.1 15.4 ± 3.4 17.4 ± 3.5 j r -3.5 ± 2.6 -2.5 ± 3.9 -3.3 ± 3.3 
lues are means ± SD. Values at the end of the run-in period did not differ significantly 
n the 3 diet groups (ANOVA with the run-in values as the dependent variables and dietary group 
:ed factor). 
Yects were analyzed by ANOVA with the change to the diet as the dependent variable and the 
group as a fixed factor. There were no significant differences in response to the diet. 
tale masses of the n-3 fatty acids in plasma phospholipids for the control group, the low linoleic 
.) group, and the high a-linolenic acid (ALA) group 1 
Control group Low LA group High ALA group 
n - 9 n = 1 0 n = 10 
pmol 
n period 22 =b 8 25 ± 7 31 ± 7 
ie " 2 ± 2 " 14 ± 5 h 20 ± 10 b 
n period 83 ± 29 89 ± 39 104 ± 40 •y 
Se- 3 ± 811 42 ± 18 b 3 ^  ± 25 b 
ri period 102 ± 37 119 ± 34 119 ± 35 f Zfi ' 5 ± 7 4 
± 
11 14 ± 24 
n period 365 62 369 ± 79 455 ± 128 
xe' -33 31 -17 ± 23 -52 53 
iicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 
Lies are means ± SD. Values at the end of the run-in period did not differ significantly between the 
groups (ANOVA with the run-in values as the dependent variables and dietary group as a fixed » 
ffects were analyzed by ANOVA with the change to the diet as the dependent variable and the 
' group as a fixed factor. Values in a row with different superscript letters are significantly 
nt, P < 0.05 (Tukey post- hoc tests for pairwise comparisons). 
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Rate c o e f f i c i e n t s , endogenous inputs and f luxes 
The effects of the diets on the rate coefficients, endogenous inputs, and fluxes are 
shown in Table 4. 
Table 4 
Kinetic parameters for the control group, the low linoleic acid (LA) group, and the high a - l ino len ic a c i d (ALA) 
group, estimated by compartmcntal modeling of ALA conversion 1 
Control g roup 
n = 9 
Low LA group 
n = 10 
High A L A group 
n ~ 10 
Rate constant k(i.j), h"1 
d(ALA, delay) or d( 1,6) 
Run-in per iod" 0 .07075 ± 0.04 a 0.06325 ± 0 . 0 2 a 0 . 0 9 6 9 9 ± 0.03 h 
Change 0.01373 ± 0,01 a 0.05209 ± 0.03 b - 0 . 0 6 6 0 7 i 0.03 c 
k(EPA, A L A ) or k (2 , l ) 
Run-in per iod" 0.48701 ± 0.15 a 0.42549 ± 0.06 a 0 . 5 4 3 2 3 ± 0.08 h 
Change 0.03445 ± 0 . 0 6 a 0.03181 ± 0 . 0 7 3 - 0 . 2 0 4 6 2 ± 0 . 1 0 b 
k(DHA, A L A ) or k (4 , l ) 
Run-in period 0 ,00054 ± 0.00 0.00078 ± 0.00 0 . 0 0 1 4 0 ± 0.00 
Change 0 .00048 ± 0.00 -0.00042 ± 0.00 - 0 . 0 0 0 3 6 i 0.00 
k( delay, EPA) or k(7,2) 
Run-in pe r iod" 0 .00492 ± 0 . 0 0 a 0.00598 ± 0 . 0 0 3 0 . 0 0 4 3 6 ± 0.00 b 
Change -0 .00029 ± 0 . 0 0 a -0.00216 ± 0.00 b 0 . 0 0 1 5 6 ± 0.00 c 
k(DHA, D P A ) or k(4,3) 
Run-in per iod 0 .00776 ± 0.00 0.00689 ± 0.00 0 ,00715 ± 0.01 
Change -0 .00028 ± 0.00 -0.00032 ± 0.00 - 0 . 0 0 0 5 2 ± 0,01 
Irreversible loss k ( 0 j ) , h*1 
d(loss f rom delay) or d(0,6) 
Run-in pe r iod" 0 .92925 ± 0.04 3 0.93675 ± 0.02 a 0 .90301 ± 0.03 b 
Change -0 .01373 ± 0.01 a -0 .05209 ± 0.03 b 0 . 0 6 6 0 7 ± 0.03 c 
k(loss f rom EPA pool) or k(0,2) 
Run-in pe r iod" 0 .49213 ± 0.10 a 0.46284 ± 0.13 a ,b 0 .74712 ± 0.32 c 
Change 0 .04088 ± 0.11 a 0.06522 ± 0.15 a -0 .35337 ± 0.22 b 
k(loss f rom D H A pool) or k(0,4) 
Run-in period 0 .01786 ± 0 .02 0.02042 ± 0.02 0 .02736 ± 0.05 
Change -0 .00093 ± 0 ,02 -0.00577 ± 0.01 - 0 . 0 1 4 5 8 ± 0.04 
Dietary A L A intake or U{5), ^mol /h 
Run-in period 160 ± 18 172 ± 17 174 ± 19 
Change 1 ± 7 a -10 ± 8 a 3 7 3 zh 38 b 
Endogenous input Hi, pmol/h 
U(EPA) or U(2) 
Run-in pe r iod" 31 ± 13 a 2 8 ± 1 0 a 53 ± 20 b 
Change 4 ± 9 a 20 ± 1 3 a - 2 0 i 20 h 
U(DPA) or U ( 3 ) 
Run-in period 0 ± 0 0 ± 0 0 ± 1 
Cliange 0 ± 0 0 ± 0 - 0 ± 0 
U(DHA) or U ( 4 ) 
Run-in period 6 ± 6 7 ± 7 12 ± 24 
Change -1 ± 7 -2 ± 5 - 8 ± 23 
60 
E f f e c t of A L A , L A , arid t h e i r r a t i o o n A L A c o n v e r s i o n 
Table 4 Continued 
Control group Low LA group High ALA group 
n = 9 n = 10 11= 10 
Flux(iJ), fimol/h 
Flux{delay, stomach) or Flux(6,5) 
Run-in period 160.04 ± 17.94 172.42 ± 17.21 173.67 ± 19.22 
Change 0.86 ± 6.97 a -10.08 ± 8.10 a 372.62 ± 38.12 b 
Flux(ALA, delay) or Flux(l,6) 
Run-in period" 11.16 ± 5.38 !l 10.79 ± 3.72 a 16.65 ± 4.88 h 
Change 2.09 £ 1.65 n 7.23 ± 3.95 b 0.29 ± 5.01 a 
Flux(loss from delay) or Flux(0,6) 
Run-in period 148.88 ± 18.85 161.63 ± 17.75 157.03 ± 19.79 
Change -1.23 ± 7.96 3 -17.31 ± 9.98 a 372.34 ± 37.11 b 
Flux(EPA, ALA) or FIux(2,l) 
Run-in period ~ 11.14 ± 5.38 a 10.76 ± 3.71 a 16.60 ± 4 . 8 8 b 
Change 2.08 ± 1.66s 7.23 ± 3.96 b 0.28 ± 4.97 " 
Flux(DHA, ALA) or Flux(4,l) 
Run-in period 0.01 ± 0.01 0.02 ± 0.01 0.04 ± 0.08 
Change 0.01 ± 0.02 -0.01 ± 0.01 0.01 ± 0.09 
Flux(Ioss from EPA) or Flux(0,2) 
38.05 ± 12.58 a'b Run-in period " 41.70 ± 18.43 a 69.26 ± 22.73 c 
Change 5,94 ± 10.77* 27.52 ± 15.43 h -19.78 ± 24.69 c 
Flux(delay, EPA) - Flux (DPA, delay) or 
Flux(7,2) = Flux(3,7) 
Run-in period 0.40 ± 0,17 0.54 ± 0.26 0.44 ± 0.17 
Change -0.01 ± 0,10 a -0.04 ± 0.20 a 0.36 ± 0.23 h 
Flux(DHA, DPA) or F1ux(4,3) 
Run-in period 0.72 rk 0.38 0.77 ± 0.45 0.81 ± 0.62 
Change 0.00 i 0.47 0.01 ± 0.28 0.02 ± 0.6) 
Flux(loss from DMA) or Flux(0,4) 
Run-in period 6.76 + 6.18 7.44 ± 7.71 13.29 ± 24.78 
Change -1.08 ± 7.68 -2.26 ±5.10 -8.34 ± 23.74 
BP A, cicosapentaenoic acid; DP A, docosapentaenoic acid; DMA, docosahexaenoic acid. 
1 All values are means ± SD. Variables with no change: k(6,5) =* 2, d(3,7) = 1, k{0,l) « 0, k{0,3) = 0, 
Flux(0,l) = 0, Flux{0,3) = 0. Diet effects were analyzed by ANOVA with the change to the diet as the 
dependent variable and the dietary group as a fixed factor. Values in a row with different superscript letters are 
significantly different, P < 0.05 (Tukey post-hoc tests for pairwise comparisons). 
2 Differences in run-in values between the 3 groups were analyzed by ANOVA with the value at the end of 
the run-in period as the dependent variable and dietary group as fixed factor. Values in a row with 
different superscript letters are significantly different, P < 0.05 (Tukey post-hoc tests for pairwise 
comparisons). Analysis of covariance with the value at the end of the experimental period as the 
dependent variable, the value at the end of the run-in period as the covariate, and diet as a fixed factor did 
not change the conclusions with regard to the diet effects. 
Effects of diets on rate coefficients 
The transfer rate coefficients k(i,j) represent the fraction of substrate that is transferred 
per unit of time (If1) from compartment j to i, whereas k(0j) equals the fraction of 
substrate per unit of time (IV1) that is irreversibly lost from compartment j (Figure 1). 
The latter represents the outflow of n-3 fatty acids that during the time frame of the 
tracer experiment does not return to plasma phospholipids. Examples of irreversible 
losses are the oxidation of a fatty acid and the loss of fatty acids into fat tissue or cell 
membranes. 
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Compared with the control diet, the fraction of dietary ALA [d(l,6)] that was 
incorporated into the plasma phospholipid pool (ALA compartment = Ql) per hour 
increased after the low LA diet (P - 0.012), whereas the fraction of dietary ALA that 
was not incorporated per hour [d(G,6)] decreased. After consumption of the high ALA 
diet, however, the fraction of dietary ALA incorporated into ALA plasma phospholipids 
per hour decreased significantly compared with both the control diet (P < 0.001) and the 
low LA diet (P < 0.001). Once incorporated into the plasma phospholipid pool, the 
fraction of ALA that was converted into EPA per hour [k(2,l)] was significantly lower 
after consumption of the high ALA diet than after both the control diet (P < 0.001) and 
the low LA diet (P < 0.001). Also, the fraction of EPA that entered the delay 
compartment per hour [k(7,2)J was significantly lower after the low LA diet than after 
the control diet (P = 0.005). In contrast, it was higher after consumption of the high 
ALA diet than after both the control diet (P = 0.005) and the low LA diet (P < 0.001). 
furthermore, the fraction of EPA that disappeared from the plasma phospholipid pool 
per hour [k(0,2)] declined significantly after consumption of the high ALA diet 
(P < 0.001 vs. control, P < 0.001 vs. low LA). The other rate coefficients were not 
significantly changed by the experimental diets. 
Effects of diets on endogenous inputs 
Except for U(5), which represents the intake of dietary ALA, the endogenous input U(i) 
corresponds with the inflow of tracee fatty acids into compartment i from endogenous 
sources other than plasma phospholipids. It represents the inflow of n-3 fatty acids into 
the plasma phospholipids pool that did not originate from dietary ALA consumed 
during the time frame of the tracer experiment. Examples of endogenous sources 
include inputs of n-3 fatty acids into plasma phospholipids that were consumed before 
the tracer experiment and released from adipose tissue, from lipid bilayers, or from lipid 
fractions other than plasma phospholipids. 
Because of the dietary manipulations, dietary intake of ALA [U(5)] was not 
significantly different between the control and the low LA group, whereas it was about 
3 times higher in the high ALA group. The endogenous input into the EPA 
compartment [U(2)] rose in the high ALA group (P - 0.006 vs. control group, P < 0.001 
vs. low LA group). The inputs into the DPA and DHA compartment did not differ 
significantly between the experimental groups. 
Effects of diets on fluxes 
The flux(ij), which is derived by multiplying the mass of compartment j by the transfer 
rate coefficient k(i,j), represents the flow of unlabeled fatty acids per unit of time 
(jimol/h) from compartment j to i. Likewise, the flux(Oj) represents the outflow of 
unlabeled fatty acids from compartment j. 
The flow of dietary ALA which did not enter the plasma phospholipids 
compartment [flux(0,6)] was significantly higher with the high ALA diet (P < 0.001 vs. 
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control diet, P < 0.001 vs. low LA diet). The flow of dietary ALA into the ALA plasma 
phospholipid compartment [flux(l,6)] and the flow from the ALA into the EPA 
(flux(2,l)) compartment, were higher after consumption of the low LA diet. 
The outflow from the EPA compartment [flux(0,2)] was significantly increased in the 
low LA group (P — 0.040 vs. control group), whereas it was significantly decreased in 
the high ALA group (P = 0.013 vs. control group, P < 0.001 vs. low LA group). 
However, in the high ALA group there was a significant rise in the flow from the EPA 
into the DP A compartment [flux (7,2); P < 0.001 vs. control group, P < 0.001 vs. low 
LA group]. 
The p e r c e n t a g e and abso lu t e amounts of A L A i n c o r p o r a t i o n and n -3 
fa t ty acid c o n v e r s i o n 
During the run-in period, 7.1 %, 6.3 %, and 9.7 % of the dietary ALA intake was 
incorporated into plasma phospholipids for the control, low LA, and high ALA groups, 
respectively (Table 5). After the low LA diet, the percentage of dietary ALA 
incorporated into the ALA plasma phospholipid compartment was significantly 
increased by 4 % compared with the control diet (P = 0.012). In contrast, consumption 
of the high ALA diet significantly decreased the incorporation by 8 % and 12% 
compared with the control diet (P < 0.001) and the low LA diet (P < 0.001), 
respectively. Expressed in absolute amounts (mg/d), calculated by multiplying the 
fractional rate constant d(l,6) by the amount of ALA consumed (mg/d), it was found 
that incorporation of dietary ALA into plasma phospholipids was higher with the low 
LA diet than with both the control and the high ALA diets (P = 0.020 vs. control group, 
P = 0.001 vs. high ALA group). In this respect, no significant differences were found 
between the control and high ALA groups. During the run-in period, 99.9 % of ALA 
from the phospholipid pool was converted into EPA in the control group, 99.8 % in the 
low LA group, and 99.7 % on the high ALA group (data not shown). Thus, 7.1 %, 
6.3 %, and 9.7 % of ALA intake was converted into EPA during the run-in period in the 
control, low LA and high ALA groups, respectively. When compared with the control 
diet, the change in the percentage of dietary ALA that was converted from ALA into 
EPA increased significantly after the low LA diet (P - 0.012), whereas it decreased after 
the high ALA diet (P < 0.001). This change was also significantly different between the 
low LA and high ALA diets (P < 0.001). The change in the percentage of dietary ALA 
intake that was converted from EPA via DPA into DHA was not significantly different 
after consumption of the 3 diets. The absolute amount of EPA in plasma phospholipids 
that was derived from dietary ALA increased after the low LA diet (P = 0.019), whereas 
it hardly changed after consumption of the high ALA diet. The change in the absolute 
amount of newly formed DHA did not differ significantly between the control and the 
low LA diet, whereas it increased significantly after the high ALA diet (P <0.001 vs. 
control diet, P < 0.001 vs. low LA diet). 
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Table 5 . 
Uptake of dietary u-linolenic acid (ALA) into plasma phospholipids and subsequent conversion into its n-3 (ally acid 
derivatives expressed in percentages and absolute amounts for the control group, the low iinolcic acid (LA) group, and the 
high a-linalemc acid group 1 
Control group 
n = 9 
Low LA group 
n= 10 
High ALA group 
i i - 10 
Dietary ALA intake (mg/d) 
115 1160 128 k Run-in period 1069 ± 120 1151 ± 
± 
• 
Change 6 47 a -67 ± 5 4 n ' 2488 i 255
 h 
Incorporation into ALA compartment (%) 
6.3 9.7 Run-in period 2 7.1 ± 3.6" ± i V aa i. ± 3.1 
Change 1.4 ± 1.2" 5 ± 3.4 -6.6 ± 2.8 ' 
Incorporation into ALA compartment (mg) 
Run-in period 2 74.5 ± 35.9 a 72.0 ± 24.8 rt'h 1 U . I i 32.6 c 
Change 13,9 ± 11.0 8 48.3 ± 26.4 11 1.9 ± 3 3.411 
Percentage of dietary ALA converted 
ALA EPA 
Run-in period " 7.1 ± 3.6 * 6.3 ± L 9.7 ± 3,1
 b 
Change 1.4 ± 1.2" 5 *> 3.4 h -6.6 ± 2.8 c 
ALA — DHA 
Run-in period 0.01 ± 0.0 0.01 ± 0.0 0.03 0.1 
Change 0.01 ± 0.0 -0.00 ± 0.0 -0.02 i 0.1 
ALA EPA DPA DMA 
Run-in period 0.06 ± 0.0 0,09 ± O.l 0.06 0.0 
Change 0.00 ± 0.0 -0.01 ± 0,0 -0.01 ± 0.0 
Absolute amount (mg) of dietary ALA converted 
ALA -> EPA 
24.8 n ' b Run-in period" 74.4 i 35.9 11 71.9 ± 110.9 32.6 c 
Change 13,9 ± i u n 48.3 ± 26.411 1.9 ± 33.2 " 
ALA —> DHA 
Run-in period 0.07 ± 0.0 0,13 ± 0.1 0,28 0.5 
Change 0.06 ± 0.1 -0.04 ± 0.1 0.05 0.6 
ALA EPA DPA DHA 
Run-in period 0,7 ± 0.3 1.0 ± 0.5 0.7 i 0.4 
Change 0.03 ± 0.2" -0.1 ± 0.5" 1.2 0.9 h 
EPA, cicosapentaenoic acid; DPA, docosapentaenoic acid; DMA, docosahexaenoic acid. 
1 All values are means ± SD. Diet effects were analyzed by analysis of variance with the change to the diet as the 
dependent variable and the dietary group as a fixed factor. Values in a row with different superscript letters are 
significantly different, P < 0.05 (Tukey post-hoc tests for pairwise comparisons). 
' Differences in run-in values between the three goups were analyzed by analysis of variance with the value at the end 
of the run-in period as dependent variable and dietary group as fixed the tor, Values in a row with different 
superscript letters arc significantly different, P < 0.05 f l u k e y post-hoc tests for pairwise comparisons). Analysis of 
covariance with the value at the end of the experimental period as dependent variable, the value at the end of the run-in 
period as the eovariate, and diet as a fixed factor did not change conclusions with regard to the diet efforts. 
D I S C U S S I O N 
In the present study, we showed that conversion of ALA into its longer and more 
unsaturated fatty acid derivatives is not determined by the ALA to LA ratio but by the 
amounts of ALA or LA in the diet. Decreasing the intake of LA increased the 
proportion of dietary ALA that was converted into EPA. On the other hand, increasing 
ALA intake increased the absolute amount of DHA synthesized. 
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Several human intervention studies have reported that increasing the intake of 
ALA or decreasing the intake of LA increased the proportions of ALA and EPA, 
whereas it does not, or only marginally, changes the proportion of DHA in plasma lipid 
fractions [8, 20-23]. In agreement with these observations, we found that the low LA and 
the high ALA diets increased the proportions of ALA and EPA in plasma phospholipids 
to the same extent, whereas proportions of DHA tended to decrease. The latter finding 
was also observed by others [23]. However, plasma steady-state fatty acid concentrations 
are actually a dynamic situation that is characterized by a continuous inflow and 
outflow of fatty acids, processes that can be quantified by the use of stable isotopes. 
Emken et al. were the first to initiate a tracer study to quantify the effects of a 
change in dietary LA intake on the conversion of ALA [6j. From measurements of 
enrichment in the total plasma lipid pool, those authors estimated that conversion of 
ALA into its LCPUFAs in young men was 18.5 % after a saturated fatty acid-rich diet 
that provided 4.7 % of energy as LA, 0.6 % of energy as ALA, with an ALA to LA ratio 
of 1:8. Estimates for the conversion of ALA into EPA from other stable isotope studies 
have varied between 0.2 % and 8 % [4]. We found that conversion following a control 
diet with a low ALA to LA ratio (7 % of energy as LA, 0.4 % of energy as ALA, ratio 
1:19) was on average 7.8 %. As discussed before [4, 17, 24 ,25] , a part of the variation in 
outcomes between various studies is due to differences in experimental approaches, 
such as the analytical method used to quantify ALA metabolism, the type of lipid 
fraction chosen to reflect hepatic conversion, and the mode of tracer administration. 
Another part of this variation, however, is due to differences in the fatty acid 
composition of the diets. Indeed, Emken et al. reported that the conversion of .AL.A. 
decreased from 18.5 % to 11 %, when LA intake increased from 4.7 % of energy to 
9.3 % of energy and ALA intake decreased from 0.6 % of energy to 0.3 % of energy 
and the ALA to LA ratio changed from 1:8 to 1:31. This 40 % decrease in total n-3 
conversion was attributed to the increased intake of LA. However, the simultaneous 
change in both ALA intake and the ALA to LA ratio could have affected n-3 fatty acid 
biosynthesis as well. In other stable isotope studies, it was also not possible to 
disentangle the effects of ALA or LA from those of the ALA to LA ratio [5-9], We found 
that a decrease in the LA content of the diet increased the incorporation of dietary ALA 
into plasma phospholipids from 6.3 % to 11.5 % of ALA intake or from 72 mg to 
120 mg. Because almost all ALA from the plasma phospholipids pool was converted 
into EPA, synthesis of EPA increased to a comparable extent. Thus, our results confirm 
the general view that a high LA intake inhibits conversion of ALA [2, 3]. In contrast, 
when the amount of ALA in the diet increased from 0.4 % to 1.1 %, ALA incorporation 
into plasma phospholipids and the successive EPA synthesis decreased from 9 % to 3 % 
of ALA intake, whereas no changes were observed when expressed in absolute 
amounts. Furthermore, the present study confirms that synthesis of DHA in humans is 
extremely limited. Moreover, our tracer results indicate that conversion from EPA into 
DPA - a step that appears to be an additional constraint in the n-3 pathway [17] - is 
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affected differently after a low LA diet than after a high ALA diet. The change in the 
percentage of dietary ALA that was converted from EPA into DPA and further into 
DHA was comparable with the control diet, regardless of whether LA intake decreased 
or ALA intake increased. In contrast, expressed in absolute amounts of ALA intake, the 
synthesis of DPA and DHA hardly changed in the low LA group, whereas it increased 
significantly in the high ALA group. Hence, even though EPA synthesis increased after 
a low LA diet, most of this marine fatty acid was not available for conversion into 
longer and more unsaturated fatty acids. An increase in ALA intake had just the 
opposite effect; because more EPA was converted into DPA and DHA. 
It has been postulated that a high LA to ALA ratio inhibits conversion of n-3 
fatty acids independent of the absolute amounts of these fatty acids in the diet ft, 8]. 
If this were true, then the metabolic parameters of the low LA and the high ALA diet 
should have been the same in the present study, because both diets had the same ALA to 
LA ratio. Clearly, this was not the case. Hence, our findings show that dietary 
recommendations should not focus on the ALA to LA ratio in the diet, but should 
consider the individual amounts of dietary ALA and LA, Furthermore, our results 
support the concept presented by Sinclair et al [2], that a reduction in dietary LA 
together with an increase in ALA intake would be the most appropriate way to enhance 
EPA and DHA synthesis from their parent fatty acid ALA. However, it is also clear that 
this approach will not lead to substantial increases in plasma phospholipid DHA 
contents as can be obtained through a moderate consumption of fish or marine oils (U. 
This agrees with findings in vegetarians and vegans who have lower proportions of 
plasma EPA and DHA [26]. 
In line with other studies [ l , 2 ,5 , 6 ,9 ,27-31] , the present study shows that a major 
part of the ingested ALA is oxidized within 9 h after consumption. p-Oxidation in 
humans ranges between 16 % and 33 % of the ingested tracer dose, depending on the 
duration of sampling [31]. Our results fall within these ranges. Our data indicate that the 
percentage of ALA oxidation over a period of 9 h after tracer intake is not affected by of 
the absolute amounts of ALA or LA or the ALA to LA ratio of the diet. 
In conclusion, the present study shows that the dietary ALA to LA ratio is not a 
determinant of n-3 fatty acid conversion. An increase in EPA synthesis can be obtained 
by lowering the amount of LA in the diet, whereas an increase in DHA synthesis is 
achieved by increasing the amount of dietary ALA. The optimal dietary approach to 
increase n-3 LCPUFA is to consume them preformed. However, in individuals 
unwilling or unable to eat seafood, exchanging LA for ALA may be the next best 
approach. 
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CHAPTER 4 
Determinants of dietary a-linolenic acid conversion and 
oxidation in healthy humans 
Petra L. L. Goyens, Mary E. Spilker, Peter L. Zock, Martijn B. Katan, 
and Ronald P. Mensink 
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A B S T R A C T 
Background 
Human in vivo studies exploring determinants of a-linolenic acid (ALA; C18:3n-3) 
metabolism are scarce. 
Objective 
To explore whether gender, age, basal metabolic rate, body composition, and the 
proportion of linoleic acid (LA; C18:2n-6) and trans fatty acids in plasma phospholipids 
are related to ALA conversion and oxidation in healthy humans. 
Design 
For 28 days, 15 men, 8 premenopausal and 7 postmenopausal women consumed a diet 
providing 7 percent of energy from LA and 0.4 % from ALA. During the last 9 days, 
multiple oral boluses of [U-nC]ALA were given; 30 mg on day 19 and 10 mg twice 
daily for the next eight days. Under steady-state conditions, conversion of dietary ALA 
was estimated using compartmental modeling of l3C- and l2CMabeled n-3 fatty acid 
concentrations in fasting plasma phospholipids. Breath was sampled to estimate 
oxidation of [U-I3C]ALA. 
Results 
The proportion of DHA in plasma phospholipids was significantly higher in 
premenopausal women than in men (P = 0.012). Conversions of ALA into EPA and 
subsequently into DHA, as well as oxidation of ALA, were similar between men and 
pre- and postmenopausal women. A positive relation was observed between the 
conversion of ALA into EPA with age (P = 0.016) and percentage of body fat mass 
(P == 0.002). Conversion of EPA into DHA was negatively correlated with the 
proportion of LA in plasma phospholipids (P = 0.004). 
Conclusion 
Gender and reproductive status were in our study not related to ALA metabolism. 
Age and percentage fat mass were however positively associated with the conversion of 
dietary ALA into EPA. LA was negatively associated with the conversion of EPA 
into DHA. 
71 
C h a p t e r 4 
I N T R O D U C T I O N 
Eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DBA; C22:6n-3), 
two long-chain polyunsaturated fatty acids (LCPUFAs) of the n-3 family, can be 
obtained through consumption of fish oil, fish and seafood. Additionally, humans can 
form these marine fatty acids from a-linolenic acid (ALA; C18:3n-3), the essential 
parent omega-3 fatty acid from vegetable sources. EPA and DHA are important for 
human health because of their structural and functional role in cells and cell 
membranes [l, 2]. Their availability is for example particularly important during fetal 
development and neonatal growth, when considerable de novo synthesis of tissues 
occurs and the infant relies heavily on the maternal supply of EPA and DHA [l]. 
Furthermore, EPA and DHA can have favorable effects on cardiovascular risk [3,4] and 
may have a beneficial impact on for example depression, vision, psychiatric disorders 
and reumatoid arthritis [5-8]. 
Like any other fatty acid, dietary ALA can be oxidized immediately after intake, 
stored in tissues, or converted into longer and more unsaturated fatty acids [9-12]. Stable 
isotope studies [2, 13-16] have now estimated that within 9 to 48 hours, approximately 
16-33 % of the ingested ALA tracer is oxidized, whereas conversion of ALA into its 
LCPUFAs is approximately 8 % [14, 17, 18]. Interestingly, women may have lower 
oxidation rates than men [2, 10, 14], whereas other findings suggest that conversion of 
ALA is higher in younger women than in men [2,14,19], 
Recently, we have performed a stable isotope study in healthy humans to 
estimate the conversion of n-3 fatty acids by means of compartmental modeling [18, 20]. 
In addition, oxidation of [U-UC]ALA was measured for 9 hours after the first bolus 
intake. In view of the recent reports on gender specific effects on ALA metabolism 
[2,14, 19, 21, 22], the primary aim of the present study was to examine if in our study 
estimates of ALA conversion and oxidation were related to gender. Secondly, we also 
studied relationships with age, basal metabolic rate, body composition, and the 
proportion of linoleic acid (LA; C18:2n-6) and trans fatty acids in plasma 
phospholipids, which may also be related to ALA metabolism [17 ,23,24] . 
M A T E R I A L A N D M E T H O D S 
Sub jec t s 
Thirty healthy participants, fifteen men and fifteen women from Maastricht and 
surrounding areas, completed the study. One male participant was excluded prior to 
analysis of the results due to gastro-intestinal complaints and related weight loss during 
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the study. The remaining 29 healthy participants did not use medication and had a stable 
body weight for at least 3 months preceding the study (< 3 kg weight gain or loss). 
Seven women were postmenopausal, and five out of the eight premenopausal women 
used oral contraceptives. Characteristics of the subjects at the end of the four-week 
run-in period are presented in Table 1. The study was approved by the Medical Ethics 
Committee of Maastricht University and written informed consent was obtained from 
each participant. 
Table 1 
Characteristics of the study population 1 
Premenopausal Postmenopausal 
Men Women women women 
n = 14 n - 15 n = 8 n - 7 
Age (y) 54 ± 12 46 ± 14 36 ± 12 58 ± 3.2 
Length (m) 1.78 ± 0.1 1.70 ± 0.1 1.72 ± 0.1 1.67 ± 0.0 
Weight (kg) 79.7 ± 9.4 67.4 ± 8.1 67.2 ± 6.5 67.8 ± 10 
Basal metabolic rate (kJ/min) 5.1 ± 0.4 4.1 ± 0.4 4.2 ± 0.2 3.9 0,4 
Fat mass (%) 22.2 ± 5.7 31.8 ± 6.5 30.1 ± 7.7 33.8 ± 4.7 
1 Values are means ± SD. 
Diet and s tudy des ign 
The diets and the design have been described in detail previously [25]. Briefly, the 
present tracer study was part of a larger dietary intervention trial that studied effects of 
polyunsaturated fatty acids on cardiovascular risk markers. For the present analysis, 
only data from the four-week run-in period were used, during which all subjects 
received the same control diet. This control diet was formulated at nine different energy 
levels that ranged between 7.5 MJ and 13.4 MJ, with 0.84 MJ difference between 
2 successive levels. Subjects were assigned to one of those energy levels, based on their 
habitual energy intake that was estimated at the start of the study with a 3-day food 
record and a Dutch food composition table [26], Body weight was recorded at each visit 
and subjects were assigned to another energy intake level, whenever weight differed 
more than 2 kg from body weight at trial entry. 
The control diet was targeted to provide 15 percent of energy (En%) protein, 
50 En% carbohydrates, and 35 En% total fat (13 En% saturated fatty acids, 13 En% 
monounsaturated fatty acids, 7 En% LA, and 0.4 En% ALA). Thus, the diet had an 
ALA:LA ratio of 1:19 and EPA and DHA intakes were less than 0.1 En% or < 350 mg. 
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These intakes were achieved through experimental products such as pies, cookies, cake 
and margarine, that were made from a fat that was especially produced by NIZO food 
research (Ede, The Netherlands) [25]. Depending on energy intake, the experimental 
products supplied provided 62-71 % of total fat intake or 22 - 25 En% of total energy. 
On a weekly basis, subjects received a specific amount of experimental products, 
depending on their assigned energy level. Additionally they were given strict written 
dietary guidelines with regard to the intake and preparation of other nonexperimental 
food items. Consumption of fish or seafood was not allowed during the entire study 
period. Body weight was monitored throughout the trial. Subjects were asked not to 
change the level of physical exercise, smoking habits, use of alcohol or oral 
contraceptives during their participation in the study. At the end of the fourth week, 
subjects had to weigh and record their food intake for two working days and one 
weekend day to estimate their energy and nutrient intakes [26]. 
Body composit ion 
On day 28, body composition was determined. First, body weight was measured on a 
digital scale (Sauter D7470, Ebingen, Germany) and height was measured using a wall-
mounted stadiometer (Seca, model 220, Hamburg, Germany). Body density was 
determined by underwater weighing [27]. Residual lung volume was estimated by 
helium dilution with a spirometer (Volugraph 2000, Mijnhardt, the Netherlands) at the 
moment of underwater weighing. Body composition was calculated according to the 
formula of Siri [28]. 
Tracer protocol , measurements and blood sampl ing 
Uniformly labeled [13C]ALA free fatty acid tracer ([U-l3C]ALA; Isotec Inc., 
Miamisburg, Ohio, USA) was diluted in olive oil and pipetted into capsules. Each 
capsule contained 10 mg tracer. Details of the study and methods have already been 
described extensively [is, 20]. 
Briefly, on day 19, after 18 days of eating the controlled diet, participants 
reported to the department after an overnight fast and abstinence from alcohol for 
24 hours. Basal metabolic rate (BMR) was measured for 45 minutes using a 
ventilated-hood system (Omnical, Maastricht University, the Netherlands). Energy 
expenditure (EE) was calculated from the measured VC02 and V02 values by means of 
the Weir equation [29]. Immediately after the BMR measurement, a breath sample and a 
blood sample were taken (t = 0 h) to measure the baseline ,3C/I2C ratio of expired C02 
and the baseline enrichment of 13C-labeled ALA, EPA, DP A and DHA in plasma 
phospholipids respectively. Thereafter, subjects received an oral bolus of 30 mg 
[U~13C]ALA, provided as 3 capsules and a standardized breakfast. 
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Subjects received a lunch, approximately 5 hours after tracer intake, which consisted of 
bread spread with experimental control margarine as well as experimental and 
non-experimental food items according to their preferences. The amount as well as the 
type of the food items met the individual's dietary guidelines. Breath samples were 
collected at 0.5, 1, 1 »5n 2-^  >3^  3^  5, 6, 7, 8 and 9 hours after tracer intake and stored at 
room temperature for later analysis. The VC02 production was measured before a 
breath sample was taken. 
For next 8 days, subjects were instructed to take 20 mg [U-13C]ALA daily, one 
10 mg-capsule at 8 a.m. and one at 8 p.m. Fasting blood was drawn in precooled EDTA 
tubes by venipuncture, on days 21 (t = 48 h after the first tracer administration), 
23 ( t - 96 h), 26 (t = 168 h), 27 (t = 192 h) and 28 (t - 216 h). Plasma was obtained by 
centrifugation of the EDTA tubes at 2000 x g, and stored at -80 °C until later analysis. 
A compartmental model, that was derived using the SAAMII version 
1.2 software package (SAAM Institute Inc., Seattle, USA), was used to quantify hepatic 
conversion of n-3 fatty acids [18]. This model was applied to the tracer and tracee 
four-week run-in data of each subject using the PopKinetics software (SAAM Institute 
Inc, Seattle, USA) [18]. 
S t a t i s t i c a l a n a l y s i s 
All variables followed a normal distribution. Results are expressed as mean ± SD. 
Differences between genders and between pre- and postmenopausal women were 
examined using unpaired t-tests. A two-tailed value of P < 0.05 was considered to be 
statistically significant. Nonparametric analysis of the effects of gender and 
reproductive status using Wilcoxon rank sum tests did not change conclusions (results 
not shown). Univariate and multiple linear regression analyses were performed with 
parameters of ALA conversion (% conversion of dietary ALA into EPA and to DHA) as 
dependent variables and subjects1 characteristics as independent variables. All analyses 
were performed using SAS (SAS System release 8.2; SAS Institute Inc., Cary, NC, 
USA). 
R E S U L T S 
Die t a ry in t ake and fa t ty acid compos i t ion of p l a s m a p h o s p h o l i p i d s 
The energy and macronutrient consumption of the study population are summarized in 
Table 2. As expected, energy intakes of premenopausal (P = 0.017) and 
postmenopausal women (P = 0.012) were lower than those of men. 
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The macronutrient composition of the diets did not differ significantly between men and 
women and between pre- and postmenopausal women. 
Table 2 
Mean daily energy and nutrient intakes of male and female subjects1 
Premenopausal Postmenopausal 
Men Women women women 
n = 14 n - 15 n = 8 n - 7 
Energy (MJ/d) 11.5 1.4 9.9 ± 1.0a 9,9 ± 1.0 b 9.8 ± 1.1c 
Protein (En%) 14.3 ± 1.7 15.0 ± 1.2 14.9 ± 0.9 15.1 ± 1.6 
Carbohydrates (En%) 49.6 ± 4.3 50.7 ± 3.5 51.1 ± 3.8 50.4 ± 3.4 
Fat (En%) 33.6 ± 3.1 33.0 ± 3.4 33.6 ± 3.8 32.5 ± 3.1 
SAFA (En%) 11.7 ± 1.3 11.1 ± 1.2 11.2 ± 13 l l . l ± 1.1 
MUFA (En%) 12.9 ± 1.5 12.6 ± 1.5 12.9 1.8 12.4 ± 1.2 
PUFA (En%) 7.8 ± 0.6 8.1 ± 0.8 8.3 ± 0.7 7.9 ± 0.7 
LA (En%) 7.2 ± 0.5 7.4 ± 0.7 7.6 ± 0.7 7.2 ± 0.7 
ALA (En%) 0.4 ± 0.0 0.4 zfc: 0.0 0.4 ± 0.0 0.4 ± 0.0 
ALA lo LA ratio 1 :19 1:20 1:20 1:19 
SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; 
LA, linoleic acid; ALA, a-linolenic acid. 
1 Values are means ± SD. 
a Men vs. all women, P < 0.05, unpaired t-test. 
b Men vs. premenopausal women , P < 0.05, unpaired t-test. 
c Men vs. postmenopausal women , P < 0.05, unpaired t-test. 
The fatty acid composition profile of plasma phospholipids (Table 3) was 
largely similar for both genders as well as for the pre- and postmenopausal women. 
However, the proportion of DPA was significantly lower in women than in men 
(P = 0.010). This was due to the lower DPA proportion in plasma phospholipids of 
premenopausal women (P = 0.001 vs. men, P = 0.009 vs. postmenopausal women). 
In contrast, the proportion of DHA was significantly higher in premenopausal women 
than in men (P = 0.012). 
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Table 3 
Fatty acid composit ion of p lasma phospholipids of male and female subjects 1 
Premenopausa l Pos tmenopausal 
Men Women women women 
n = 14 n = 15 n = 8 n - 7 
X Saturated fatty acids 45.3 ± 1.2 44.7 ± 0.9 44.6 ± 1.0 44.8 ± 0.9 
Monounsaturated fatty acids 12.9 1.0 12.9 ± 0.5 12.9 ± 0.4 12.9 ± 0.6 
O A : C 1 8 : l n - 9 8.2 ± 0.8 8.2 ± 0.5 8.2 ± 0.4 8.2 0.6 
D Polyunsaturated fatty acids 40.9 £ 1.0 41.7 ± 0.9 41.8 ± 1.0 41.5 ± 0.8 
X n-6 fatty acids 36.3 ± L i 36.8 ± 1.3 37.0 ± 1.2 36.7 ± 1.5 
LA: C18:2n-6 22.2 2.1 22.0 ± 2.7 "M 5 
<M 1 * V ' 
± 2.8 5 ••14« r v ± 2.7 
X n-3 fatty acids 4,5 ± 0.5 4.7 ± 0.8 4.7 ± 0.6 4.7 ± 1.0 
ALA: CI8:3n-3 0.15 ± 0.04 0.17 ± 0.05 0.16 ± 0.05 0.19 ± 0.04 
EPA: C20:5n-3 0.61 ± 0.20 0.59 ± 0.19 0.52 ± 0.17 0.67 0.19 
DPA: C22:5n-3 0.93 ± 0.16 0.75 ± 0.20 n 0.63 ± 0.17 b < 0.88 0.13 
DHA: C22:6n-3 2.71 ± 0.37 3.07 0.63 3.24 ± 0.53 b 2.89 ± 0.72 
X trans fatty acids 0.8 ± 0.2 0.7 ± 0.0 0.7 ± 0.2 0.8 0.2 
O A , oleic acid; LA, linoleic acid; ALA, ot-linolenic acid; EPA, e icosapentaenoic acid; D P A , docosapentaenoic 
acid; DMA, docosahexaenoic acid. 
1 Values are m e a n s ± SD. 
a Men vs. all w o m e n , P < 0.05, unpaired t-test. 
b M e n vs. p remenopausa l women , P < 0.05, unpaired M e s t . 
c Premenopausal vs. postmenopausal women, P < 0.05, unpaired t-test. 
Oxi da t ion of [ U - 1 3 C ] A L A and conve r s ion of d ie ta ry A L A 
As can be seen from Table 4, the percentage of [U-i3C]ALA tracer that was recovered 
as 13C02 in expired breath as well as the percentage of dietary ALA that is converted 
into EPA and DHA, were not significantly different between men, pre- and 
postmenopausal women. 
Results of the univariate and multiple linear regression analyses examining the 
relation between the percentage of synthesized EPA and DHA with subject 
characteristics are listed in Table 5. Univariate regression results showed that 
conversion of dietary ALA into EPA was positively related to age (p = 0.016, 
b - 0.107), percentage of fat mass (P = 0.002, b -0.228) and BMI (P - 0.006, b = 0.53). 
After multiple regression analysis, age (P = 0.016, b = 0.092) and percentage of fat mass 
(P = 0.002, b = 0.208) remained significant determinants for the conversion of ALA to 
EPA conversion. The conversion of EPA to DHA was negatively associated with the 
linoleic acid content of plasma phospholipids (P = 0.004) as determined with univariate 
and multivariate regression. 
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Estimated values for oxidation of [U-nC]ALA and the intake and conversion of dietary ALA in male and female subjects 5 
Men Women Premenopausal Postmenopausal 
n = 1 4 n = 1 5 women women 
n = 8 n - 7 
Dietary ALA intake (mg/d) 1195 ± 119 1067 ± 95 3 1085 ± 48 b 1046 ± 131 c 
ALA oxidation (% of tracer intake) 18.3 ± 4.1 20.1 3.1 20.3 ± 2.6 19.9 ± 3.8 
% Dietary ALA incorporation 7.3 ± 2.6 8.1 ± 3.8 7.0 ± 3.9 9.4 i 3= 3.5 
% Conversion of dietary ALA EPA 7.3 ± 2.6 8.1 =fc 3.8 7.0 ± 3.9 9.4 ± 3.5 
% Conversion of dietary ALA -> DHA total 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
% Conversion of dietary ALA DHA 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
% Conversion of dietary ALA EPA~> DPA -> DHA 0.1 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 
1 Values are means ± SD. 
a Men vs. all women, P < 0.05, unpaired t-test 
b Men vs. premenopausal women , P < 0.05, unpaired t-test. 
c Men vs. postmenopausal women , P < 0.05, unpaired t-test. 
Table 5 
Results of regression models for the conversion of ALA into EPA and EPA into DHA 
% Dietary ALA -» EPA % EPA DHA 
Estimate 
Lower 
95 % CI 
Upper 
95 % CI P-vaiue Estimate 
Lower 
95 % CI 
Upper 
95 % CI P-value 
Independent variables of the univariate regression models 1 
Age (y) 0.107 0.022 0.193 0.016 -0.005 -0.020 0.010 0.513 
Female 0.870 -1.624 3.364 0.4S0 -0.082 -0.485 0.322 0.681 
Cumulative oxidation (% tracer intake) -0.003 -0.348 0.343 0.987 -0.043 -0.096 0.010 0.111 
Fat mass (%) 0.228 0.090 0.367 0.002 -0.010 -0.036 0.017 0.455 
BMI (kg/m2) 0.530 0.170 0.891 0.006 -0.038 -0.103 0.028 0.246 
BMR (kJ/min) -1.129 -3.051 0.793 0.239 0.043 -0.274 0.360 0.784 
LA in plasma PL (% of total fatty acids) -0.439 -0.949 0.071 0.088 -0.113 -0.187 -0.039 0.004 
£ trans fatty acids in plasma PL (% of total fatty acids) -5.659 -12.902 1.583 0.121 -0.558 -1.757 0.641 0.348 
Independent variables of the fitted multiple regression mode! 2 
Conversion of % ALA EPA 
Age (y) 0.092 0.019 0.165 0.016 
Fat mass (%) 0.208 0.081 0.335 0.002 
LA, linoleic acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PL, phospholipids; CÏ, confidence interval; BMI, body mass 
index; BMR, basal metabolic rate. 
1 Univariate regression results. •ar* 
2 Multivariate regression results. 
C h a p t e r 4 
D I S C U S S I O N 
The primary aim of the present study was to examine if gender was related to n-3 fatty 
acid metabolism in healthy humans. In addition, associations with age, BMR, BMI, 
percentage fat mass, and the proportions of linoleic and trcms fatty acids in plasma 
phospholipids were studied. We found that n-3 fatty acid conversion and ALA oxidation 
did not differ between men, premenopausal and postmenopausal women. Conversion of 
dietary ALA into EPA however increased with age and percentage fat mass, while 
conversion of EPA into DHA was negatively related to the percentage of LA in plasma 
phospholipids. 
Associations with gender 
Data from recent studies [2,14,19,21,22] have suggested that conversion of ALA into its 
LCPUFAs is higher in women of reproductive age than in men of the same age group. 
From a tracer study with six young women, Burdge et al, have estimated that 
conversions of ALA into EPA and DHA were 21 % and 9 % respectively, as quantified 
from total plasma lipids using the area under the l3C-labeIed n-3 fatty acid concentration 
time curves [2]. For the six men, these values were 9 % and 0 % [14]. Giltay et al. 
observed significantly higher proportions of DHA in plasma cholesteryl esters of 
women than of men, independent of dietary differences [19]. In addition, female subjects 
taking oral contraceptives had 10% higher DHA levels than females that were not 
taking oral contraceptives. Finally, they found that DHA levels of plasma cholesteryl 
esters increased in male-to-female transsexual subjects that received oral ethinyl 
estradiol, but not transdermal 17 b-estradiol. In contrast, DHA levels decreased in 
testosteron treated female-to-male transsexual subjects. The authors concluded that the 
higher DHA levels may have been caused by an increased DHA synthesis from ALA 
due to the action of estrogen. Burdge et al. also hypothesized that estrogen up regulates 
DHA synthesis from ALA [2, 10,30]. In a stable isotope study in young females, they 
11 
observed a higher excursion of C-labeled DHA in plasma phosphatidiylcholine in 
women taking oral contraceptives compared to those not taking oral contraceptives [2], 
Pawlosky et al. [2i] also reported that the four women in the study synthesized more 
DHA from ALA than the four men. However, effects were dependent on the 
composition of the background diet, since only significant gender differences were 
observed when subjects consumed a beef-based diet. In contrast, conversion of DPA 
into DHA only tended to be larger in women than in men after the ad libitum diet and 
was similar after the fish-based diet. In the present study, we did not observe that the 
conversion of ALA into EPA and DHA was significantly related to gender or 
reproductive status. The diet consumed in the present study was, with respect to LA and 
ALA intake, very comparable to the ad libitum diet from Pawlosky's study [2l]. 
This may explain why we did not observe gender differences. 
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Burdge et al. [141 even reported that 13C-labeled DHA was not detectable in 
plasma lipids from men. In our study, however, all men could convert ALA into DHA. 
If it is indeed true that .male subjects do not or hardly synthesize DHA, this would imply 
that vegetarian men who do not eat fish and vegan men would be prone to develop 
deficits in their DHA levels. However, findings from a study by Rosell et al. in 
196 British meat-eating, 231 non-fish consuming vegetarian and 232 vegan men, 
indicate that this does not seem to be the case [311. In this study it was however found 
that plasma EPA and DHA proportions were lower in vegetarian and vegan men than in 
meat-eating men. The duration of adherence to the vegetarian and vegan diet was not 
related to the proportions of plasma EPA and DHA. It was therefore concluded that, 
when animal foods are excluded from the diet, the endogenous production of these 
marine fatty acids results in low but stable plasma EPA and DHA levels [31]. 
Nevertheless, it is notable that in our study the percentage of DHA in plasma 
phospholipids at the end of the 4 week run-in period was significantly higher in 
premenopausal women than in men, despite the fact that the conversion of dietary ALA 
into DHA was similar. It should be realized, however, that the n-3 fatty acids profiles of 
plasma phospholipids were steady state values, reached after consuming the run-in diet 
for 4 weeks. It is possible that under non steady-state conditions (e.g. a large (bolus) 
intake of ALA or shortly after the start of oral contraceptive use or hormone therapy), 
DHA synthesis increases temporarily and then returns to baseline levels. This may 
explain why we observed higher DHA levels in premenopausal women than in men, but 
under the steady-state conditions of our study no differences in conversion. It needs to 
be realized however that under steady-state conditions higher DHA levels are not 
necessarily explained by higher synthesis rates. Low DHA levels may also be 
accompanied by high synthesis rates, as long as the inflow of DHA into the plasma 
phospholipid compartment equals the outflow (which is always the case under 
steady-state conditions). To conclude, there is evidence that premenopausal women 
have higher DHA levels than men [2, 14, 19, 21]. The present tracer studies however do 
not provide a clear mechanism to explain these gender related differences [2 ,14 ,21] . 
Associations with other baseline characteristics 
So far, the relation between age and ALA metabolism has not been assessed in tracer 
studies. However, in a cross-sectional study, Sands et al. [23] observed a significant 
positive relation between age and the level of EPA + DHA in red blood cells (RBC) in a 
group of 163 individuals (74 men, 83 women) between 20 - 80 y. This association 
persisted after adjusting for fish intake. The authors speculated that, compared to 
younger subjects, older individuals might have a slower turnover of n-3 fatty acids in 
tissues, might consume more ALA, or might convert more ALA into its LCPUFAs [23]. 
Our results suggest that conversion of dietary ALA into EPA indeed increased with age. 
We estimated that in middle-aged subjects an increase in age of 10 years was related to 
an increased conversion of dietary ALA into EPA of approximately 1 %. 
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In contrast, age was not associated with conversion of ALA into DHA. The latter 
pathway was negatively related to the percentage of LA in plasma phospholipids. 
In addition, we found that the percentage of fat mass was positively related to the 
incorporation of ALA into the plasma phospholipid pool and to its subsequent 
conversion into EPA. This supports the finding of Sands et al. [23], who reported a 
positive association between BMI and the proportion of EPA + DHA in RBC. 
As especially postmenopausal women had a significantly higher fat mass than male 
subjects, analyses were repeated after adjusting for gender and reproductive status. 
The results, however, did not change. Finally, it has been suggested that trans fatty 
acids inhibit n-3 fatty acid conversion [24]. The findings from the present study, 
however, did not confirm this hypothesis. 
Associations with ALA oxidation 
The majority of the studies examining oxidation of ALA tracer have been performed in 
male subjects or did not present the results of men and women separately [14-16, 32-34]. 
In one tracer study however it was found that in young women [2] about 22 % of the 
ingested ALA-dose was recovered as C02 in breath over a period of 24 hours. Using the 
same protocol, this value was 33 % for young men [14]. It was postulated that this 
difference might be due to the higher muscle mass content of the men, which in turn 
could explain the lower availability of the ALA tracer for conversion into its long chain 
derivates. However, we did not observe a higher oxidation of ALA in men than in 
women. Furthermore, we did not find a significant inverse relation between the 
oxidation of ALA and its incorporation and subsequent conversion into EPA and DHA. 
This contrasts findings by Vermunt et al. [16], who observed a negative correlation 
between the recovery of 13C02 in breath from the oxidation of [13C]ALA over 12 hours, 
and the maximal [!3C]EPA and [13C]DPA amounts in plasma total lipids. It should be 
noted that the duration of breath sampling in our study was 9 hours as opposed to 
24 hours in the two studies of Burdge et al. [2, 14]. Although we did not find a 
relationship between gender or reproductive status and ALA oxidation at any of the 
time points, it is theoretically possible that changes might have been evident after 
9 hours. 
Conclusion 
To summarize, our results do not suggest that under steady-state conditions conversion 
and oxidation of dietary ALA are related to gender or reproductive status. However, 
conversion of dietary ALA into EPA was positively related to age and percentage fat 
mass whereas conversion of EPA into DHA was negatively related to the proportion of 
LA in plasma phospholipids. 
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CHAPTER 5 
The dietary a-linolenic acid to linoleic acid ratio does 
not affect the serum lipoprotein profile in humans 
Petra L. L. Goyens, and Ronald P. Mensink 
Based on 
Journal of Nutrition 2005; 135:2799-2804. 
E s s e n t i a l f a t t y a c i d s a n d l i p o p r o t e i n p a r t i c l e s 
A B S T R A C T 
a-Linolenic acid (ALA; 18:3n-3) and linoleic acid (LA; 18:2n-6) have comparable 
effects on serum lipid and lipoprotein concentrations, but their effects on lipoprotein 
subclass distributions and particle sizes are unknown. It is also not known whether these 
effects are changed by the ALA:LA ratio in the diet. To address these questions, healthy 
subjects n = 54 consumed a control diet providing 7 % of energy (En%) as LA and 
0.4 En% as ALA during a 4-wk run-in period. For the following 6 wk of intervention, 
each diet was consumed by 18 subjects: the control diet, a low LA diet (3 En% LA, 
0.4 En% ALA), or a high ALA diet (7 En% LA, 1.1 En% ALA). The ALA:LA ratio for 
the control diet was 1:19 and was 1:7 for the other 2 diets. Compared with the control 
group, LDL cholesterol decreased significantly in the ALA group (-0,32 mmol/L, 
P = 0.024), as did total cholesterol, apolipoprotein (apo) B, and the total:HDL 
cholesterol ratio. None of the dietary interventions affected HDL cholesterol, apo A-l, 
or triacylglycerol concentrations. The decrease in total VLDL particle concentrations in 
the low LA group was due mainly to a decrease in medium VLDL (-16 nmol/L, 
P = 0.018) and in the high ALA group to a decrease in small VLDL (-14 nmol/L, 
P = 0.044). We conclude that the ALA:LA ratio does not affect the serum lipoprotein 
profile. Compared with the control and LA diets, ALA lowered LDL cholesterol 
concentrations, possibly caused by the decrease in small VLDL. 
I N T R O D U C T I O N 
A mixture of eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid 
(DHA; 22:6n-3), 2 fish-oil derived members of the n-3 fatty acid family, decreases 
serum triacylglycerol (TG) concentrations [1]. At the same time, LDL cholesterol 
concentrations may increase slightly, especially in hypertriacylglycerolemic subjects [2]. 
On the other hand, lipoprotein particle distributions might be favorably affected [3]. 
These effects are not shared by a-linolenic acid (ALA; 18:3n~3), an essential fatty acid 
from the n-3 family and a precursor for EPA and DHA synthesis [4]. In fact, the few 
intervention studies on the effects of ALA on lipid metabolism indicate that ALA has 
effects on serum lipid concentrations similar to those of linoleic acid (LA; 18:2n-6), its 
n-6 fatty acid counterpart [5-7]. In these studies, ALA:LA ratios differed between the 
diets. Because the metabolism of ALA and LA are interrelated, which is particularly 
evident in the competition for the same elongation and desaturation enzymes, a change 
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in this ratio might also affect lipid metabolism, independently of changes in the intake 
of ALA or LA. The studies conducted to date were not able to disentangle the effects on 
serum lipid concentrations of the ALA:LA ratio from those of the 2 individual fatty 
acids. Furthermore, the effects of dietary ALA, LA, and the ALA:LA ratio on 
lipoprotein particle sizes and subclass distributions have not been investigated together 
in detail. In only 1 human study, it was reported that walnuts, a source rich in both ALA 
and LA, decreased cholesterol concentrations preferentially in the small LDL 
subfractions [8], The aim of the present study therefore was to compare side-by-side the 
effects of ALA, LA, and the ALA:LA ratio on fasting serum lipids and apolipoproteins 
concentrations, and on lipoprotein particle subclasses in humans. 
SUBJECTS AND METHODS 
Subjects 
Subjects were recruited from Maastricht and the surrounding area through posters in 
public buildings and advertisements in local newspapers. Men and women n - 90, 
between 18 and 65 y old, applied for enrollment in this controlled dietary intervention 
study. The purpose and nature of the study, as approved by the Medical Ethics 
Committee of Maastricht, were fully explained to all applicants. These subjects were 
invited for 2 screening visits after they had given their written informed consent. 
Subjects' eligibility was evaluated by means of a medical questionnaire, a urine test to 
exclude glucosuria, and measurements of serum lipids concentrations in 2 blood 
samples taken while fasting; there was an interval of at least 3 d between the samples. 
In addition, after a 10-min rest period, 3 blood pressure measurements were obtained 
during the first screening visit. When mean diastolic blood pressure of the last 
2 measurements was > 85 or systolic > 150 mmHg, blood pressure was measured again 
during the 2nd screening visit. 
Of these 90 subjects, 65 met the following eligibility criteria: BMI < 30 kg/m2, 
stable body weight with a maximum change < 3 kg in the past 3 mo; mean serum total 
cholesterol < 8.0 mmol/L, mean serum TG < 2.5 mmol/L; mean diastolic and systolic 
blood pressure < 95 mmHg and < 160 mmHg, respectively; no use of medication or 
prescribed diets known to affect serum lipids; no glucosuria; and no history of coronary 
heart disease. Ten subjects, 5 men and 5 women, withdrew from the study because of 
moving to another area n = 2, job commitments n = l , illness n = l , or difficulties 
complying with the strict study protocol n = 6. Before data analysis, results from 1 man 
were excluded because of gastrointestinal illness during wk 3 and 4 of the study. Of the 
54 subjects (21 men and 33 women) that completed the study, 6 women and 4 men 
smoked, 6 women used oral contraceptives, and 14 women were menopausal. 
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The 21 men that completed the study were (means ± SD) 52.6 ± 13.7 y old, had a 
T 
BMI of 24.3 ± 4.4 kg/m , a systolic blood pressure of 125 ± 15 mmHg, and a diastolic 
blood pressure of 78 6 mmHg. The 33 women that completed the study were 
47.7 ± 11.1 y old, had a BMI of 23.9 ± 2.7 kg/m2, a systolic blood pressure of 
124 ± 18 mmHg, and a diastolic blood pressure of 78 ± 9 mmHg. For the men, the mean 
fasting concentrations of serum total cholesterol, LDL cholesterol, HDL cholesterol, 
and TG at the screening were 5.44 ±1.11 mmol/L, 3.80 ± 1.03 mmol/L, 
1.10 ± 0.23 mmol/L, and 1.16 ± 0.62 mmol/L, respectively. In women, they were 
5.42± 1.14 mmol/L for total cholesterol, 3.49± 1.13 mmol/L for LDL, 
1.44 ± 0.47 mmol/L for HDL, and 1.07 ± 0.58 mmol/L for TG. 
Des ign and d ie ts 
The study was designed as a randomized, double-blind, parallel intervention study. 
The total study duration comprised a period of 10 successive weeks: a run-in period of 
4 wk followed by an intervention period of 6 wk. During the run-in period, all subjects 
consumed a control diet, which reflected the mean daily intake of the Dutch 
population [9]. After the run in period, subjects were randomly allocated to 1 of the 
3 possible dietary intervention groups, stratified for gender, age, and total cholesterol 
concentrations as determined during the screening. The first group (control group, 
n = 18) continued to consume the control diet. This diet was made up of 7 % of energy 
(En%) from LA and 0.4 En% from ALA, resulting in an ALA:LA ratio of 1:19. 
The second (low LA group, n = 18) and the third group (high ALA group, n = 18) 
followed a diet with a higher ALA:LA ratio of 1:7. Although the ALA:LA ratio was 
comparable between these 2 groups, the proportions of energy from LA and ALA 
differed. For the low LA group, LA consumption was decreased to 3 En%, whereas 
ALA intake was not changed. For the high ALA group, however, ALA intake was 
increased to 1.1 En%, whereas LA intake was identical to that in the control group. 
The 3 study diets, each supplying 15 En% as protein, 50 En% as carbohydrates, 
and 35 En% as fat, were formulated at 9 levels of energy, ranging from 7.5 to 13.4 MJ. 
The difference between 2 successive levels was 0.84 MJ. Before the start of the study, 
subjects were asked to weigh and record their habitual food intakes during 2 working 
days and 1 weekend day. Energy intake and macronutrient composition of the habitual 
dietary intake were calculated using the Dutch food composition table [10]. Based on the 
data of the food records, subjects were assigned to 1 of the 9 energy groups. 
For each energy level, dietary guidelines were composed with respect to type, 
daily amounts, and preparation of nonexperimental food items. Subjects had to follow 
these guidelines strictly. Consumption of fish and other marine foods was not allowed. 
The nonexperimental food items supplied 1 0 - 1 3 En% as fat, which was equivalent to 
29 - 38 % of total fat intake. In addition, experimental products were supplied, which 
provided 22 - 25 En% as fat. 
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These products were made from experimental fats (Table l).The control fat consisted of 
a mixture of 30.4 % sunflower oil, 33.1 % olive oil, 11.5 % rapeseed oil, and 25 % 
hardstock made from fully hydrogenated palm kernel and palm oil. The experimental fat 
low in LA was composed of 63 % olive oil, 9 % rapeseed oil, and 28 % hardstock. 
The fat rich in ALA consisted of 20 % sunflower oil, 5 % olive oil, 52.5 % rapeseed oil, 
and 22.5 % hardstock. From these fats, a margarine was made containing 84 % 
absorbable fats and 16 % water. Both the fats and the margarines were made by NIZO 
food research. Volunteers were required to use the margarines for cooking, baking, and 
as spread on bread. In addition, a local bakery prepared pastries, such as pies, cookies, 
and cake from these margarines. Depending on energy intake, subjects had to consume 
a specific amount of experimental products on a daily (cookies, margarine for cooking 
and as spread) or weekly (pies and cake) basis. Each volunteer visited the department 
1 time/wk to receive a new supply of experimental products. 
Subjects had to Fill out daily diaries in which they noted in detail any signs of 
illness, medication used, its date and time of occurrence, duration, and date of 
resolution. Furthermore, they were asked to record menstrual phase, any deviations 
from the protocol, and the daily amounts of products used. Each week, diaries were 
checked in the presence of the subjects by a registered dietician. Subjects were urged 
not to change the level of physical exercise, smoking habits, alcohol or oral 
contraceptive use during their participation in the study. Body weight of all participants 
was measured once a week. Whenever body weight changed by > 2 kg compared with 
body weight at trial entry, subjects were reassigned to a different energy level. At the 
end of both the run-in and the intervention periods, subjects had to weigh and record 
their food intakes for 2 working days and 1 weekend day to estimate energy and nutrient 
intakes [10]. 
Blood sampl ing and analysis 
At the end of the run-in period (wk 3 and 4), as well as at the end of the intervention 
period (wk 9 and 10), blood samples were drawn from fasting subjects to measure 
concentrations of lipoprotein particles, serum lipids, apolipoprotein (apo) A-I and apoB. 
To determine the fatty acid composition of plasma phospholipids, a blood sample was 
taken at the end of wk 4 and 10. Subjects were instructed to abstain from alcohol the 
day before a blood sampling and not to consume any food at all at least 12 h before 
sampling. Tea, without sugar or milk, and water, however, were allowed. Venous blood 
samples were taken from the antecubital vein, under minimal stasis, with the subject in a 
supine position. Venipunctures were performed under standardized conditions using a 
0.9 x 38 mm needle (PrecisionGlide, Becton Dickinson Vacutainer System) by the same 
technician, at the same location, and usually at the same time and on the same weekday 
for each subject. 
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Blood for analysis of serum lipids, apolipoproteins, lipoproteins, and their 
subclasses was sampled in a 10-mL clotting tube (BD Vacutainer Systems, Becton 
Dickinson). After blood was allowed to clot for a minimum of 1 h at room temperature, 
serum was obtained by centrifugation at 2000 x g for 30 min at 4 °C. Serum samples 
were then stored in small portions at -80 °C until later analysis. For determination of the 
fatty acid composition of plasma phospholipids, precooled EDTA tubes were used for 
blood collection. Within 1 h after sampling, blood was centrifuged at 2000 x g for 
30 min at 4 °C, and the plasma samples obtained were snap-frozen in liquid nitrogen 
and stored at -80 °C. 
Serum lipids and lipoprotein concentrations were measured separately in the 
serum samples from wk 3, 4, 9, and 10. Serum total cholesterol and HDL cholesterol, 
after precipitation of apoB-containing lipoproteins (HDL Cholesterol precipitant, Roche 
Diagnostics), were analyzed with the CHOD-PAP method (ABX Diagnostics). 
Serum concentrations of TG, also determined enzymatically, were corrected for free 
glycerol (GPO Trinder; Sigma Diagnostics). Serum LDL cholesterol concentrations 
were calculated with the Friedewald equation [i l]. The CV within assays was 0.9 % for 
total cholesterol, 2.4 % for HDL, and 2.3 % for TG. 
Serum samples of wk 3 and 4, as well as of wk 9 and 10 were pooled before 
analysis of apolipoproteins and lipoprotein particles. Serum concentrations of 
lipoprotein subclasses and lipoprotein particle sizes were measured using NMR 
spectroscopy (Liposcience) in a randomly chosen subgroup of 29 subjects, 15 women 
and 14 men [12, 13]. Apo A-l and apoB concentrations were analyzed in the pooled 
serum samples of all participants using commercially available kits (ABX 
DIAGNOSTICS). The CV within assays was 1.9 % for apo A-l and 2.3 % for apoB. 
Total lipids were extracted from plasma following a modified Folch procedure [14]. 
Thereafter, phospholipids were isolated from total lipids using an Extract-Clean 
NH2-aminopropylsilyl column (500 mg, 4.0 mL; Alltech Associates) and subsequently 
hydrolyzed and methylated into FAMEs [15, 16]. Separation and quantification of the 
FAMEs was obtained with GC-flame ionization detection (Perkin Elmer Autosystem), 
using a CP-Sil 88 capillary column (50 m x 0.25 mm, 0.20-|am film thickness; 
Chrompack) as described previously [17]. All samples from each subject were analyzed 
in one single assay at the end of the study. 
S ta t i s t i c s 
The power to detect a difference in serum LDL cholesterol concentrations of 8 % 
between 2 treatment groups with an of 0.05 was 80 %. For each subject, serum lipids 
and lipoprotein values from wk 3 and 4, as well as from wk 9 and 10, were averaged. 
Results are expressed as means ± SD. Responses to the experimental diets were 
calculated for each subject by subtracting the value of a variable obtained at the end of 
the run-in period from the value at the end of the experimental period. 
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The effects of the diets were examined with ANOVA, using the General Linear Models 
(GLM) procedure in SAS (SAS System release 8.2; SAS Institute). The response to the 
experimental diet was defined as the dependent variable and dietary group as a fixed 
factor. When significant differences were found (P < 0.05), a Tukey post hoc test was 
used to make a pair-wise comparison of the diets. 
Table 1 
Fatty acid composition of the experimental fats 
Control group Low LA group High ALA group 
g/100 g fatty acids 
Saturated fatty acids 29.3 32.6 26.2 
Monounsaturated fatty acids 41.0 59.0 41.9 
Polyunsaturated fatty acids 29.4 8.2 31.7 
LA 27.9 6.8 26.6 
ALA 1.3 1.4 4.7 
ALA to LA ratio 1:21 1:5.0 1:5.6 
Trans fatty acids 0.2 0.11 0.11 
LA, linoleic acid; ALA, a-linolenic acid. 
Except for the ALA to LA ratio, values are expressed in g/100 g fatty acids. 
The experimental fats provided 22 - 25 En% of total energy intake. Mean daily energy and nutrient intakes 
of the diets are presented in Table 2. 
RESULTS 
Dietary intake and body weight 
Changes in energy intake, the proportions of energy from protein, carbohydrate, and 
total fat, as well as the amounts of cholesterol and fiber, were negligible and did not 
differ among the 3 groups. Differences in dietary fatty acid intake were as expected 
(Table 2). Compared with the control group, the intake of LA was reduced in the LA 
group, due mainly to an exchange for oleic acid (OA) plus some SFA. In the high ALA 
group, the intake of ALA was slightly increased. These dietary fatty acid changes 
resulted in an ALA:LA ratio of 1:19 in the control group, and of 1:7 in the 
2 experimental groups. 
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Table 2 
Daily energy and nutrient intakes at the end of the 4-wk run-in period when all subjects consumed the control diet 
and changes after consumption of the control diet, the low I..A diet, and the high ALA diet for 6 wk ' 
Control group Low LA group High ALA group 
Energy (MJ/d) 
Run-in period 10.4 ± 1.8 10.5 ± 1.4 10.9 ± 1.2 
Experimental period 10.5 ± 2.1 10.3 dc 2.0 10.8 1.3 
Change 0.1 ± 0.9 -0.2 ± 1.0 -0.1 ± 1.0 
Protein (En%) 
Run-in period 14.7 ± 1.6 14.6 ± 1.2 15.0 ± 1.5 
Experimental period 14.5 ± 1.4 14.9 1.3 15.5 ± 1.1 
Change -0.2 ± 1.8 0.3 ± 1.4 0.5 1.7 
Carbohydrates (En%) 
Run-in period 50.3 ± 3.9 49.7 ± 4.0 50.2 ± 3.5 
Experimental period 50.5 ± 3.1 49.8 ± 4.1 50.4 ± 4.2 
Change 0.3 ± 3.4 0.1 ± 3.5 0.1 ± 3.7 
Fat (En%) 
Run-in period 33.6 ± 2.9 33.5 ± 3.2 33.3 ± 3.8 
Experimental period 33.5 ± 2.5 34.0 ± 3.9 32.6 ± 3.7 
Change -0.1 2.8 0.5 ± 3.0 -0.7 ± 2.4 
SAFA (En%) 
Run-in period 11.6 ± 1.3 11.4 ± 1.3 11.3 ± 1.4 
Experimental period 11.6 ± 1.1 12.4 ± 1.8 
• 
10.4 ± 1.5 
Change -0.0 ± 1.3 a 1.0 ± 1.6 b -1.0 ± 1.0 
MUFA (En%) 
Run-in period 12.9 ± 1.3 12.8 ± 1.4 12.7 ± 1.9 
Experimental period 12.8 ± 1.1 16.9 ± 1.9 12.6 ± 1.6 
Change -0.1 ± 1.1 a 4.1 ± 1.2 b -0.1 ± 1.0 
PUFA (En%) 
Run-in period 7.9 ± 0.8 ± 0.6 8.1 0.7 
Experimental period 8.0 ± 0.7 3.7 ± 0.4 
* 
8.6 0.7 
Change 0,1 ± 0.6a -4.5 ± 0.6 b 0.4 ± 0.7 
LA (En%) 
Run-in period 7.2 ± 0.8 7.5 ± 0.6 7.4 ± 0.6 
Experimental period 7.3 ± 0.7 3.0 ± 0.3 
• 
7.1 ± 0.6 
Change 0.1 ± 0.5 n -4.5 ± 0.5 b -0.3 ± 0.8 
ALA (En%) 
Run-in period 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 
Experimental period 0.4 ± 0.0 0.4 ± 0.1 1.1 ± 0.1 
Change 0.0 ± 0.1 0 0.0 ± 0.0a 0.7 ± 0.1 
LA to ALA ratio 
Run-in period 19 ± 1 20 ± 1 20 ± 1 
Experimental period 19 2 7 ± 1 
* 
7 ± 0 
« 
Change -0 ± 2 a -12 ± l h -13 ± 2 
Cholesterol (mg/MJ) 
Run-in period 13.6 ± 2.5 11.6 ± 2.9 12.6 ± 3.9 
Experimental period 12.6 ± 2.9 11.7 ± 4.4 12.1 ± 3.1 
Change -0.9 ± 3.6 0.1 ± 4.5 -0.5 ± 4.6 
Dietary fiber (g/d) 
Run-in period 30.8 ± 4.2 30.6 ± 5.5 34.1 ± 7.0 
Experimental period 29.5 ± 5.3 29.1 ± 6.8 33.2 4.5 
Change -1.3 ± 5.6 -1.5 i 3.6 -0.9 ± 5.5 
SAFA, saturated fatty acids; MUFA, monounsaturated fatly acids; PUFA, polyunsaturated fatty acids; 
LA, linoleic acid; ALA, a-linolenic acid. 
1 Values are means ± SD, n = 18. Means in a row with superscripts without a common letter differ, P < 0.05. 
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During the experimental period, body weight decreased marginally by 
-0.1 ± 0.8 kg in the control group, -0.1 ± 1.5 kg in the low LA group, and -0.2 ± 0.8 kg 
in the high ALA group, changes that did not differ from one another (P = 0.934). 
Dietary compliance was further confirmed by changes in the fatty acid composition of 
plasma phospholipids (Table 3). Compared with the control group, the change in the 
proportion of monounsaturated fatty acids (MUFA) was increased, whereas that of LA 
was reduced when subjects consumed the low LA diet. The proportions of MUFA and 
PUFA remained unchanged after consumption of the high ALA diet. The changes in the 
proportions of total n-3 fatty acids and of ALA and EPA were greater in the low LA and 
high ALA groups than in the control group. The proportion of docosapentaenoic acid 
(DPA) increased, only after consumption of the diet high in ALA. None of the 3 diets 
affected the proportions of SFA and of DHA in plasma phospholipids. Inspection of the 
diaries did not reveal any serious deviations from the protocol. 
Serum lipids, apol ipopro te ins , and l ipopro te in subc lasses 
In the high ALA group, serum total cholesterol concentrations were reduced further 
than in the control group (P = 0.006), mainly because of a decrease in LDL cholesterol 
concentrations (P = 0.024) (Table 4). Because HDL cholesterol concentrations did not 
change, the totakHDL cholesterol ratio was also lower in the high ALA group compared 
with the control group (P = 0.001). In agreement with the changes in LDL and HDL 
cholesterol, apoB concentrations decreased (P = 0.0116) in the high ALA group, 
compared with the control group, whereas apo A-I was not affected. Changes in apoB 
and apo A-I concentrations did not differ between the low LA and high ALA groups 
(Table 5). 
Compared with the control group (Table 6), concentrations of total VLDL 
particles decreased in the low LA group (P = 0.026) and in the high ALA group 
(P - 0.032). In the low LA group, the fall in VLDL lipoproteins was due mainly to a 
decrease in the medium-sized VLDL particles (P = 0.018). In the high ALA group, 
however, small VLDL particles were decreased (P = 0.044). Changes in HDL particle 
size distributions and VLDL, LDL, and HDL mean particle sizes did not differ among 
the 3 groups (data not shown). 
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Table 3 
Fatty acid composition of plasma phospholipids at the end of the 4-wk run-in period when all subjects consumed the control diet and changes after consumption 
of the control diet, low LA diet and high ALA diet for 6 wk 1 
Control group Low LA group High ALA group 
Run-in period Change Run-in period Change Run-in period Change 
g/100 g total fatty acids identified 
Z Saturated fatty acids 45.8 ± 1.5 -0.1 ± 0.9 45.5 ± 1.2 -0.5 ± 0.9 45.7 ± 1.2 -0.5 ± 0.8 
Z Monounsaturated fatty acids 12.9 ± 0.8 0.1 ± 0.8 3 12.8 ± 0.8 3.4 ± 0.8 b 12.7 ± 0.8 0.2 ± 0.7 a 
OA: C18:ln-9 8.4 1 0.9 0.1 ± 0.8 a 8.3 j 0.8 2.9 ± 0.7 b 8.1 ± 0.6 -0.2 ± 0.7 a 
Z Polyunsaturated fatty acids 40.6 ± 1.6 0.0 ± 1.2 a 41.0 1 1.1 -2.8 ± 0.9 b 40.9 ± 0.9 0.2 ± 0.8 3 
Z n-6 fatty acids 35.9 ± 1.7 0.2 ± 1.3 a 36.5 ± 1.2 -3.1 ± 1.1 b 36.2 1.0 -0.2 ± 0.8 a 
LA: C18:2n-6 21.5 ± 2.0 OA ± 1.7 a 21.9 ± 2.3 -2.4 ± 1.3 b 22.0 ± 2.6 OA ± 0.8 a 
Z n-3 fatty acids 4.5 ± 0.5 -0.2 ± 0.4 a 4.3 ± 0.4 0.2 > 0.2 b 4.6 ± 0.8 0.4 ± 0.3 b 
ALA: C18:3n-3 0.2 ± 0.1 0.0 t 0.1 a 0.1 ± 0.0 0.1 dt 0.0 b 0.2 ± 0.0 0.1 ± 0.0 b 
EPA: C20:5n-3 0.6 ± 0.2 0.0 ± 0.1 a 0.5 ± 0.2 0.2 ± 0.1 b 0.6 ± 0.2 0.2 ± 0.1 b 
DPA: C22:5n-3 0.8 ± 0.2 0.0 ± 0.1 a 0.8 ± 0.2 0.0 ± 0.1 a 0.8 ± 0.2 0.1 ± 0.1 b 
DHA: C22:6n-3 2.8 ± 0.5 -0.2 ± 0.3 2.7 ± 0.5 -0.1 0.2 2.9 ± 0.6 -0.1 ± 0.2 
Z trans fatty acids 0.7 ± 0.2 -0.0 ± 0.1 0.7 ± 0.2 -0.0 ± 0.2 0.7 ± 0.2 0.0 ± 0.2 
OA, oleic acid; LA, linoleic acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. 
1 Values are means ± SD, n = 18. Means in a row with superscripts without a common letter differ, P < 0.05. 
Table 4 
Serum lipoprotein concentrations at the end of the 4-wk run-in period when all subjects consumed the control diet, and changes after consumption of the control 
diet, low LA diet, and high ALA diet for 6 wk 1 
Total cholesterol LDL cholesterol HDL cholesterol TG Total: HDL cholesterol ratio 
mmol/L 
Control group 
Run-in period 
Experimental period 
Change 
Low LA group 
Run-in period 
Experimental period 
Change 
High ALA group 
Run-in period 
Experimental period 
Change 
5.69 ± 1.36 3.83 ± 1.20 1.40 ± 0.49 LOO ± 0.51 4.44 ± 1.73 
5.83 ± 1.41 3.93 ± 1.20 1.39 » zc 0.52 1.11 ± 0.63 4.58 ± 1.75 
0.14 ± 0.30* 0.10 ± 0.25 a -0.01 ± 0.14 0.11 ± 0.23 0.13 ± 0.42 a 
5.71 ± 0.78 3.76 ± 0.79 1.50 ± 0.36 0.99 ± 0.55 4.03 ± 1.27 
5.73 ± 0.69 3.78 ± 0.75 1.53 ± 0.36 0.90 ± 0.39 4.01 ± 1.39 
0.01 ± 0.36 0.03 ± 0.29 0.03 ± 0.12 -0.09 ± 0.31 -0.02 ± 0.36 ^ 
5.72 ± 0.99 3.81 ± 0.99 1.38 ± 0.46 1.16 ± 0.53 4.61 ± 1.74 
5.46 0.99 3.59 ± 1.05 1.38 ± 0.42 1.07 ± 0.38 4.33 ± 1.74 
-0.26 ± 0.44 b -0.22 ± 0.48 b 0.01 ± 0.13 -0.10 ± 0.26 -0.29 ± 0.45 b 
1 Values are means ± SD, n = 18. Means in a column with superscripts without a common letter differ, P < 0.05. 
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Table 5 
Apolipoprotein A-I and B concentrations at the end of the 4-wk run-in period when all subjects consumed 
the control diet, and their changes after consumption of the control diet, low LA diet and high ALA diet 
for 6 wk 1 
Apo A-I ApoB 
mg/L 
Control group 
Run-in period 1526 ± 283 1021 ± 290 
Experimental period 1590 ± 352 1094 ± 320 
Change 64 ± 111 73 ± 80 11 
Low LA group 
Run-in period 1671 ± 222 1008 ± 220 
Experimental period 1671 ± 218 1015 190 
Change 0 90 7 ± 100 a"h 
High ALA group 
Run-in period 1498 ± 297 1021 ± 251 
Experimental period 1529 ± 352 1003 i 255 
Change 31 
± 
139 -18 ± 91 b 
LA, linoleic acid; ALA, a-linolenic acid. 
1 Values are means ± SD, n = 18. 
Means in a column with superscripts without a common letter differ, P < 0.05. 
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Table 6 
Lipoprotein subtract ions and mean lipoprotein particle s ize at the end of the 4 - w k run-in period when all subjects consumed the control diet and changes af ter consumption of the 
control diet, low L A diet, and high A L A diet for 6 wk 1 
Control group L o w L A group High A L A group 
Run-in period Change Run-in period Change Run-in period Change 
V L D L Particle Concentrat ions {nmol/L 
V L D L Particles (total) 74 ± 31 16 ± 1 7 a 79 4- 31 - 9 ± 21 b 91 ± 33 -8 ± 20 h 
Large VLDL/Chy lomic rons 2 ± 1 Î ± Ï 4 ± 5 0 ± 3 3 ± 2 -1 ± 2 
M e d i u m V L D L 2 6 ± 32 7 ± 1 0 a 34 ± 17 -8 ± 11 b 34 ± 18 -2 ± 1 3 x b 
Small V L D L 4 7 ± 23 8 ± 9 3 41 ± 18 0 ± g a. h 53 ± 19 -6 ± 15 h 
L D L Particle Concentrat ions (nmol/L) 
L D L Part icles (total) 974 ± 302 8 9 ± 129 1179 ± 402 -31 ± 157 1241 ± 436 20 ± 133 
IDL 2 8 ± 25 5.6 ± 25.4 29 37 -1 ± 2 0 44 ± 44 -6 43 
Large L D L 481 ± 185 16 ± 62 581 ± 171 52 ± 104 548 ± 274 -40 ± 141 
Small L D L (total) 466 ± 286 6 8 ± 157 569 ± 4 4 8 -82 ± 206 649 ± 566 66 ± 221 
Med ium Small L D L 89 -L 56 14.0 ± 31.9 111 ± 94 -19 ± 4 8 128 ± 114 n _L 50 
Very Smal l L D L 377 ± 230 54 ± 126 4 5 8 ± 355 -63 ± 160 521 ± 452 55 ± 173 
H D L Part icle Concentrat ions ( j imol /L) 
H D L Particles (total) 33 ± 4 2 ± 3 36 ± 6 1 ± 2 35 ± 7 I ± 2 
1 Values are means ± SD, n = 9, in control g roup and n = 10 in the low LA and high A L A groups. 
Means in a r o w with superscripts wi thout a c o m m o n letter differ , P < 0.05. 
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D I S C U S S I O N 
In the present study with normocholesterolemic subjects, we found that a slight increase 
in the intake of ALA effectively lowered LDL cholesterol. This decrease might be 
related to the significant decrease in the small VLDL subparticles. It has long been 
thought that LA lowered serum total and LDL cholesterol concentrations compared with 
OA [18]. This conclusion was challenged by studies conducted in the late 1980s and 
1990s, which demonstrated comparable effects of LA and OA on the serum lipoprotein 
profile [19, 20]. However, a recent meta-analysis indicated that LA may still lower LDL 
cholesterol compared with OA, although differences in effects are small [21]. Our results 
from the control and the low LA groups agree with these findings. When the low LA 
diet was consumed, the decrease in LA was compensated by an increase in OA and a 
slight increase in SFA. Based on a recent meta-analysis [21], we calculated that 
consumption of the low LA diet would decrease LDL cholesterol concentrations by 
0.08 mmol/L compared with the control diet. Hence, the study findings concerning total 
LDL cholesterol concentrations are in line with expectations. 
Like LA, ALA is an essential fatty acid. Intakes of ALA are much lower, 
however, than those of LA. On average, ALA intake varies between 1 and 2 g/d, 
whereas the mean daily LA intake is 15 g [22,23]. Several studies with 
normocholesterolemic subjects suggested that an exchange of ALA for LA does not 
affect serum lipid concentrations. Pang et al , for example, found no significant effects 
on the serum lipoprotein profile when LA consumption was decreased from 6.7 En% 
(21 g/d) to 3.1 En% (12 g/d), and ALA intake was increased simultaneously from 
0.1 En% (1 g/d) to 3.5 En% (10 g/d) [6]. Mantzioris et al. also found no change in serum 
lipid concentrations when a typical Western diet providing 7.8 En% (20.3 g/d) from LA 
and 0.4 En% (LI g/d) from ALA was replaced by a diet that supplied 3 3 En% (8.4 g/d) 
LA and 5.3 En% (13.7 g/d) ALA [5]. Also, in 2 studies with hyperlipidemic subjects, 
comparable effects of ALA and LA on serum LDL cholesterol were reported [24, 25]. 
In our study, we increased the intake of ALA from 0.4 En% (1.1 g/d) to 1.1 En% 
(3.1 g/d) at the expense of some LA, OA, and SFA. The slight decrease in total fat 
intake of 0.7 En% was compensated mainly by a slight increase in protein intake. 
If ALA and LA would indeed have comparable effects on serum LDL cholesterol, then 
a difference of 0.04 mmol/L between the control and high ALA groups could be 
expected [21]. In fact, a significant difference of 0.32 mmol/L was observed in favor of 
the high ALA group. This result does not agree with findings from previous studies [5-7, 
26, 27]. The question then arises whether this is a chance finding or whether it can be 
explained by differences among studies in experimental design. 
The metabolisms of ALA and LA are mutually dependent, as shown by the 
competition for the same elongation and desaturation enzymes [28-30]. 
99 
C h a p t e r 5 
In most studies conducted to date, the intakes of LA and ALA, and consequently their 
ratio, changed at the same time. The present study was therefore specifically designed to 
disentangle the effects of the ALA:LA ratio on the serum lipid profile from those of the 
absolute amounts of ALA and LA in the diet. The low LA and high ALA diets had a 
comparable ALA:LA ratio of 1:7, which was much higher than the ratio of 1:19 of the 
control diet. Despite similar ALA:LA ratios, serum LDL cholesterol concentrations 
were significantly lowered only in the high ALA group. This suggests that the ALA:LA 
ratio itself does not affect serum LDL cholesterol concentrations. The finding that the 
ALA:LA ratio is not important implies that the increase in dietary ALA should have 
caused the observed decrease in LDL cholesterol. Yet, the increase in ALA intake was 
rather small compared with studies that did not demonstrate a difference in the effect on 
LDL cholesterol between ALA and LA [5 ,6 ,27] . It can also be argued that the relatively 
high LA intake, which was 7 En% in the high ALA group, modulated the effects of 
ALA. However, similar effects of LA and ALA on LDL cholesterol were found 
independently of LA intake [5-7,26]. In fact, Valsta et al. explicitly concluded that in the 
presence of considerable amounts of LA in the diet, ALA affects serum lipoprotein 
levels similarly to LA [7]. Finally, we speculate that the effects of ALA do depend on 
the intake of cholesterol, as was postulated for palmitic acid [31]. In the present study, 
dietary cholesterol was low for all diets and was 12.1 mg/MJ or 132 mg/d in the high 
ALA diet. In this respect, it is noteworthy that in the studies of Valsta et al. and Zhao et 
al., cholesterol intake was 2 times higher [7,25], Unfortunately, the few other studies that 
compared the lipidemic effect of ALA and LA did not report the cholesterol levels of 
their diets [5, 6, 24, 26, 27]. In agreement with other studies, HDL cholesterol and TG 
concentrations did not change significantly in our study [6 ,24,27] , 
The effects of dietary n-3 and n-6 fatty acids on lipoprotein particle distributions 
and lipoprotein particle sizes, which are related to cardiovascular risk [32-34], have 
scarcely been studied. For the marine PUFAs, it was suggested that fish oil may 
favorably lower concentrations of small and medium VLDL particles [3]. Only 1 study 
examined changes in the lipoprotein particle profile of hyperlipidemic subjects after 
consuming low- and high-fat diets with and without walnuts, rich in ALA but also in 
LA [8]. It was reported that consumption of the high-fat diet walnut supplementation 
favorably decreased small LDL cholesterol and large HDL particle concentrations. 
However, results are difficult to interpret because not only ALA and LA changed after 
consumption of the walnuts, but also total fat intake, which is also a determinant of 
lipoprotein particle size and subclass distribution [35, 36]. We observed a comparable 
decrease in total VLDL particle concentrations in the low LA and high ALA groups, but 
effects on VLDL subclasses differed. Compared with the control group, the low LA diet 
decreased medium VLDL subfraction concentrations, whereas the high ALA diet 
lowered small VLDL subclasses. The latter observation may explain the decrease in 
LDL cholesterol concentrations in the high ALA group. Small VLDL particles, rather 
then large VLDL particles, are considered to be the preferred substrate for conversion 
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into LDL lipoproteins [37, 38]. Hence, a decrease in small VLDL particles may lower 
LDL synthesis and consequently LDL cholesterol concentrations. The finding that both 
the low LA and high ALA diets decreased total VLDL particle concentrations was also 
observed after consumption of fish oil, which is rich in EPA and DHA In the present 
satdy, the proportion of EPA in plasma phospholipids was significantly increased with 
consumption of both experimental diets, whereas DHA was not affected. This raises the 
question whether EPA might have caused the change in VLDL particle concentrations. 
In conclusion, the present study indicates that the ALA:LA ratio is not a 
determinant of serum lipids and lipoproteins concentrations. Only the diet with a small 
increase in ALA intake caused a significant decrease in LDL cholesterol and apoB 
concentrations. This decrease might have been caused by the decrease in small VLDL 
particles, the precursor to LDL lipoproteins. Effects of ALA on LDL cholesterol 
contrasted, however, with those of previous reports and warrant further study. 
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CHAPTER 6 
Effects of a-linolenic acid versus those of EPA/DHA on 
cardiovascular risk markers in healthy elderly subjects 
Petra L. L. Goyens, and Ronald P. Mensink 
Based on 
European Journal of Clinical Nutrition 2006; 60:978-984. 
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A B S T R A C T 
Objective 
To compare the effects of a-linolenic acid (ALA; C18:3n-3) to those of 
eicosapentaenoic acid (EPA; C20:5n-3) plus docosahexaenoic acid (DHA; C22:6n-3) on 
cardiovascular risk markers in healthy elderly subjects. 
Design 
A randomized double-blind nutritional intervention study. 
Setting 
Department of Human Biology, Maastricht University, the Netherlands. 
Subjects 
Thirty-seven mildly hypercholesterolemic subjects, 14 men and 23 women aged 
between 60 and 78 years. 
Interventions 
During a run-in period of 3 weeks, subjects consumed an oleic acid-rich diet. The 
following 6 weeks, 10 subjects remained on the control diet, 13 subjects consumed an 
ALA-rich diet (6.8 g/d) and 14 subjects an EPA/DHA-rich diet (1.05 g EPA/d + 0.55 g 
DHA/d). 
Results 
Both n-3 fatty acid diets did not change concentrations of total-cholesterol, 
LDL-cholesterol, HDL-cholesterol, triacylglycerol and apoA-1 when compared with the 
oleic acid-rich diet. However, after the EPA/DHA-rich diet, LDL-cholesterol increased 
by 0.39 mmol/L (P = 0.0323, 95 % CI [0.030, 0.780 mmol/L]) when compared with the 
ALA-rich diet. Intake of EPA/DHA also increased apoB concentrations by 14 mg/dL 
(P = 0.0031, 95 % CI [4, 23 mg/dL]) and 12 mg/dL (P = 0.005, 95 % CI [3, 21 mg/dL]) 
versus the oleic acid and ALA-rich diet, respectively. Except for an EPA/DHA-induced 
increase in tissue factor pathway inhibitor (TFPI) of 14.6 % (P = 0.0184 vs. ALA diet, 
95 % CI [1.5, 18.3 %]), changes in markers of hemostasis and endothelial integrity did 
not reach statistical significance following consumption of the two n-3 fatty acid diets. 
Conclusions 
In healthy elderly subjects, ALA might affect concentrations of LDL-cholesterol and 
apoB more favorably than EPA/DHA, whereas EPA/DHA seems to affect TFPI more 
beneficially. 
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I N T R O D U C T I O N 
Several intervention studies, such as the GISSI-Prevenzione trial and the Cardiovascular 
Health Study, have shown that an increased intake of eicosapentaenoic acid (EPA; 
C20:5n~3) and docosahexaenoic acid (DHA; C22:6n-3) lowers the risk of coronary 
heart disease (CHD) [l, 2]. Humans can acquire these long chain fatty acids (LCFAs) of 
the n-3 family directly through consumption of oily fish and seafood, as well as through 
conversion of a-linolenic acid (ALA; C18:3n-3), a plant-derived n-3 fatty acid which 
may also protect against CHD [3]. However, results from tracer studies indicate that 
ALA conversion is too limited to function as a surrogate for fish intake [4-7]. 
This suggests that these n-3 fatty acids derived from different sources, might have their 
own specific effects on cardiovascular risk markers. However, the number of human 
studies that have directly compared the influence of ALA and its LCFA derivates on a 
wide range of cardiovascular risk markers is sparse. It is known, however, that the 
potential to lower triacylglycerol concentrations in blood by the marine fatty acids is not 
shared by ALA [8], In contrast, results from a recent study by Finnegan et al. suggest 
that ALA and EPA/DHA have comparable effects on blood coagulation and fibrinolytic 
factors 19,10]. Studies with regard to the effects of plant and marine derived n-3 fatty 
acids on endothelial markers are still sparse. 
Most studies so far have been performed in young and middle-aged subjects. 
Surprisingly, less effort has been made to elucidate how ALA and fish oil affect 
cardiovascular risk markers in elderly subjects, considering that the risk for CHD builds 
up with increasing age and the occurrence of CHD is most overt from the age of 
60 years [11]. As decreasing cardiovascular risk is of benefit for this population, elderly 
may also profit from increased n-3 fatty acid consumption to lower the cardiovascular 
risk [12,13]. However, for aged subjects it is not clear to what extent cardiovascular risk 
markers are susceptible to dietary modulation with n-3 fatty acids. Therefore, the aim of 
the present study was to assess the effects of ALA with those of EPA/DHA on 
lipoprotein profile, on coagulation and fibrinolytic factors, and on endothelial function 
in subjects aged between 60 and 78 years. 
M A T E R I A L A N D M E T H O D S 
S u b j e c t s 
Subjects were recruited in Maastricht and surroundings through advertisements in local 
newspapers and posters in university and public buildings. People, who were interested, 
were informed in detail about the nature and purpose of the study, which was approved 
108 
E f f e c t s o f n - 3 f a t l y a c i d s on c a r d i o v a s c u l a r r i sk m a r k e r s in h e a l t h y e l d e r l y s u b j e c t s 
by the Medical Ethics Committee of Maastricht University. After giving their written 
informed consent, 48 volunteers participated in the screening procedure, which 
consisted of measurement of height, weight and blood pressure, and collection of a 
morning specimen of urine to verify the absence of glucose and protein. Further, 
subjects had to fill out a medical questionnaire, while two fasting blood samples, 
separated by a period of at least 3 days, were drawn to determine serum lipids and 
lipoprotein concentrations. A total of 41 subjects, who met the following inclusion 
criteria, were enrolled in the study: serum total cholesterol concentration <8.0 mmol/L, 
triacylglycerol concentration <3 .0 mmol/L, absence of glucose and proteinuria, and no 
use of medication or prescribed diets known to affect the parameters of interest. 
All subjects were apparently healthy, as indicated by a medical questionnaire. 
Two subjects were excluded during the study, as they had to take non-steroidal 
anti-inflammatory drugs, whereas one subject stopped due to family circumstances. 
The remaining 38 mildly hypercholesterolemic subjects, 14 men and 23 women, 
completed the study. The subjects' characteristics of each study group as measured at 
the start of the study are presented in Table 1. Thirty-seven subjects were studied as one 
female subject was excluded prior to analysis of the results, due to incomplete data. 
Table 1 
Subject characteristics measured at the start of the study 
Oleic acid group ALA group EPA/DHA group 
n — 10 n ~ 13 a — 14 
Number of men/women 4/6 5/8 5/9 
Men 
Age (y) 63 ± 3 63 ± 2 63 ± 2 
Weight (kg) 86 ± 7 77 ± 5 82 ± 11 
Height (m) 1.76 ± 0.04 1.72 ± 0.05 1.7 ± 0.04 
Women 
Age (y) 67 ± 7 66 ± 5 66 ± 4 
Weight (kg) 62 ± 9 73 ± 12 68 ± 5 
Height (m) 1.58 ± 0.06 1.65 ± 0.05 1.67 ± 0,05 
Values are means ± SD. 
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E x p e r i m e n t a l des ign and diets 
During the run-in period of 3 weeks, all 37 subjects consumed an oleic acid-rich diet 
For the subsequent 6 weeks, 10 subjects continued on the run-in oleic acid diet, 
13 subjects received a diet rich in ALA and the remaining 14 subjects received a diet 
enriched with EPA and DHA. Subjects were randomly allocated to the three 
intervention groups, stratified for gender, as was described previously [14]. 
Subjects were provided with a specific amount of products made from 
experimental shortenings (Table 2). The experimental products were free of charge and 
consisted of chocolate paste, pies, cake, and spreads. They were supplied, on a weekly 
basis, to each participant individually. In order to prevent oxidation of the highly 
unsaturated fatty acids, no heating was used for the preparation of the experimental 
products and subjects were not allowed to use the spreads for baking or frying. Each 
subject consumed on average 30 g of experimental shortenings, which provided 6,8 g 
ALA for the ALA group and 1.05 g EPA plus 0.55 g DHA for the EPA/DHA group. 
At the end of both the run-in and the intervention periods, subjects had to weigh and 
record their food intakes for two working days and one weekend day to estimate energy 
and nutrient intakes [15]. In addition, subjects were asked to list in a diary any signs of 
illness, medication used, alcoholic beverages and deviations from the study protocol. 
Diaries were checked weekly and in the presence of the subjects. Subjects of the oleic 
acid and ALA group were not allowed to consume fish or seafood. Further, all subjects 
were asked not to change their usual physical activity pattern, smoking habits and use of 
oral contraceptives during the course of the study. Body weight, without shoes or heavy 
clothing, was recorded once a week and, if necessary, energy intake was adjusted. 
B lood s a m p l i n g and ana lyses 
During the last week of both the run-in period and the experimental period, blood was 
sampled three times after an overnight fast of at least 12 h, abstinence of smoking on the 
morning before blood sampling and a 24 h abstinence of alcohol After 15 mill of rest, 
an infusion needle (1.0 mm/G19, Microflex, Ecouen, France) was inserted into an 
antecubetal vein with the subject in a recumbent position. Blood was first drawn into a 
10 mL clotting-tube for measurements of serum lipids and lipoproteins. Then blood was 
sampled into two 5 mL tubes containing citrate, theophylline, adenosine and 
dipyridamole (CTAD) and centrifuged at 2000 g (10 rnin, 4 °C). One tube was kept for 
analysis of plasminogen activator inhibitor (PAI) activity, whereas the other tube was 
further centrifuged at 11500 g (30 min, 4 °C) and used for analysis of coagulation 
factors. Standard pool plasmas were obtained from 15 normolipidemic men and women 
according to the methods described above. Factor Vllam and tissue factor pathway 
inhibitor (TFPI) activities were expressed as percentage of standard plasma. 
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After clotting for at least 1 h at room temperature, serum was obtained by centrifugation 
of the clotting-tubes at 2000 g for 30 min at 4 °C. Serum samples were stored at -80 °C 
until later analysis. At the end of the study, the three samples from the run-in period as 
well as the three samples from the experimental period were pooled (1:1:1, v/v) prior to 
the analyses and all samples from one subject were analyzed within one run. 
Serum concentrations of total cholesterol (CHOD-PAP method; Monotest 
cholesterol, Boeliringer Mannheim, Mannheim, Germany), HDL cholesterol 
(precipitation method; Monotest cholesterol, Boehringer Mannheim, Mannheim, 
Germany) and triacylglycerols (GPO-Trinder; Sigma Diagnostics, S t Louis, MO, USA) 
were analyzed enzymatically. Concentrations of LDL cholesterol were calculated with 
the Friedewald equations [16]. Apolipoprotein (apo) A-l and apoB were measured in 
serum, with an immunoturbidimetric reaction (UNI-KIT apoA-I and UNI-KIT apoB, 
Roche, Basel, Switzerland). Plasma fibrinogen concentrations were measured according 
to the method of Clauss [17]. Factor VII amidolytic (factor Vllam) activity was 
determined using a two-stage chromogenic assay as described elsewhere (Coaset F.VII, 
Chromogenix Instrumentation Laboratory, Milano, Italy) while prothrombin activation 
fragment I + 2 was determined with an enzyme-linked immunoassay (ELISA; 
Enzygnost F 1 + 2 micro, Behring Diagnostics Inc., Westwood, MA, USA) [18]. TFPI 
activity was determined according to the method of Sandset [19] and PAI activity was 
measured with a two-stage indirect chromogenic assay (Spectrolyse®/pL PAI, Biopool, 
Umea, Sweden). Commercially available ELISAs were used to measure concentrations 
of von Willebrand factor (Asserachrom vWF, Boehringer Mannheim, Germany) 
thrombomodulin (Asserachrom Thrombomodulin, Diagnostica Stago, Asniere, France), 
E-selectin (sE-selectin ELISA, Bender MedSystems, Boehringer Ingelheim 
Bioproducts, Germany) and P-selectin (sP-selectin ELISA, Bender MedSystems, 
Boehringer Ingelheim Bioproducts, Germany) and vascular cell adhesion molecule-1 
(sVCAM-1 ELISA, Bender MedSystems, Boehringer Ingelheim Bioproducts, 
Germany). Analysis of the fatty acid composition of erythrocyte neutral phospholipids 
has already been described in detail [14]. 
S t a t i s t i c s 
The statistical power to detect a true difference of at least 20 % in the parameters of 
interest was more than 80 % for the thrombotic parameters and more than 90 % for the 
lipoproteins. For each subject, the responses to the treatments were analyzed with 
one-factor analysis of covariance, using the GLM procedure in SAS (SAS version 8.0, 
Copyright 1999 SAS Institute Inc., Cary, NC, USA). The parameters of interest 
followed a normal distribution. The values at the end of the experimental period 
represented the dependent variables, whereas the values at the end of the run-in period 
were included as covariates and the type of the diet was defined as a fixed factor. 
I l l 
C h a p t e r 6 
When a significant effect of the diet was found (P < 0.05), a Tukey post-hoc test was 
used to compare the diets pair wise. All values were expressed as means with their 
standard deviation. 
Table 2 
Fatty acid composition of the experimental shortenings 
Type of shortening 1 
Oleic acid group ALA group EPA/DHA group 
n = 10 n - 13 n = 14 
E Saturated fatty acids 27.7 22.0 26.6 
C14:0 0.6 0.3 3.3 
C16:0 18.2 13.3 * / 13.8 CI 8:0 6.9 7.1 7.1 
E Monounsaturated fatty acids 63.1 45.1 56.4 
Cl6 : ln -7 0.1 0.1 3.8 
Cl8:In-9 62.0 43.9 50.9 
£ Polyunsaturated fatty acids 9.4 32.7 15.1 
£ n-6 fatty acids 9.2 11.0 9,1 
C18:2n-6 9 y «. m 10,9 8.7 
£ n-3 fatty acids 0.2 21.7 6.2 
C18:3n~3 0.1 21.5 0.5 
C20:5n-3 0.0 0.0 3 * 2! 
C22:6n-3 0.0 0.0 1.6 
Values are expressed in% of total falty acids identified. 
' For details of shortenings, see p, 184 in Wcnsing et ai (1999). 
R E S U L T S 
Body w e i g h t , d i e t a ry intake and e ry th rocy te p h o s p h o l i p i d s 
c o m p o s i t i o n 
Changes in body weight during the experimental period were not significantly different 
(P = 0.201) between the three groups and were -0.1 ± 0.8 kg (mean± SD) for the oleic 
acid group, 0.1 ± 1.2 kg for the ALA group and 0.5 ± 0.6 kg for the EPA/DHA group. 
Energy intake during the study was not significantly different between the three study 
groups (Table 3). Compared to the oleic acid group, MUFA intake decreased however 
significantly by 3.6 En% in the ALA group (P = 0.027, 95 % CI [-5.3, -0.3 En%]). 
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The total PUFA intake was increased in the ALA group by 5.1 En% when compared to 
the oleic acid group (P <0.001, 95 % CI [1.7, 6.4 En%]) and by 3.1 En% when 
compared to the EPA/DHA group (P - 0.02, 95 % CI [0.4, 4.4 En%]. 
The effects of the three study diets on the fatty acid composition of the 
erythrocytes neutral phospholipids have already been described [14]. Briefly, none of the 
three diets changed the proportions of SAFA, MUFA and PUFA significantly in the 
erythrocyte phospholipids. As expected, the proportion of ALA remained unchanged 
after consumption of the oleic acid and EPA/DHA diet, whereas it significantly 
increased with 0.4 % after consumption of the ALA diet (P < 0.001 vs. control diet and 
vs. EPA/DHA diet). Compared to the oleic acid and ALA groups, the proportion of 
CI8:2n-6 decreased significantly with 2.2 % in the EPA/DHA group (P<0.01 vs. 
control group and P < 0.001 vs. ALA group). This decrease was accompanied by a 
significant increase of 1.3 % in the proportion of EPA (P = 0.001 vs. control and vs. 
ALA group) and of 0.8 % in the proportion of DHA (P = 0.001 vs. control and vs. ALA 
group). 
Lip ids and l i pop ro t e in s 
Changes in total cholesterol were not significantly different between the three groups 
(Table 4). Compared with the oleic acid diet, the ALA diet and the EPA/DHA diet also 
had similar effects on LDL. When compared with the ALA group, however, the 
EPA/DHA diet increased LDL cholesterol with 0.39 mmol/L (P - 0.0323, 95 % 
confidence interval for the difference in change: [0.030, 0.780 mmol/L]). These effects 
were also evident for apoB. No difference was observed between the oleic acid group 
and the ALA group, while apoB concentrations increased in the EPA/DHA group with 
14 mg/dL (P = 0.0031, 95 % CI [4, 23 mg/dL]) when compared with the oleic acid 
group and with 12 mg/dL when compared with the ALA group (P - 0.005, 95 % 
CI [3,21 mg/dL]). Triacylglycerol concentrations decreased insignificantly on the 
EPA/DHA group when compared to both the oleic acid and ALA group. Changes in 
HDL cholesterol, the total to HDL cholesterol ratio, and apoA-1 were also comparable 
between the three diets. 
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Table 3 
Mean daily energy and nutrient intakes of the oleic acid group, the ALA group and the EPA/DHA group 1 
Oleic acid group ALA group EPA/D1IA group 
n = 10 n = 13 n = 14 
Energy (MJ/d) 
Run-in period 9.0 ± 1.7 8.8 ± 1.7 9.6 ± 1.5 
Experimental period 9..3 ± 2.4 9.2 ± 2.0 8.4 ± 1.5 
Change 0.3 ± 2.2 0.3 ± 1.2 -1.2 ± 1.6 
Protein (En%) 
Run-in period 13.9 ± 2.4 14.8 ± 2.2 13.3 ± 1.8 
Experimental period 13.7 ± 1.9 13.3 1.5 13.5 ± 2.5 
Change -0.2 ± 2.1 -1.5 ± 1.7 0.3 ± 3.2 
Carbohydrates (En%) 
Run-in period 43.5 ± 6,8 42.3 ± 3.9 40.9 ± 5.0 
Experimental period 41.7 ± 5.9 44.2 5.3 43.0 ± 3.0 
Change -1.8 ± 5.3 1.9 ± 4.2 2.1 ± 6.2 
Fat (En%) 
Run-in period 40.0 ± 6.0 41.4 ± 4.5 43.4 ± 4.3 
Experimental period 40.8 ± 7.1 41.0 ± 5.2 41.9 ± 2.8 
Change 0.8 ± 7.1 -0.4 ± 4.6 -1.6 ± 5.2 
SAFA (En%) 
Run-in period 13.2 ± 2.6 14.4 ± 1.9 14.6 ± 1.8 
Experimental period 14.2 ± 3.2 13.5 ± *> 2 14.2 ± 1.4 
Change 1.0 ± 2.7 -0.9 ± 1.9 -0.4 ± 1.8 
MUFA (En%) 
Run-in period 17.4 ± 2.9 19.0 3.3 20.4 dt 2.8 
Experimental period 17.7 ± 3.9 15.7 ± 2.0 17.7 ± 2.2 
Change 0.3 ± 3.011 »3.3 ± 2.4 b -2.7 ± 3.0 
PUFA (En%) 
Run-in period 6.5 ± 1.6 4.9 ± 0.9 5.9 ± 1.0 
Experimental period 5.5 ± 1.9 9.1 ± 2,4 7.0 ± 1.5 
Change -0.9 ± 2.3 a 4.2 ± 2.1 b 1.1 ± 2.0 a 
LA (En%) 
Run-in period 4.9 ± 1.2 3.8 ± 0.8 4.6 ± 1.0 
Experimental period 4.1 ± 1.8 4.7 ± 1.9 4.6 ± 1.9 
Change -0.8 2.2 0.9 ± 1.7 0.0 ± 9 0 
ALA (En%) 2 
Run-in period 0.02 0.01 0.02 ± 0.01 0.02 ± 0.01 
Experimental period 0.01 ± 0.01 3.23 ± 0.70 0.06 ± 0.02 
Change -0.00 0.00a 3.21 0.70b 0.05 ± 0.02 
EPA/DHA (En%) 2 
Run-in period 0.0 ± 0.0 0.0 ± 0.0 0.0 0.0 
Experimental period 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.1 
Change 0.0 ± 0.0 a 0.0 ± 0.0 a 0.7 ± 0.1 b 
SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; 
LA, linoleic acid; ALA, a-linolenic acid. 
1 Values are means ± SD. Data were analyzed using analysis of covariance with the values from the end of 
the run-in period as covariatc, and diet as fixed factor. Means in a row with superscripts without a 
common letter differ, P < 0.05 (Tukey post-hoc tests for pairwise comparisons), 
2 As provided by the experimental fats only. 
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Table 4 
Effects of diets on serum lipid and lipoprotein concentrations 1 
Oleic acid group ALA group EPA/DHA group 
n = 10 n = 13 n — 14 
Run-in period 6.16 ± 0.94 6.28 ± 0.89 6.57 ± 1.24 
Experimental period 6.17 ± 0.83 6.04 ± 0.98 6.69 ± 1.21 
Change 0.01 ± 0.46 -0.24 ± 0.52 0.12 ± 0.53 
LDL cholesterol (mmol/L) 
Run-in period 4.00 ± 0.84 4.36 ± 0.84 4.48 ± 1.20 
Experimental period 4.06 ± 0.71 4.13 ± 0.83 4.64 1.17 
Change 0.06 ± 0.37 3 11 -0.23 ± 0.413 0.16 ± 0.44 
HDL cholesterol (mmol/L) 
Run-in period 1.60 ± 0.67 1.42 ± 0.35 1.55 ± 0.37 
Experimental period 1.62 ± 0.67 1.42 ± 0.50 1.59 ± 0.46 
Change 0.02 ± 0.17 0.00 ± 0.21 0.04 ± 0.21 
Triacylglycerol (mmol/L) 
Run-in period 1.13 ± 0.51 1.03 ± 0.38 1.10 ± 0.58 
Experimental period 0.99 ± 0.46 0.99 ± 0.52 0.92 ± 0.46 
Change -0.14 ± 0.27 -0.03 ± 0.22 -0.18 ± 0.31 
Total to HDL cholesterol ratio 
Run-in period 4.41 ± 1.70 4.64 ± 1.12 4.42 ± 1.17 
Experimental period 4.29 ± 1.45 4.58 ± 1.25 4.47 ± 1.34 
Change -0.12 ± 0.91 -0.06 ± 0.42 0.04 zfc 0.54 
Apo AI (mg/dL) 
Run-in period 167 zfc 46 167 ± 42 167 ± 30 
Experimental period 165 ± 47 165 45 172 ± 39 
Change -2 12 -2 ± 10 5 ± 16 
Apo B (mg/dL) 
Run-in period 108 ± 21 117 ± 20 116 ± 28 
Experimental period 104 ± 20 115 ± 17 126 ± 34 
Change -4 7 n -2 ± 10a 10 
± 
10b 
i Values are means ± SD. Data were analyzed using analysis of covariance with the values from the end of 
the run-in period as covariate, and diet as fixed factor. Means in a row with superscripts without a 
common letter differ, P < 0.05 (Tukey post-hoc tests for pairwise comparisons). 
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M a r k e r s fo r endo the l i a l f u n c t i o n , adhes ion m o l e c u l e s , blood 
c o a g u l a t i o n and f i b r ino ly t i c pa r ame te r s 
The change in TFPI was significantly different between the ALA and EPA/DHA group 
(P = 0.0184, 95 % CI [1.5, 18.3 %]) (Table 5). Other changes in markers for blood 
coagulation and fibrinolysis were not different between the three groups. No significant 
dietary effects were found on markers for endothelial function (Table 6). 
Table 5 
Effects of diets on coagulation and fibrinolysis 1 
Oleic acid group ALA group EPA/DHA group 
n = 10 n = 13 n = 14 
Fibrinogen (g/L) 
Run-in period 3.0 ± 0.4 3.1 ± OA 3.0 ± 0.2 
Experimental period 3.0 ± 0.3 3.0 ± 0.4 3.1 ± 0.4 
Change 0.0 ± 0.3 0.0 ± 0.3 0.1 ± 0.3 
Factor VHam activity (% of standard) 
Run-in period 83.8 ± 24.4 91.5 ± 15.8 87.6 ± 25.0 
Experimental period 88.2 ± 27.2 89.5 ± 16.1 89.9 26.0 
Change 4.4 ± 8.1 -2.1 ± 9.5 0 ^ <M| J ± 6.8 
Fragment 1+2 (nmol/L) 
Run-in period 1.6 ± 0.4 1.3 ± 0.3 1.9 ± 1.4 
Experimental period 1.6 ± 0.3 1.5 ± 0.4 1.5 ± 0.4 
Change 0,0 ± 0.3 0.2 ± 0.2 -0.4 ± 1.1 
Tissue factor pathway inhibitor (TFPI) (% of standard) 
Run-in period 93.8 ± 8.8 99.2 ± 11.0 92.6 ± 7.9 
Experimental period 98.3 ± 10.2 96.5 ± 10.1 104.5 ± 4.9 
Change 4.5 ± 6.9 a 'b -2.7 ± 13.2 a 11.9 ± 9.9 b 
Plasminogen activator inhibitor activity (PAI) (1U/L) 
Run-in period 13.2 ± 7.2 13.2 ± 8.4 12.8 ± 7.0 
Experimental period 13.2 ± 9.2 14.8 ± 8.6 13.0 ilr 6.4 
Change 0.0 ± 6.6 1.6 ± 5.9 0.2 ± 5.1 
1 Values are means ± SD. Data were analyzed using analysis of covariance with the values from the end of 
the run-in period as covariate, and diet as fixed factor. Means in a row with superscripts without a 
common letter differ, P < 0.05 (Tukey post-hoc tests for pairwise comparisons). 
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Table 6 
Effects of diets 011 markers for endothelial function and adhesion molecules 1 
Oleic acid group ALA group EPA/DHA group 
n ^ I O n ~ 13 n = 1 4 
Von Willebrand factor (% of standard) 
Run-in period 108 ± 21.4 113.9 ± 10.5 116.4 ± 13.2 
Experimental period 108.7 16.7 116.7 ± 12.4 111.5 ± 14.3 
Change 1 ± 19.8 2.8 ± 6.5 -4.9 ± 15.7 
Thrombomodulin (ng/mL) 
Run-in period 18.4 =fc 8.4 21.3 13.0 18.9 ± 9.8 
Experimental period 16.4 ± 6.3 21.2 ± 12.0 17.7 ± 9.7 
Change -2.1 ± 7.1 -0.1 ± 4.3 -1.2 ± 5.9 
E-selectin (ng/mL) 
Run-in period 42.2 ± 15.6 46.0 ± 10.9 45.3 ± 11.9 
Experimental period 44.5 ± 12.8 50.0 ± 9.1 45.8 ± 15.8 
Change 2.4 ± 10.8 4.0 ± 11.4 0.5 ± 9.6 
P-seleclin (ng/mL) 
Run-in period 353 ± 136.6 355.3 115.6 385.1 ± 143.2 
Experimental period 367.6 ± 143.7 344.2 ± 138.0 346.9 ± 160.7 
Change 15 78.8 -11.1 ± 74.7 -38.2 ± 79.0 
VCAM (ng/mL) 
Run-in period 1280 ± 209 1479.2 ± 264.4 1446.8 ± 276.3 
Experimental period 1286.8 ± 300.4 1507.9 ± 407.2 1465.5 ± 326.7 
Change 6 ± 208 28.7 
± 
279.7 18.7 i 128.6 
1 Values are means ± SD. Data were analyzed using analysis of covariance with the values from the end of 
the run-in period as covariate, and diet as fixed factor. There were no significant differences between 
the 3 diets. 
D I S C U S S I O N 
In the present study, the effects of the plant-derived ALA and the fish-derived EPA and 
DHA were examined on cardiovascular risk markers in mildly hypercholesterolemic 
elderly subjects. We found that EPA/DHA significantly increased LDL-cholesterol and 
apoB concentrations as well as TFPI activity when compared with ALA. 
The number of studies which have addressed side-by-side the effects of ALA and 
EPA/DHA 011 cardiovascular risk markers is scarce. In a recent study, Finnegan et al. 
gave hyperlipidemic subjects aged 25 - 72 years for 4 weeks an n-6 fatty acid-rich 
control diet [10]. For the next 6 months, subjects were randomized over the control diet, 
a diet providing 0.8 g or 1.7 g EPA/DHA per day, or a diet supplying 4.5 g or 9.5 g 
ALA daily. None of the diets enriched with n-3 polyunsaturated fatty acids changed 
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fasting serum lipid concentrations, when compared with the n-6 fatty acid control diet. 
These results agreed well with our results, as we also observed no significant changes in 
serum lipid and lipoprotein concentrations of the two n-3 fatty acid diets, when 
compared with the control diet rich in oleic acid. Finnigan et al. [10] further reported that 
serum triacylglycerol concentrations decreased and those of LDL tended to increase in 
the group consuming 1.7 g EPA/DHA when compared to the 9.5 g ALA group. In our 
study, EPA/DHA also increased LDL cholesterol concentration when compared with 
ALA. An LDL-cholesterol increasing effect of fish oil is a common phenomenon, 
especially in hypertriglyceridemic subjects [8]. Furthermore, we did not observe a 
significant hypotriglyceridemic effect after a comparable EPA/DHA intake of 1.6 g/d 
either. However, as reviewed by Harris, triacylglycerol decreased (from I % to 34 % 
compared to control) in studies which provided less than 2 g EPA/DHA per day, but this 
decrease was often not statistically significant [20]. Furthermore, subjects in the present 
study had a rather low baseline triacylglycerol concentration, which might have 
hampered a possible triacylglycerol-lowering effect of marine fatty acids. 
It has been suggested by Sanders that elderly might benefit more from an 
improvement of factors influencing blood clotting and fibrinolysis than of other factors 
involved in the atherogenic process [21]. The few studies in young and middle aged 
subjects that have examined the influence of ALA on factors of coagulation or 
fibrinolysis did, in general, not report any significant effects [22], whereas studies with 
fish fatty acids yielded equivocal results. The activity of the fibrinolytic factor PA1-1, 
for example, did either not change or even increased after EPA/DHA supplementation 
[23. 24]. In view of these contrasting findings, Hansen et al. therefore pooled data 
obtained from 17 studies which provided n-3 fatty acids in doses varying from 1.6 g/d to 
9.0 g/d [25]. It was concluded that there is no strong evidence for unfavorable, clinically 
relevant effects of n-3 fatty acids on PAI-1 activity in plasma [25]. However, as recently 
reviewed [26], modulating effects of EPA/DHA on coagulation factors such as 
fibrinogen, factor VII and von Willebrand factor were in general observed after intakes 
of at least 4 g/d, while most studies could not detect an effect when EPA/DHA intake 
was between 0.9 g/d and 4 g/d. In addition, studies that have specifically compared side-
by-side effects of plant and marine derived n-3 fatty acids suggest that these fatty acids 
have similar effects on hemostasis and fibrinolysis in young and middle-aged subjects, 
both at realistic and rather high intakes [9, 27]. Though most markers of blood 
coagulation and fibrinolysis did not change significantly after consumption of any of 
our study diets, we did observe an increase in TFP1 activity after consumption of the 
EPA/DHA diet when compared to the ALA diet. However, we did not find an effect of 
the EPA/DHA diet on TFPI activity when compared to the oleic-acid rich control diet. 
Grundt et al. found also no effect on TFPI when subjects with combined hyperlipidemia 
consumed for 12 weeks either a daily supplement of 4 g EPA/DHA or a corn oil 
supplement, rich in linoleic acid [28]. 
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In contrast, Berretini et al. found a significant increase in TFPI levels in plasma of 
subjects with chronic atherosclerotic disease following a daily supplementation with 3 g 
EPA/DHA over a period of 16 weeks [29]. 
Results of Miles et al suggested that effects of fish oil on endothelial activation 
were age-dependent. In that study, fish oil did not affect sVCAM-1 and increased 
sE-selectin in young men (< 40 years) but significantly decreased sVCAM-1 and tended 
to lower sE-selectin in the older subjects (> 55 years) [30]. Thies et al. compared the 
influence of moderate intakes of ALA, DHA, and fish oil on plasma-soluble adhesion 
molecules [31]. It was found that, in contrast to DHA alone, both ALA and fish oil 
supplementation decreased sVCAM-1 and sE-selectin compared to the placebo 
supplement (an 80:20 mix of palm and sunflowerseed oils). This finding implies that the 
observed favorable effects are specific for EPA and/or ALA. Zhao et al. also found a 
decrease in sVCAM-1 and sE-selectin in hypercholesterolemic subjects aged between 
36 and 65 years, after consumption of a diet rich in ALA (6.5 En% ALA/day or 
13-28 g/d) [32]. In the study by Rallides et al. a decrease in sVCAM-1, but not in 
sE-selectin was observed in dyslipidemic subjects, after intake of 8.1 g ALA/day 
(15 mL/d of linseed oil) over a period of 12 weeks [33]. In contrast to these studies, our 
study shows that all three diets had comparable effects on plasma-soluble adhesion 
molecules and soluble selectins. Hence, based on our results, we can not attribute a 
beneficial effect to ALA or the marine fatty acids with regard to markers of endothelial 
integrity in healthy elderly. We do not think that the amount of ingested EPA/DHA in 
the present study was too low to induce an effect on endothelial markers, as other 
studies showed beneficial effects after low to moderate intakes of n-3 fish fatty acids [30, 
31, 34-36]. Our study duration was however shorter than that of other studies, which may 
have masked any beneficial effects of EPA/DHA on these endothelial markers. In 
combination with the study duration, the intake of ALA might also have been too low to 
observe effects on sVCAM-1 and sE-selectin within a period of 6 weeks. Even though 
ALA intake in the study by Thies et al [31] was lower (2 g/d than in the present study, 
the study duration was two times longer. In contrast, the study by Zhao et al. [32] also 
lasted 6 weeks, but ALA intake was at least twice as high. Thus, no clear explanation 
exists to explain the divergent effects of ALA on endothelial markers. 
In summary, our findings indicate that n-3 fatty acids from both plant and marine 
sources do not affect the lipid profile equally favorable in elderly subjects as oleic acid. 
Except for the already beneficial effects on aggregation [14], fish fatty acids also seem to 
influence TFPI activity favorably. These positive effects of EPA/DHA are however 
counterbalanced by an increase in LDL-cholesterol and apoB concentrations. Adhesion 
molecules were not affected by any of the n-3 fatty acids when compared to oleic acid. 
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CHAPTER 7 
General Discussion 
G e n e r a l D i s c u s s i o n 
In recent years interest has increased to examine if foods rich in a-linolenic acid (ALA; 
C18:3n-3) are a good dietary source to increase plasma and tissue levels of EPA and 
DHA. ALA, which can be converted into the fish fatty acids EPA and DHA, is a 
plant-derived fatty acid that is present in a wide variety of products such as rapeseed oil, 
soybean oil, lineseed oil, nuts and nut oils and to a lesser degree in green leafy 
vegetables. The few studies that have estimated ALA conversion into EPA and DHA 
have suggested that conversion is limited [1-7]. However, estimates vary widely due to 
different experimental approaches that do not always mimic physiological situations. 
Furthermore, in some studies, the intake of ALA as well as its n-6 counterpart LA 
changed simultaneously, which inevitably also modified the ALA-to-LA ratio. As the 
enzymatic conversions of ALA and LA are interrelated, it is likely that a change in ALA 
intake modulates the n-3 conversion pathway differently from a change in LA intake or 
a change in their ratio. 
The primary emphasis of the present thesis lies on the estimation of the in vivo 
conversion of dietary ALA in healthy humans. A stable isotope study was performed in 
11 
which - for the first time - multiple oral tracer boluses of [U- C]ALA were given 
during a longer-term period of 9 days. A compartmental model was developed to 
quantify n-3 conversion, and to unravel the effects of a change in ALA, LA and their 
ratio on ALA metabolism. Because the mathematical model forms the cornerstone of 
the present work, we discuss our modeling framework, and its benefits and potential 
pitfalls against other modeling approaches that have been applied to date. 
D E V E L O P M E N T O F A C O M P A R T M E N T A L M O D E L F O R A L A 
C O N V E R S I O N 
At the time our experiment was performed, Pawlosky et al. published the first study in 
which a compartmental model was proposed to describe the conversion of ALA in 
human adults [2]. In that study, eight healthy subjects consumed a beef-based diet during 
21 days. At the end of this dietary period, subjects received a single large oral bolus of 
1 g deuterated alpha-linolenate (d5-18:3n-3 ethyl ester) dissolved in a low-fat yogurt. 
Subjects received also a breakfast and a lunch. Blood samples, both fasting and 
postprandial, were taken at 0, 8, 24, 48, 72, 96 and 168 hours after tracer intake, while 
the different n-3 fatty acid tracer concentrations were measured in total plasma lipids. 
The compartmental model of Pawlosky et al. consisted of 5 compartments: the first 
compartment represented isotope administration and gastrointestinal absorption, 
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whereas the other four compartments corresponded to the plasma total lipid pools of 
ALA, EPA, DPA, and DMA, respectively [2], It was assumed that 98 % of the tracer 
bolus was absorbed and ended up in total plasma lipids. With this model, it was 
estimated that not more than 0.2% of plasma ALA was used for EPA synthesis, 
whereas 63 % of plasma EPA was converted into DPA and 37 % of DPA was further 
converted into DHA. In view of the experimental differences, we had to develop 
another compartmental model. In contrast to the model developed by Pawlosky et al. [2], 
our model also made optimal use of the information available from both the labeled and 
unlabeled n-3 fatty acid data. 
Briefly, a compartmental model is a mathematical construct which describes a 
set of time-varying tracer data and is based on the principle of mass balance. The set-up 
of our compartmental model consisted of several steps. First a model was developed 
using the averaged tracer data of the 29 subjects. With this tracer model, the transfer 
rate coefficients k(i,j) were determined. Transfer rate coefficients correspond to the 
fraction of a substrate that is transferred per unit of time from compartment j to i. Then a 
structurally identical tracee model was built and linked to the tracer model. 
The averaged tracee data of 29 subjects, the daily dietary ALA intake and the kinetic 
parameters derived from the tracer model were incorporated into the tracee model. Both 
the tracer and tracee model were then solved simultaneously. The main advantage of 
using averaged tracer and tracee data was that the noise in the data was minimized and a 
more reliable model could be developed. To implement the transfer rate coefficients on 
the tracee data to estimate tracee movements in the system, the tracee system has to be 
in a steady-state. During tracee steady-state, the differential equations, which describe 
the tracee fatty acid system, become algebraic equations. The latter can then be solved 
using the k(i,j) estimates from the tracer experiment. Using this approach, we found that 
approximately 7 % of dietary ALA was incorporated into plasma phospholipids and that 
almost all of the incorporated ALA was completely converted into EPA, but only 
marginally further into DHA, Furthermore, the main bottleneck within the n-3 pathway 
was the limited incorporation of dietary ALA into the plasma phospholipids pool rather 
than the delta-6 desaturation step. Our results did not agree with the results obtained by 
Pawlosky et al. [2]. This is, as will be discussed below, largely due to the differences in 
experimental approach. 
C H O I C E OF L I P I D F R A C T I O N AS T H E M O D E L I N G F R A M E W O R K 
As is widely accepted, we assumed that the liver is the main and most significant site 
for conversion. Because it is not possible to determine in vivo n-3 fatty acid metabolism 
directly in the human liver, plasma phospholipids were chosen to reflect hepatic ALA 
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metabolism. Dietary ALA and most of the de novo synthesized long chain derivates will 
assemble in the phospholipids of the newly secreted lipoproteins. It was further assumed 
that, the estimation of ALA conversion based on the different n-3 fatty acids in plasma 
phospholipids will closely resemble the hepatic ALA conversion. 
It might be argued that hepatic ALA conversion is better approximated when 
quantification is based on the n-3 fatty acids content of total plasma lipids or, 
alternatively, when estimated for each of the major lipid class components of total 
plasma lipids. However, we believe that it is more accurate to restrict the modeling 
framework to plasma phospholipids instead of expanding it to total plasma lipids. Total 
plasma lipids consist of free fatty acids, chylomicrons, cholesterylesters (CEs), 
triacyl glycerol (TG) and phospholipids. The first three lipid fractions, however, are not 
suitable representatives to estimate hepatic ALA conversion. From the tracer studies by 
Burdge et alM for example, it is known that the plasma n-3 free fatty acid concentration 
is negligible [5, 6]. Furthermore, if chylomicrons contain any long-chain 13C-labeled n-3 
fatty acids at all, they are most likely obtained from conversion of the ALA tracer in the 
enterocyte and not from hepatic conversion. CEs that are synthesized in the liver 
represent hepatic conversion whereas those from intestinal or peripheral origin do not. 
In the latter situation, the n-3 fatty acids that are used for synthesis of CE are derived 
from phospholipids and as a result do not lead to other insights into ALA conversion. 
Actually, the n-3 fatty acids that are transferred from phospholipids to CEs are already 
part of the irreversible loss parameters leaving each n-3 compartment. Moreover, data 
from the study by Emken et al. showed that CEs are rather poor in n-3 LCPUFAs [1]. 
TG, on the other hand, could also reflect hepatic conversion. TGs are richer in ALA 
than plasma phospholipids, but just like CEs, contain less long-chain n-3 fatty acids. 
11 
However, from our measurements we could not detect any ' C-labeled n-3 LCPUFAs. 
If total plasma lipids are used as a surrogate to model hepatic conversion of 
dietary ALA, the mass of the [ l3C]ALA compartment would increase substantially. 
The increases in the masses of the EPA, DPA and DHA compartments, however, will 
be rather modest compared to that of ALA. Consequently, the incorporation of dietary 
ALA into the ALA compartment and the irreversible loss of ALA from that 
compartment will increase considerably whereas the transfer rate coefficient of ALA 
into the EPA compartment will decrease. Findings from the study by Pawlosky et a l 
provide an excellent illustration [2]. In that study» it was assumed that 98 % of dietary 
ALA would end up into the plasma total lipid ALA compartment pool. However, 
despite the large incorporation into the ALA compartment pool, only 0.2 % of this pool 
was estimated to be converted into EPA. 
Additionally, caution should be taken how results are presented. Irrespective of 
the lipid fraction used, expressing conversions only as percentages of plasma pools 
might not be informative. To avoid misinterpretation, results should also be presented as 
the percentage or amount of dietary ALA that is converted. 
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F A S T I N G V E R S U S F A S T I N G A N D N O N - F A S T I N G S A M P L E S 
In contrast to the study by Pawlosky et al. [2], we deliberately chose to base the model 
on the outcomes of fasting blood samples only. In this way, we avoided mixing fasting 
and postprandial blood samples. In the latter case, a major part of labeled ALA is 
present in the chylomicron fraction. However, this ALA tracer is not yet available for 
hepatic metabolism, since chylomicrons have not passed the liver. Furthermore, if 
present at all, isotopically labeled EPA, DPA and DHA in chylomicrons can only be 
derived from intestinal conversion. In fact, Burdge et al. did detect labeled EPA and 
DPA within 2 hours after tracer intake in the TG fraction of chylomicrons, but they 
could not exclude a possible contamination of the chylomicron-rich fraction with 
VLDL [5]. Furthermore, nC-labeled ALA will account for nearly all labeled n-3 fatty 
acids present in chylomicrons. Therefore, adding the labeled n-3 fatty acid content of 
this lipid fraction to those of plasma phospholipids will increase the mass of the ALA 
compartment considerably, whereas it will hardly affect the compartmental masses of 
the other n-3 fatty acids. As a result, comparable effects on the estimates of kinetic 
parameters are expected when total lipids are used: the transfer rates for the 
incorporation and the irreversible loss from the ALA compartment will increase 
whereas the transfer rate describing the conversion from ALA to EPA will decrease. 
S I N G L E L A R G E B O L U S V E R S U S L O N G T E R M S M A L L B O L U S 
INTAKE 
Tracers have the important characteristics that they are detectable and distinguishable 
from their unlabeled analogues whereas their kinetic behavior is similar [8]. However, 
the latter property is only true when the tracer is provided in trace quantities. 
Large amounts of tracer intake might perturb the metabolic system and compromise 
tracee behavior. The prerequisite of administering minute tracer quantities was certainly 
not met in the study by Pawlosky et al. [2], since the 1000 mg deuterated 
alpha-linolenate ethyl ester (d5-C18:3n-3) was about 8 9 % of the daily dietary ALA 
consumption. Demmelmair et al. have indeed shown by using compartmental modeling 
that estimates for the conversion of LA into dihomo-y-linoleic acid and arachidonic acid 
were higher after a fractionated intake than after one bolus of the same tracer 
quantity [9J. We therefore provided our subjects on the first day with a single bolus of 
30 mg [U-I3C]ALA and for the next eight days a dose of 10 mg twice daily. 
In this way, daily tracer intake was only about 2.7 % and 1.8 % of total daily ALA 
intake, respectively. In addition, we administered the tracer for a longer-term according 
to a fractionated dosing schedule, as our aim was to mirror the effects of longer-term 
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supply on the conversion of ALA into EPA and DHA. With this approach, the 
tracer-tracee balance was not disrupted, while at the same time reliable estimates for 
DHA synthesis could be obtained. In an earlier study by Vermunt et al., it was shown 
that after a low dose of 45 mg [U-I3C]-labeled ALA enrichment of especially DHA 
increased slowly and marginally [10]. Thus, in addition to the amount of tracer intake, 
the scheduling of tracer administration might also have influenced the differences in the 
estimates of ALA conversion between our study and that of Pawlosky et al [2]. 
E F F E C T S O F A C H A N G E IN D I E T A R Y L A , A L A A N D T H E I R R A T I O 
ALA and its n-6 counterpart LA compete for the same desaturation and elongation 
enzymes . Although ALA is the preferred substrate for the desaturase enzymes, LA has 
a competitive advantage because it is much more abundant in most diets than ALA 
[11-13]. Thus, changing the intake of ALA or LA might induce shifts in the synthesis of 
the longer chain fatty acids EPA and DHA. In addition, the ALA to LA ratio in the diet 
might affect conversion of dietary ALA independent of the absolute intakes of ALA and 
LA. 
To date, the tracer study by Emken et al. is the only study that quantitatively 
examined the effect of an increased LA intake on the conversion of ALA, which was 
estimated by calculating the area under the curve (AUC) [1]. In this study, it was found 
that conversion of ALA decreased by 40 %: from 18.5 % after a saturated fatty acid rich 
diet (4.7 energy percent (En%) LA, 0.6 En% ALA, ALA to LA ratio of 1:8) to 11 % on 
a polyunsaturated fatty acid enriched diet (9.3 En% LA, 0.3 En% ALA, ALA to LA 
ratio of 1:30). This decrease in ALA conversion was completely ascribed to the 
increased LA intake. However, it might also have been caused by the simultaneous 
decrease in ALA intake or in the ALA to LA ratio. 
Theoretically, ALA conversion may be increased by increasing the availability 
of ALA for the converting enzymes through a decrease in LA intake, an increase in 
ALA intake, or an increase in their ratio. Whether these dietary changes have 
quantitatively the same effects on n-3 fatty acid conversion is however not known. 
Our tracer study is the first to quantitatively unravel the effects of a change in the 
absolute amounts of ALA and LA and their ratio on the in vivo conversion of dietary 
ALA. We found that a limiting step in the conversion cascade of ALA is its 
incorporation into plasma phospholipids. Furthermore, not the ALA to LA ratio, but the 
amounts of ALA and LA in the diet determined n-3 fatty acid conversion. In fact, as can 
be seen in Figure 1 and Figure 2, a decrease in LA intake has different effects on the 
absolute and relative conversion of dietary ALA than an increase in ALA intake. 
When the consumption of LA is decreased, the relative and absolute conversion of 
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dietary ALA into EPA is increased, whereas synthesis of DHA does not change. 
Increasing the intake of ALA, however, did not affect conversion of dietary ALA into 
EPA, whereas it did increase the absolute amount of DHA synthesized. 
It should be emphasized that there is an apparent contradiction between the 
information derived from the n-3 fatty acid composition of plasma phospholipids and 
the findings obtained with the stable isotope study. As mentioned previously, based on 
the results of the tracer study, we concluded that not the ALA-to-LA ratio but the 
amounts of ALA and LA in the diet determine how much EPA and DHA are 
synthesized from dietary ALA. However, the n-3 fatty acid content of plasma 
phospholipids suggests exactly the opposite: not the dietary masses of ALA and LA are 
important but their ratio. For example, the EPA proportion in plasma phospholipids 
increased when subjects changed from the control diet with an ALA to LA ratio of 1:19 
to a diet with a ratio of 1:6. Hence, regardless of whether the low LA diet or high ALA 
diet was consumed, the same ratio led to the same changes in the proportions of EPA in 
plasma phospholipids. In contrast, from the tracer conversion study we concluded that 
the conversion of dietary ALA to EPA increased on the low LA diet, but not on the high 
ALA diet. However, it should be noted that the EPA plasma phospholipid profile is a 
resultant of a continuous inflow of EPA fatty acids balanced by an outflow of EPA fatty 
acids. The inflow of EPA consists of dietary ALA that was consumed during the 
experimental period but also of dietary ALA and dietary EPA that were consumed 
before the study period. The latter were most likely released from endogenous sources 
such as for example fat tissue, lipid bilayers, or plasma lipid fractions. The outflow of 
EPA from the phospholipid pools might for example circulate in the body in other lipid 
fractions and return to plasma phospholipids as EPA at a later time point, might be 
directed towards storage pools or might be oxidized to C02 . Thus, similar pool sizes (as 
measured under steady-state condition) may be the resultant from different kinetics (as 
measured with stable isotopes). 
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Conversion ALA —• EPA 
Proportion 
(% EPA formed) 
Absolute amount 
(mg EPA formed) 
Low LA diet High ALA diet 
î 1 
î 
Figure 1 
Overview of the effects of the low LA diet and high ALA diet on the synthesis of EPA from dietary ALA 
Conversion ALA —• EPA —* DHA 
Low LA diet High ALA diet 
Proportion 
(% DHA formed) I Z 
Absolute amount 
(mg DHA formed) I f 
Figure 2 
Overview of the effects of the low LA diet and high ALA diet on the synthesis of DHA from dietary ALA 
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E F F E C T S O F A L A A N D FISH F A T T Y A C I D S ON C H D R I S K 
M A R K E R S 
As extensively reviewed [14-16], prospective studies suggest that marine n-3 LCPUFAs 
reduce the risk of coronary heart disease. Intervention studies have also suggested that 
these fatty acids lower cardiovascular risk [17, 18]. A recent meta-analysis however did 
not find any positive effects of fish oil fatty acids on overall mortality, combined 
cardiovascular events [19]. Although this meta-analysis has been criticized [20-22], it does 
show that effects of fish oil on cardiovascular risk are equivocal. Also the recent Study 
on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA-trial) could not demonstrate 
positive effects of fish oil supplementation [23]. Interest in the cardioprotective effects of 
ALA rose after the results of the Lyon Heart Study [24, 25]. In this study, however, the 
experimental diet not only provided more ALA, but also more monounsaturated fatty 
acids and fibers from fruits, vegetables and cereals, whereas it contained less linoleic 
acid and saturated fatty acids [26]. This makes it impossible to draw any firm 
conclusions on the effects of ALA itself Whatever the precise effects of n-3 fatty acids 
on cardiovascular risk are, the background of these possible effects is also not clear. 
In our studies, we mainly focused on the effects of these fatty acids on the serum 
lipoprotein profile. 
Considering that the conversion of ALA into EPA and DHA is very limited, the 
effects of the fish fatty acids might differ from those of ALA. EPA and DHA have the 
characteristic to lower serum TG concentrations, while they may increase LDL 
cholesterol levels slightly, especially in hypertriacylglycerolemic subjects [27, 28]. 
In our study we could not detect a significant decrease in TG after an EPA/DHA intake 
of 1.6 g/day in elderly subjects. This is, however, not an uncommon finding for studies 
providing less than 2 g EPA/DHA daily [29]. The fish fatty acids did however increase 
LDL cholesterol concentrations compared to ALA. As expected, an increase in dietary 
ALA did not lower serum TG levels, compared to oleic; acid. In another study, we 
compared the effect of ALA, LA and their ratio on serum lipids, lipoprotein 
concentrations, lipoprotein subclass distributions and particle sizes. We found that the 
ALA to LA ratio did not determine the serum lipid profile. Furthermore, in contrast to 
findings from other studies [30-34], ALA decreased LDL cholesterol significantly 
compared to oleic acid and LA, possibly through a decrease in small VLDL particles. 
Findings from a few recent studies [35,36] suggest that plant and marine n-3 fatty 
acids have comparable effects on blood coagulation and fibrinolytic factors. Our results 
agree with these findings as most markers of blood coagulation and fibrinolysis did not 
differ between the EPA/DHA enriched diet and the ALA enriched diet. Only an increase 
in TFPI activity was observed after an increased consumption of EPA/DHA. 
EPA/DHA, but not ALA, may also have beneficial effects on platelet aggregation when 
compared to oleic acid [37]. Markers for endothelium function however were affected 
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comparably. Thus, effects of n-3 fatty acids on serum lipoproteins and haemostatic 
function are too small to explain their potential positive effects on cardiovascular risk, 
when compared to other cw-unsaturated fatty acids. 
C O N C L U D I N G R E M A R K S A N D R E C O M M E N D A T I O N S F O R F U T U R E 
S T U D I E S 
Our results show that in humans in vivo conversion of ALA is limited considering that 
less than 10 % of ALA in the diet is converted. Nearly all of this ALA is converted into 
EPA, but only marginally and slowly into DHA. Furthermore, the in vivo conversion of 
dietary ALA is not determined by the ALA to LA ratio of the diet, but by the separate 
amounts of these two fatty acids. Dietary ALA and LA have, however, different effects 
on ALA conversion. More specifically, a decrease in LA intake increases the synthesis 
of EPA, whereas an increase in ALA intake increases the synthesis of DHA. 
In apparently healthy, non-hypertriacylglycerolemic subjects, effects on the serum 
lipoprotein profile were comparable, although ALA unexpectedly decreased LDL 
cholesterol and apoB concentrations compared to LA. 
It should be emphasized that our studies were not designed to define and propose 
optimal dietary intakes for LA, ALA and their LCPUFA derivates. However, our 
findings do indicate that the emphasis of dietary recommendations should be placed on 
the individual intakes of dietary ALA and LA and not on their ratio. A decrease in LA 
intake coupled to an increase in ALA intake is the most opportune approach to increase 
the synthesis of the fish fatty acids EPA and DHA from plant derived ALA. Conversion 
of the latter source will however not elevate the DHA plasma phospholipid levels as 
substantially as a moderate consumption of fish or marine oils will [l lj. 
In fact, consumption of EPA and DHA remains the most efficient way to improve n-3 
LCPUFA status [11]. 
The present work focused on the modulating effects of dietary ALA, LA and 
their ratio on the metabolism of dietary ALA and on its effects on serum lipids in 
healthy humans. It might be interesting to extend quantitative n-3 fatty acid conversion 
studies to other population groups, such as for example non-fish consuming vegetarian 
and vegan subjects, to examine whether their n-3 fatty acid conversion capacity differs 
f rom that of omnivore subjects. Vegetarian and vegan subjects have lower plasma n-3 
fatty acid concentrations than omnivores [38]. Furthermore, the ALA content, and even 
more so the LA content is higher in vegetarian and vegan diets than in omnivore 
diets [ 38 ,39 ] . Vegans and vegetarians are supposed to be optimal LCP synthesizers [12]. 
Perhaps they might benefit more form a change in the ALA and LA intake than 
omnivore subjects. Furthermore, Burdge et al. have recently proposed to consider 
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gender differences in the metabolism of n-3 fatty acids when defining dietary 
recommendations concerning the n-3 fatty acids [40], Several studies have indeed 
suggested that premenopausal women have higher DHA levels than men of the same 
age group [5,6,41-43]. However, before gender specific dietary recommendations should 
actually be considered, more studies, that are specifically designed to determine 
quantitatively the effect of gender and reproductive status on ALA conversion, are 
warranted. It is now well established that conversion of ALA into EPA and in 
particularly into DHA is limited in humans. The underlying cause of the restricted 
LCPUFA synthesis is however unclear. Studies at the molecular level might also 
provide insight in ALA conversion. Furthermore it has been suggested that DHA 
synthesis from DPA is downregulated via feedback inhibition of the plasma DHA 
concentration in subjects following a fish based diet [3]. Studies could be performed to 
examine quantitatively the effect of a change in dietary n-3 LCPUFAs on the 
conversion of ALA. Further, it would be of interest to examine the contribution of other 
tissues to the conversion of ALA into its n-3 LCPUFAs. So far most quantitative studies 
have aimed to estimate hepatic conversion. However, desaturase expression has also 
been found in human brain, heart and long [44, 45], whereas studies with primates 
suggest that nervous tissue is also able to convert ALA [46]. Finally, it has recently been 
shown that there is a strong association between the fatty acid composition of serum 
phospholipids - among others ALA, EPA, DHA - and the variants of the human delta-5 
and delta-6 desaturase gene clusters FASD1 and FASD2 [47]. If these gene clusters are 
indeed important for the conversion of ALA into EPA/DHA, then it would be 
interesting to see of these clusters are also related to diseases in which LCPUFA may 
play a role. 
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a-LinoIenic acid (ALA, C18:3n-3) is a fatty acid of the n-3 fatty family. It is called 
essential because humans cannot synthesize it de novo, despite that it is vital for their 
health. Once ingested, ALA can be converted into longer and more unsaturated fatty 
acids such as eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, 
C22:6n-3). EPA and DHA are also known as fish fatty acids, as they are mainly present 
in fatty fish and fish oil. Over the years, interest in EPA and DHA has increased, 
because of their postulated beneficial effects on a wide variety of health parameters 
such as cardiovascular risk. Despite all efforts, consumption of these marine fatty acids 
remains below dietary recommendations. However, because ALA is the precursor for 
EPA and DHA synthesis and because it is easily available from plant derived sources, 
an increased ALA intake might be helpful to increase the EPA and DHA status of the 
body. To resolve whether dietary ALA is a suitable alternative for the marine fatty 
acids, it is necessary to have a quantitative understanding of its metabolic pathways. 
The extent of dietary ALA conversion appears to be very low. However, most studies 
only allowed a qualitative or semi-quantitative description of ALA conversion. Despite 
that quantification remains complex, it is possible to quantify the in vivo conversion of 
ALA in humans using stable isotopes and compartmental modeling. Furthermore, the 
conversion of ALA may depend on the intake of linoleic acid (C18:2n6; LA), which 
might complicate estimation of dietary ALA conversion even more. ALA and LA share 
the same converting enzymes. Therefore, conversion of dietary ALA might be increased 
in three distinct ways: through an increase of ALA intake, via a decrease in LA 
consumption, or by increasing the ratio in the diet. So far, the outcome of each separate 
approach has not been quantitatively assessed in humans. 
To estimate hepatic in vivo conversion of dietary ALA, 29 subjects (14 men and 
15 women) followed for 4 weeks a diet providing 7 % of energy from LA and 0.4 % 
from ALA. On day 19, subjects received a single tracer bolus of 30 mg uniformly 
labeled [13C]ALA and for the following 8 days 10 mg twice daily. Fasting plasma 
phospholipid concentrations of 12C- and 13C-labeled ALA, EPA, docosapentaenoic acid 
(DPA; C22:5n-3), and DHA were determined oil days 19, 21, 23, 26, 27, and 28. 
Conversion of ALA into its longer-chain polyunsaturated fatty acids was estimated by 
compartmental modeling. To this end, a tracer model was developed based on the 
11 
averaged C-labeled fatty acid data of the participants. A similar tracee model was set 
up, which contained the averaged l2C-labeled fatty acid data, the mean daily ALA 
intake, and the kinetic parameters derived from the tracer model, Both models were 
solved simultaneously to estimate the incorporation of dietary ALA into plasma 
phospholipids and its subsequent conversion into its LCPUFAs. It was estimated that 
7 % of dietary ALA was incorporated into plasma phospholipids. Nearly all of this ALA 
pool was converted into EPA and 1 % of the EPA plasma phospholipid pool, which 
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corresponds to 0.07 % of dietary ALA intake, was converted into DP A and 
subsequently into DHA. The limited conversion of ALA-derived EPA into DPA might 
therefore be an obstacle for DHA synthesis. 
After these 4 weeks, subjects received for 6 weeks one of the 3 experimental 
diets to examine whether ALA metabolism is influenced by the intakes of ALA, LA or 
their ratio. Nine subjects continued to consume the control diet, ten subjects received a 
low LA diet (3 En% LA, 0.4 En% ALA, ratio = 1:7), and ten subjects a high ALA diet 
(7 En% LA, 1.1 En% ALA, ratio = 1:7). Ten days before the end of this experimental 
period, subjects were provided with oral boluses of [U-13C]-ALA during 9 days and 
* * * 13 breath was sampled during the first 9 hours to estimate oxidation of [U-°C]ALA. 
* \ \ 
Conversion of ALA was estimated using compartmental modeling of the individual C-
and l2C n-3 fatty acid concentrations in fasting plasma phospholipids obtained during 
run-in and the experimental periods. We found that the incorporation of ALA into 
plasma phospholipids increased by 3.6 % in the low LA group and decreased by 8.0 % 
in the high ALA group. In absolute amounts, it increased by 34.3 mg in the low LA 
group, but did not change significantly in the High ALA group. Nearly all ALA from 
the plasma phospholipid pool was converted into EPA. In the 3 groups, conversion of 
EPA into DPA and DHA hardly changed and was < 0.1 % of dietary ALA. In absolute 
amounts, synthesis of DHA was unchanged in the low LA group, whereas it increased 
from 0.7 to 1.9 mg in the high ALA group. The dietary interventions did not change the 
oxidation of ALA. Our results suggest that the amounts of ALA and LA in the diet - but 
not their ratio - determine ALA conversion. 
Determinants of the in vivo metabolism of ALA in humans are poorly 
understood. We therefore explored whether ALA conversion and oxidation are related 
to gender, age, basal metabolic rate, body composition, and the proportion of linoleic 
acid and trans fatty acids in plasma phospholipids. The conversion of dietary ALA into 
EPA was positively associated with age and percentage fat mass, while the conversion 
of EPA into DHA was negatively associated with the proportion of LA in plasma 
phospholipids. In our study, we did not find an association between gender or 
reproductive status with the conversion and oxidation of dietary ALA. 
Aside from its role as a precursor for the synthesis of the marine fatty acids, 
ALA might have beneficial effects on cardiovascular risk markers. A sparse number of 
studies have suggested that ALA has similar effects on serum lipid levels as its n-6 fatty 
acid analog LA, but an effect of a change in the ALA:LA ratio cannot be excluded. 
Furthermore, the effects of ALA, LA and their ratio on lipoprotein subclass distributions 
are unknown. Finally, we have compared side-by-side the effects of ALA with those of 
EPA/DHA on cardiovascular risk markers in elderly subjects aged between 60 - 78 y. 
We found that the ALA to LA ratio did not determine the serum lipid profile, 
in addition, ALA decreased LDL cholesterol significantly compared to oleic acid and 
LA, possibly through a decrease in small VLDL particles. In healthy elderly subjects, 
ALA affected concentrations of LDL cholesterol and apoB more favorably than 
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EPA/DHA did. Furthermore, our findings suggested, that ALA and its long chain 
derivatives have comparable effects on markers of blood coagulation, fibrinolysis, and 
endothelium function. 
In conclusion, in vivo conversion of dietary ALA in humans is less than 10 %, 
Conversion depends on the amounts of ALA and LA in the diet, but not on their ratio. 
However, ALA and LA affect ALA conversion differently, as an increased LA intake 
increased EPA synthesis, while DHA synthesis increased after an increased ALA 
intake. ALA and the marine n-3 fatty acids had comparable effects on markers of blood 
coagulation, fibrinolysis and endothelium function. Except for an unexpected decrease 
in LDL cholesterol and apoB concentrations, ALA affects serum lipid concentrations 
and lipoprotein profile comparably to LA in healthy non-hypertriacylglycerolemic 
individuals. The serum lipid concentrations and lipoprotein subclass distributions are 
not affected by the ALA:LA ratio. 
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a-Linoleenzuur (ALA; C18:3n-3) is een vetzuur dat behoort tot de n-3 vetzuur familie. 
ALA wordt een essentieel vetzuur genoemd omdat het noodzakelijk is voor de 
gezondheid terwijl het menselijk lichaam het niet zelf kan produceren. Na opname via 
de voeding kan ALA worden omgezet in langere en meer onverzadigde vetzuren, zoals 
eicosapentaeenzuur (EPA; C20:5n-3) en docosahexaeenzuur (DHA; C22:6n-3). EPA en 
DHA staan ook bekend als de zogenaamde visvetzuren, omdat ze voornamelijk 
aanwezig zijn in vette vis en visolie. De interesse voor EPA en DHA is groot, vanwege 
hun veronderstelde gunstige effecten op een groot aantal gezondheidsparameters zoals 
het verlagen van het risico op hart- en vaatziekten. Ondanks alle inspanningen om de 
consumptie van visvetzuren te verhogen, blijft de consumptie van deze visvetzuren vaak 
lager dan aanbevolen. Een verhoogde ALA-inname kan mogelijk helpen bij het 
toenemen van de hoeveelheid EPA en DHA in het lichaam, omdat ALA kan worden 
gebruikt voor de synthese van EPA en DHA en het gemakkelijk te verkrijgen is uit 
plantaardige bronnen. Om na te gaan of ALA uit de voeding een geschikt alternatief is 
voor de consumptie van visvetzuren, is het nodig om te weten hoeveel ALA uiteindelijk 
wordt omgezet in EPA en DHA. Uit eerdere studies is gebleken dat deze omzetting 
beperkt is. In de meeste studies echter, is deze omzetting niet gekwantificeerd. Hoewel 
moeilijk, is het mogelijk om de omzetting van ALA in mensen te kwantificeren met 
behulp van stabiele isotopen en modellering. Daarbij dient rekening te worden 
gehouden met het feit dat de omzetting van ALA waarschijnlijk afhankelijk is van de 
linolzuurinname (C18:2n6; LA), omdat ALA en LA dezelfde omzettingsenzymen delen. 
Theoretisch kan de conversie van voeding-ALA dan ook op drie manieren worden 
verhoogd: door een toename in ALA-inname, door een daling in LA-consumptie, of 
door het verhogen van de ALA:LA-verhouding in de voeding. Deze drie mogelijkheden 
om de omzetting van ALA te verhogen zijn tot op heden nog niet met elkaar vergeleken. 
Om de conversie van ALA door de lever (het belangrijkste orgaan voor de 
omzetting van ALA) te schatten, volgden 29 personen (14 mannen, 15 vrouwen) 
gedurende 4 weken een voeding, die 7 energie procent (En%) LA en 0.4 En% ALA 
1 
bevatte. Op dag 19 kregen de personen 30 mg uniform gelabeld [ C]ALA en gedurende 
de volgende 8 dagen tweemaal per dag 10 mg. Plasma fosfolipiden concentraties van 
,2C en 13C gelabeld ALA, EPA, DPA (C22:5n-3) en DHA werden bepaald op dag 19, 
21, 23, 26, 27, en 28 bij de proefpersonen. De omzetting van ALA in de lange keten 
onverzadigde vetzuren (EPA, DPA en DHA) werd geschat door modellering. Hiervoor 
werd een tracer model ontwikkeld, op basis van de gemiddelde 13C gelabelde vetzuur 
data van de deelnemers. Er werd een vergelijkbaar tracee model opgesteld dat gebruik 
maakte van de gemiddelde ~C gelabelde vetzuur data, de gemiddelde ALA inname en 
de kinetische parameters uit het tracer model. Beide modellen werden gelijktijdig 
opgelost om de inbouw van voeding-ALA in de plasma fosfolipiden en de 
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daaropvolgende conversie in zijn lange keten vetzuren te schatten. Het bleek dat 7 % 
van het voeding-ALA werd ingebouwd in de fosfolipiden. Dit ALA werd vervolgens 
grotendeels omgezet in EPA. Slechts 1 % van het EPA werd omgezet in DPA en 
vervolgens in DHA. Dit komt overeen met 0.07 % van de ALA inname. 
De beperkte omzetting van het uit ALA verkregen EPA naar DPA, is dus een verklaring 
voor de zeer lage DHA synthese uit voeding-ALA. 
Na deze 4 weken kregen de personen gedurende 6 weken, 1 van de 
3 experimentele voedingen om na te gaan of de omzetting van ALA kan worden 
beïnvloed door de inname van ALA, LA of hun ratio te veranderen. Negen personen 
bleven de controle voeding consumeren, 10 personen kregen een lage LA-voeding 
(3 En% LA, 0.4 En% ALA, ratio = 1:7), en 10 personen een hoge ALA-voeding (7 En% 
LA, 1.1 En% ALA, ratio = 1:7). Tien dagen voor het einde van deze experimentele 
periode werd wederom met behulp van stabiele isotopen de omzetting van ALA 
gemeten. Tevens werd gedurende 9 uur uitademinglucht verzameld om de oxidatie van 
[U-BC]ALA te schatten. De conversie van ALA werd geschat door middel van 
modellering van de individuele ,3C en ,2C n-3 vetzuur concentraties van de nuchtere 
plasma fosfolipiden. We constateerden dat de inbouw van ALA in de plasma 
fosfolipiden toenam met 3.6 % in de lage LA-groep, maar afnam met 8 % in de hoge 
ALA-groep. Als deze percentages echter werden omgerekend naar absolute waarden, 
dan werd er in de lage LA-groep 0.34 mg meer ALA uit de voeding omgezet in EPA, 
terwijl de omzetting in de hoge ALA-groep niet veranderde. Het ALA uit de plasma 
fosfolipiden werd bijna volledig omgezet in EPA. De omzetting van EPA in DPA en 
daaropvolgend in DHA veranderde nauwelijks in de 3 groepen en was minder dan 
0.1 % van het voedings-ALA. In absolute waarden was de synthese van DHA 
onveranderd in de lage LA-groep, terwijl deze toenam van 0.7 tot 1.9 mg in de hoge 
ALA-groep. De voedingsinterventies hadden geen effect op de ALA-oxidatie. 
Deze resultaten laten zien dat de hoeveelheid ALA en LA in de voeding - maar niet hun 
ratio - de omzetting van ALA bepalen. 
Er is weinig bekend over de determinanten van de omzetting en oxidatie van 
ALA door de mens. Daarom zijn we nagegaan of de ALA conversie en oxidatie zijn 
gerelateerd aan geslacht, pre- en postmenopauzale status, leeftijd, basaal metabolisme, 
lichaamssamenstelling, en het percentage linoizuur en trans vetzuren in plasma 
fosfolipiden. De omzetting van ALA naar EPA was positief gerelateerd aan leeftijd en 
het percentage vetmassa, terwijl de omzetting van EPA in DHA negatief gerelateerd 
was aan het percentage LA in plasma fosfolipiden. Er werd geen verband gevonden 
tussen tussen geslacht of de pre- en postmenopauzale status en de omzetting of oxidatie 
van ALA uit de voeding. 
Behalve voor de vorming van EPA en DHA, kan ALA zelf ook gunstige effecten 
hebben op cardiovasculaire risico markers. Een beperkt aantal studies hebben 
gesuggereerd dat ALA vergelijkbare effecten heeft op de serum lipidenwaarden als zijn 
n-6 vetzuur analoog LA. Echter, een effect van een verandering in de ALA:LA ratio kon 
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niet worden uitgesloten. Bovendien zijn de effecten van ALA, LA en hun ratio op de 
grootte van de lipoproteïnen deeltjes onbekend. Tot slot hebben we in een 
voedingsinterventiestudie van 9 weken, de effecten van ALA vergeleken met die van 
EPA/DHA op de cardiovasculaire risico markers bij oudere personen tussen 
60 - 78 jaar. We vonden dat de ALA:LA ratio het serum lipidenprofiel niet veranderde. 
Verder verminderde ALA het LDL cholesterol significant in vergelijking met oliezuur 
en LA. Dit kwam mogelijk door een daling in het aantal kleine VLDL deeltjes. 
Bij gezonde oudere personen beïnvloedde ALA de LDL-cholesterolconcentraties en 
apoB gunstig in vergelijking met EPA/DHA. Onze bevindingen suggereerden verder, 
dat ALA en EPA/DHA vergelijkbare effecten hebben op de markers van bloedstollmg, 
flbrinolyse en vaatwandfunctie. 
Op basis van deze bevindingen concluderen wij dat de omzetting van ALA uit de 
voeding in EP A beperkt is en minder dan 10 % bedraagt. Deze omzetting wordt bepaald 
door de hoeveelheden ALA en LA in de voeding, maar niet door de ALA:LA 
verhouding. Een toegenomen LA inname verhoogde de EPA synthese, terwijl de DHA 
synthese toenam na een verhoogde ALA-inname. Verder hadden in de 9-weekse 
interventiestudie ALA en de visvetzuren vergelijkbare effecten op markers voor de 
bloedstolling en fibronolyse en vaatwandfunctie. Behalve een onverwachte daling in 
LDL-cholesterol en apoB concentraties, zijn de effecten van ALA en LA op de serum 
lipidenconcentraties en het lipoproteïnenprofiel vergelijkbaar. Een laatste conclusie is 
dat de effecten op het serum lipoproteïnenprofiel niet worden bepaald door de 
ALA:LA ratio. 
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